Award Number: W81XWH-06-1-0149

TITLE: VatuximabTM: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

PRINCIPAL INVESTIGATOR: Ralph P. Mason, Ph.D.

CONTRACTING ORGANIZATION: UT Southwestern Medical Center at Dallas
Dallas, TX 75390-9058

REPORT DATE: December 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
## Abstract
Targeting the vasculature of tumors promises a new effective therapy for prostate cancer. We propose a new approach targeting the blood vessels in the tumor. Specifically, a novel antibody 3G4, which targets phosphatidylserine (PS) expressed on tumor vasculature was developed by Thorpe et al. and is being developed by Peregrine Pharmaceuticals for clinical trials. Normally, PS exclusively resides on the cytosolic leaflet of the plasma membrane. However, in tumors PS becomes externalized and provides a viable target. The agent not only targets various tumors, but also induces vascular damage and tumor regression with minimal accompanying toxicity. In developing a new therapy, critical issues include scheduling, optimal combination with other interventions to achieve synergy and early assessment of efficacy. Magnetic resonance imaging allows us to follow the induction and development of tumor vascular damage providing new insight into spatial and temporal activity and facilitating effective combination with the hypoxic cell selective cytotoxin tirapazamine. Importantly, this therapy may be effective at any stage of tumor development, and could be most effective for advanced disease. Success will confirm the potential of this new therapeutic approach to prostate cancer in man and lay the foundation for future clinical trials.

## Subject Terms
No subject terms provided.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>20</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>20</td>
</tr>
<tr>
<td>Conclusion</td>
<td>21</td>
</tr>
<tr>
<td>References</td>
<td>22</td>
</tr>
<tr>
<td>Appendices</td>
<td>24</td>
</tr>
</tbody>
</table>
Introduction
Targeting tumor vasculature promises new effective therapy for prostate cancer (1, 2). It avoids issues of drug delivery and is potentiated by massive downstream effects where one blood vessel may supply the nutrients for thousands of tumor cells. Thus, disrupting the vascular supply should generate magnified tumor cell kill. This research combines the expertise of three laboratories (Pharmacology, Urology, and Radiology) to investigate and optimize a novel therapeutic approach to prostate cancer. Thorpe et al. pioneered the concept of targeting tumor vasculature for therapeutic gain using antibodies (3). Recently, they generated a novel antibody 3G4, which targets phosphatidylserine (PS) expressed on tumor vasculature. 3G4 is a naked antibody, which recruits host defense cells to attack tumor vasculature (4-6). In collaboration with Peregrine Pharmaceuticals, this agent has been chimerized and is now being developed for clinical trials as Bavituximab (it should be noted that until last year the name Vatuximab™ had been proposed) (7). Normally, PS exclusively resides on the cytosolic leaflet of the plasma membrane. However, in tumors PS becomes externalized and provides a viable target. The agent not only targets various tumors, but also induces vascular damage and tumor regression with minimal accompanying toxicity. In developing any new therapy, critical issues include scheduling, optimal combination with other interventions to achieve synergy and early assessment of efficacy. Magnetic resonance imaging will allow us to follow the induction and development of tumor vascular damage in vivo providing new insight into spatial and temporal activity and facilitating effective combination with the hypoxic cell selective cytotoxin tirapazamine.

This research program will evaluate the ability of the agent Bavituximab to generate damage in tumor vasculature and induce prostate tumor growth delay. MRI will be used to assess the onset and distribution of tumor vascular damage in a series of Dunning prostate rat tumors (R3327- AT1, MAT-Lu, HI, and H) (8, 9) (10-14). This will provide an indication of the efficacy with respect to tumors exhibiting diverse histologies (anaplastic to well differentiated), a range of volume doubling times (1.5 to 20 days). Importantly, all these tumors are subclones of the original R3327-H tumor, and hence, together they represent a strong analogy for the clinical situation of advanced multi focal multi clonal prostate cancer. We will assess tumor response at different sizes and the value of repeated doses. Ultimately, we will investigate the synergistic application of Bavituximab with the hypoxia selective cell cytotoxin, tirapazamine (15-17). The experience in diverse subcutaneous models will be translated to human tumor xenografts in intraosseous models of advanced metastatic prostate cancer (18). Here, PSA levels and bioluminescence will provide primary indications of tumor growth and MRI will be applied to examine the tumor pathophysiology.

Successful completion of this project will confirm the potential of this new therapeutic approach to prostate cancer in man. It will lay the foundation for future clinical trials and promises a highly effective novel therapy obviating the need for radical prostatectomy, with its inherent costs, risks, and complications. Ultimately, this approach could lead not only to increased survival time with quality of life, but also cure of the prostate cancer patient.

It should be noted that the antibody Bavituximab was formerly variously called Vatuximab™ or Tarvacin.

Body and Progress
Phase 1 Evaluate efficacy of Bavituximab to control diverse syngeneic rat prostate tumors: assess physiological parameters (e.g., \(pO_2\)) as surrogate markers of prostate tumor control and mechanisms of response.

Task 1 Months 1-3

Implant tumors of the four Dunning prostate sublines R3327- MAT-Lu, AT1, HI, and H in Copenhagen rats.

Completed Year 1
Task 2 Months 2-15

Measure baseline $pO_2$ (*FREDOM*), perfusion characteristics (DCE MRI), and ADC (Apparent diffusion coefficient) of tumors and changes with respect to Bavituximab infusion to assess acute response over two hours.

Investigations completed Year 2, with ongoing data analysis

**Tumor oximetry**

*FREDOM* (Fluorocarbon Relaxometry using Echo Planar imaging for Dynamic Oxygen Mapping) (19) was successfully applied to measure tumor $pO_2$ and dynamic response to interventions. Under baseline air breathing conditions all tumors show quite similar oxygenation patterns typically ranging from regions of hypoxia to others with $pO_2 \sim 40$ torr (Figure 1). Comparison of $pO_2$ values using ANOVA (Analysis of Variance) with Fisher’s post hoc test showed that the H tumors had significantly lower $pO_2$ than the AT1 or HI tumors (Tables 1&2). Following bavituximab administration MAT-Lu, AT1 and H tumors showed no particular change. However, several HI tumors showed hypoxiation over about 1 h. One week later both HI and H tumors showed elevated $pO_2$ (Figs 6 &6).

![Relaxation curve](image1)

**Figure 1 Oximetry in Dunning prostate tumors. Left** A typical $^{19}$F NMR T1 relaxation curve for the signal intensity of the reporter molecule hexafluorobenzene from a single voxel within a tumor. The relaxation rate is directly proportional to $pO_2$. Based on such curves maps were generated for representative MAT-LU, HI and H tumors growing on anesthetized rats breathing air with isoflurane anesthesia. Voxel dimension 1.25 mm in plane with 10 mm thickness.

<table>
<thead>
<tr>
<th></th>
<th>Count</th>
<th>Mean</th>
<th>Std. Dev.</th>
<th>Std. Err.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT1</td>
<td>15</td>
<td>10.459</td>
<td>9.635</td>
<td>2.488</td>
</tr>
<tr>
<td>H</td>
<td>12</td>
<td>1.751</td>
<td>2.610</td>
<td>.753</td>
</tr>
<tr>
<td>HI</td>
<td>24</td>
<td>8.233</td>
<td>9.258</td>
<td>1.890</td>
</tr>
<tr>
<td>MAT-LU</td>
<td>18</td>
<td>5.283</td>
<td>8.079</td>
<td>1.904</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Mean Diff.</th>
<th>Crit. Diff.</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT1, H</td>
<td>8.708</td>
<td>6.404</td>
<td>.0085 S</td>
</tr>
<tr>
<td>AT1, HI</td>
<td>2.226</td>
<td>5.442</td>
<td>.4170</td>
</tr>
<tr>
<td>AT1, MAT-LU</td>
<td>5.176</td>
<td>5.781</td>
<td>.0784</td>
</tr>
<tr>
<td>H, HI</td>
<td>-6.482</td>
<td>5.846</td>
<td>.0303 S</td>
</tr>
<tr>
<td>H, MAT-LU</td>
<td>-3.533</td>
<td>6.162</td>
<td>.2565</td>
</tr>
<tr>
<td>HI, MAT-LU</td>
<td>2.950</td>
<td>5.156</td>
<td>.2574</td>
</tr>
</tbody>
</table>

**Tables 1 (left) and 2 (right) Baseline oxygenation of four Dunning prostate R3327-tumor lines.**

ANOVA showed that H tumors had significantly lower $pO_2$ than AT1 or HI. This is contrary to our previous observations and we are examining histology and repeating tests to further clarify the $pO_2$ values observed in the H tumors.
Figure 2 Oxygen dynamic in Dunning prostate R3327 tumors with respect to bavituximab infusion.

Two or three baseline pO2 maps were generated in individual tumors and then bavituximab was infused IP (arrow). Further pO2 maps were generated over the following 2 hours. Only HI tumors showed significant change (hypoxiation) following infusion (Fig 5). Pink lines show pO2 measurements seven days later. For HI tumors the decline in pO2 was significant within 30 mins.

Figure 3 Oxygen dynamics in Dunning prostate R3327-AT1 tumors with respect to bavituximab infusion.

Variation in mean pO2 for a group of 7 small AT1 tumors with respect to infusion of bavituximab IP at 2.5 mg/kg. No significant changes were seen.
Figure 4 Oxygen dynamics in Dunning prostate R3327-MAT-Lu tumors with respect to bavituximab infusion. Variation in mean pO\textsubscript{2} for each of a group of 5 small MAT-Lu tumors with respect to infusion of bavituximab IP at 2.5 mg/kg. Vertical dashed lines indicate time of bavituximab administration. Data are summarized (bottom right) for a group of six tumors. No significant changes were seen.
Figure 5 Oxygen dynamics in Dunning prostate R3327-HI tumors with respect to bavituximab infusion. Variation in mean pO₂ for each of a group of 5 small HI tumors with respect to infusion of bavituximab IP at 2.5 mg/kg. Data are summarized for a group of eight tumors in graph. Significant decreases in mean pO₂ were seen over the following two hours as shown in Table based on Fisher’s PLSD test and indicated by asterisks on graph. One week later pO₂ had risen significantly.
Figure 6 Oxygen dynamics in Dunning prostate R3327-H tumors with respect to bavituximab infusion. Variation in mean pO2 for each of a group of 4 small H tumors with respect to infusion of bavituximab IP at 2.5 mg/kg. Data are summarized for a group of six tumors in graph. No significant acute changes were seen, but 1 week later pO2 was significantly elevated.

Dynamic contrast enhanced MRI

DCE was performed using ¹H MRI at 4.7 T with the small paramagnetic contrast agent Omniscan (0.1 umol /kg (~250 ul) infused IV in tail using catheter vein by hand rapidly (~ 1 s). Data were examined in terms of ΔSI (max change in signal intensity). There was distinct heterogeneity between center and periphery of each tumor type as shown in Figures 7-12. In some cases we have compared regional differences and undertaken measurements of the exchange function kep. Baseline data have been submitted for publication (see appendix)
**Figure 7 DCE for MAT-Lu tumor.** Top left: Relative signal intensity map for T1 weighted MRI pre therapy and before contrast agent. Top center: 4 mins after contrast showing strong peripheral enhancement; Bottom left baseline MRI 2 h after administration of bavituximab; Bottom center 4 mins post contrast, 2 h after bavituximab. Right curves show mean signal enhancement for three representative image slices before and 2 h after bavituximab. There were no significant changes. Clearly, further analyses will be required on a regional signal intensity basis.

**Untreated**

![Untreated](image)

**Base Gd injection (20 seconds)**

![Base Gd injection (20 seconds)](image)

**After Bavituximab**

![After Bavituximab](image)

**Figure 8 DCE for AT1 tumor.** Top left: Relative signal intensity map for T1 weighted MRI pre therapy and before contrast agent. Top center: 20 s after contrast showing strong peripheral enhancement; Bottom left baseline MRI 2 h after administration of bavituximab; Bottom center 20 s post contrast, 2 h after bavituximab.
Right curves show mean signal enhancement for three representative image slices before (top) and 2 h after (bottom) bavituximab.

**Figure 9** Comparison of signal intensity during DCE experiments for a group of AT1 tumors. A significant difference in signal response was observed between central and peripheral regions of tumor.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Central</th>
<th>Periphery</th>
</tr>
</thead>
<tbody>
<tr>
<td>$(\Delta SI)/DCE$</td>
<td>24±1</td>
<td>43±1*</td>
</tr>
<tr>
<td>$%\text{response}$</td>
<td>24±1</td>
<td>43±1*</td>
</tr>
<tr>
<td>$K_{ep}$ (min$^{-1}$)</td>
<td>2.59±0.51</td>
<td>3.11±0.44</td>
</tr>
</tbody>
</table>

**Table 3** Comparison of DCE parameters. For a group of AT1 tumors showing significant difference in signal response between central and peripheral regions of tumor (*). No differences were observed for $K_{ep}$.

**Figure 10** DCE for HI tumor. Left Mean signal intensity kinetics following infusion of contrast agent. Right: Relative signal intensity map for T1 weighted MRI 2 h post therapy (4 minutes after contrast agent) showing heterogeneous perfusion.
**Figure 11**  
**DCE for H tumor.** Left: Mean signal intensity kinetics following infusion of contrast agent. Pre (blue), 2h post bavituximab (pink), 7 days post (yellow). On most occasions DCE indicated considerably lower signal response in the H tumors 2 h after bavituximab. To verify this result we will both use histology following administration of Hoechst perfusion dye and ensure that future studies include normal tissue following assessment of arterial input function. This is cruel to verify that the contrast agent injections are all similarly successful. Right: Relative signal intensity map for T1 weighted MRI pre and 4 minutes after contrast agent showing heterogeneous perfusion pre bavituximab.

<table>
<thead>
<tr>
<th>(ΔSI)DCE⁺</th>
<th>Mean</th>
<th>55±2‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Periphery</td>
<td>31±1</td>
</tr>
<tr>
<td></td>
<td>Center</td>
<td>124±6*‡</td>
</tr>
</tbody>
</table>

| Kep (min⁻¹) | Mean | 3.20±0.39 |
|            | Periphery | 3.34±0.46 |
|            | Center   | 2.95±0.54 |

**Table 4 Comparison of DCE parameters.**  
For a group of H tumors there was a significant difference in signal response between central and peripheral regions of tumor. No differences were observed for Kep.

**Figure 12**  
**Comparison of signal intensity during DCE experiments for a group of H tumors.** A significant difference in signal response was observed between central and peripheral regions of tumor, but here the center showed a larger change, whereas for AT1 tumors in Figure 9, the opposite was observed.

**Apparent diffusion coefficient (ADC)** maps are shown for thin slices from representative Dunning prostate tumors of each subline in Figures 13 and 14. Each tumor shows some heterogeneity. In Figure 14 color representations are provided for a representative AT1 tumor, with 3 selected slices before and two hours after administration of Bavituximab. Table 5 provides mean values and compares the statistical significance of difference between the sublines. While the maps showed no significant differences between the AT1 and MAT-
Lu tumor types, all the other comparisons revealed significantly differences and the H showed much lower ADC values.

Figure 13  Apparent diffusion maps obtained by proton MRI at 4.7 T of Dunning prostate R3327 tumors growing in rats. Each image represents a slice of a tumor observed in vivo presenting diffusion maps obtained with 4 b-value diffusion gradients (MR parameters, FOV = 30 mm, TR = 2,300 ms, TE= 50 ms, in plane resolution 230 um, slice thickness 2 mm with a total acquisition time of 20 mins)

Figure 14  Apparent diffusion maps obtained by proton MRI at 4.7 T of Dunning prostate R3327-AT1 tumor. Data as for Figure 9, but showing three consecutive image slices in representative AT1 tumor. Distinct baseline heterogeneity is apparent with mean ADC ranging from 10.2x10^-4 to 16.2 x10^-4 mm^2/s. The lower image shows the same slices 2 h after administration of 2.5 mg/kg bavituximab. There were no significant acute changes.
<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>Std. Dev.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT1</td>
<td>12.9</td>
<td>.92</td>
</tr>
<tr>
<td>H</td>
<td>2.6</td>
<td>3.83</td>
</tr>
<tr>
<td>HI</td>
<td>16.7</td>
<td>2.80</td>
</tr>
<tr>
<td>MAT-Lu</td>
<td>11.8</td>
<td>2.44</td>
</tr>
</tbody>
</table>

**Table 5 Left** Relative ADC values for groups of Dunning prostate tumors. **Right** Statistical comparison of ADC values for tumor types showing levels of significance for analysis of variance based on Fisher’s test.

For HI tumors below:

**Figure 15** Variation in ADC with respect to bavituximab administration. Data shown for a group of 7 HI tumors. No significant changes were observed.

**Task 3** Months 3-15

Response to multiple doses of Bavituximab. Use MRI to measure pO₂, perfusion characteristics and diffusion characteristics of tumors with respect to repeated Bavituximab administration (assess response over a period of weeks/months by MRI and tumor volume).

MAT-Lu tumors show heterogeneous baseline pO₂, but generally minimal acute response to administration of bavituximab.

**Figure 16** Chronic changes in pO₂ accompanying multiple doses of bavituximab in MAT-Lu tumors. **Left:** Histogram presents distribution of pO₂ values measured using ¹⁹F MR oximetry for a group of 8 small tumors. Blue bars are pre therapy and purple 7 days later after 3 doses (2.5 mg/kg) of bavituximab. Distinct hypoxiation of these tumors is apparent. This may be due to the drug, but is likely attributable to rapid growth.
seen in the tumor which has about 2 day volume doubling time (VDT). Further tests are underway to verify the cause of the hypoxiation. **Right:** There appear to be correlations between pre-therapy baseline pO$_2$ and time to double in volume during bavituximab therapy (thrice weekly). However, tumors appear to fall into two separate groups, requiring further evaluation.

![HI pO2 2007](image)

**Figure 17 Chronic changes in pO$_2$ accompanying multiple doses of bavituximab in HI tumors.**

**Upper:** Histogram comparing pO$_2$ pre treatment and after 7 days (3 doses) of bavituximab or erbitux.

**Lower graphs- left-** Change in pO$_2$ over 7 days of treatment ($\Delta$pO$_2$) with erbitux (pink) or bavituximab (blue) appears to be related to baseline pO$_2$ prior to therapy. Right: Time to double in volume during therapy appears to be related to baseline pO$_2$, as also seen for MAT-Lu tumors in Figure 16.
Figure 18 Growth curves for HI tumors with respect to bavituximab therapy.

Left: individual small tumors all receiving bavituximab; right: individual medium sized tumors receiving treatment (thrice weekly) with erbitux (red) or bavituximab (blue).

H tumors indicated strong therapeutic response (Figure 19). Each tumor showed either reduction in growth or tumor shrinkage. Tumors of the faster growing cell lines appeared to respond less well to therapy. However, they generally develop massive central necrosis with only a thin peripheral rim of viable tumors. In many cases this was revealed as ulceration leaving a donut cavity. Thus, there is extensive tumor control, but volume measurement based on respective dimensions alone does not appropriately reveal the control.

Figure 19 Growth curves for H tumors with respect to bavituximab therapy.

Growth curves for groups of control and bavituximab treated H tumors. Separate curves are shown for highly responsive small H tumors (yellow; n=2); responsive small tumors (blue; 1 tumor) and somewhat less responsive large tumors (pink; 2 tumors). Bavituximab treated tumors received 2.5 mg/kg IP thrice weekly starting on day 1. For comparison a large tumor designated by green label received equivalent dose of control, antibody rituximab.
Task 4 Months 3-18

Histological analysis - assess distribution of Bavituximab, necrosis, hypoxia, perfusion based on dyes and antibodies.

Treated tumors have been stored and histology is underway. Data were included in the manuscript accepted for publication in Clinical Cancer research (appended).

Figure 20 Histology of poorly differentiated Dunning prostate AT1 tumors.

Top left: Staining with antiCD31 (vasculature) represented in red and bavituximab (anti-PS) in green.

Top right: Triple staining shows extensive hypoxia (pimonidazole-green), few blood vessels (CD31-red), and some perfused vessels (Hoechst- blue).

Bottom: Staining showing coincidence of CD31 and PS with overlay of green and red generating yellow.
Figure 21 Histology of moderately differentiated Dunning prostate HI tumors.

Whole mount hosing bavituximab (PS) green on CD31 red; b) magnification showing overlap in blood vessel. c) Color separation of a showing CD31 in red; d) color separation of a showing bavituximab in green; and e) PS I green and hypoxia based on pimonidazole in blue.
Task 5  Month 12
Prepare annual report and manuscript.
Completed and approved for Year 1- manuscripts in appendix.

Task 6  Months 15-18
Implant tumors of the four sublines R3327- MAT-Lu, AT1, HI and H (6 tumors of each of 4 sublines with 3 treatment sizes (0.5 cm, 1 cm, 1.5 cm diameter; respectively 0.06 cm$^3$, 0.5 cm$^3$, 1.7 cm$^3$) = 144 experimental rat tumors: Tasks 7 and 8 are based on these rats))
Completed year 2

Task 7  Months 16-30
Assess tumor growth delay in response to combined Vatuximab™ with tirapazamine (SR4233: 3-amino-1,2,4-benzotriazine 1,4 dioxide). Use MRI to assess differential response to therapy compared with tumors receiving Vatuximab™ alone.
Growth of small AT1 tumors based on external caliper measurements with respect to various drug combinations. Bavituximab from Task 3 for comparison with Figures 18 and 19. Since tumors are expected to be hypoxic the hypoxia selective cytotoxin tirapazamine was added. For comparison data are shown for the standard chemotherapeutic docetaxel. These studies are ongoing.

![Relative Growth Rate](image)

**Figure 22 Growth curves for groups of treated AT1 tumors**
Purple * control untreated tumors; brown ● Bavituximab at 2.5 mg/kg thrice weekly; cyan x Bavituximab (2.5 mg/kg IP thrice weekly) + tirapazamine (25 mg/kg IP weekly); blue ◆ control antibody –erbilux (2.5 mg/kg thrice weekly); yellow▲ docetaxel (5 mg/kg, ip - only 4 doses due to toxicity) pink ■ Bavituximab (2.5 mg/kg IP thrice weekly) + docetaxel (2.5 mg/kg, ip - only 4 doses due to toxicity)
Task 8  Month 24
Prepare annual report and manuscript.

KEY RESEARCH ACCOMPLISHMENTS:

- Examined changes in tumor oxygenation in response to bavituximab administration. Only HI tumors showed significant hypoxiation.
- Examined changes in tumor perfusion following bavituximab. Only H tumor showed significant change (reduction)
- No changes in apparent diffusion coefficients were found following batuximab administration.
- Most H tumors showed significant reduction in growth rate (based on tumor volume) and growth delay (or shrinkage) were maintained over many weeks while additional doses of bavituximab were administered.
- The faster growing tumors showed central necrosis and tumor control based on histological examination, but simply measuring whole tumor volume did not readily reveal tumor control due to peripheral rim which continued to grow.
- Preliminary data suggest that addition of tirapazamine to bavituximab enhances therapeutic growth delay.
- By comparison bavituximab + docetaxel gives strongest growth delay, but docetaxel causes weight loss and severe toxicity.

REPORTABLE OUTCOMES:

1  Peer-reviewed Papers
During this second year two significant peer reviewed manuscripts have been accepted for publication. Each credits this grant and is based in part on studies funded by the grant. The papers are included in the appendix.


2  Book Chapter

3  Peer-reviewed Grants
Research results and the needs of this current grant have directly assisted in UT Southwestern winning two significant grants for infrastructure from the NCI. These will both enhance the current studies and future prostate cancer research at UT Southwestern and the surrounding community.

- **IS10RR024757-01 (PI Mason)**
  - NIH/National Cancer Institute
  - $334,600
  - Small Animal Bioluminescence and Fluorescence Imaging System (with 3D capability)
  - Major Goal: Purchase a commercial bioluminescence imaging system to accelerate development of new therapies in cancer research

- **1U24CA126608-01 (PI Mason)**
  - NIH – SAIR
  - $300,000 annual
  - UT Southwestern Small Animal Imaging Resource Program
  - Major Goal: Oversight of multi-modality imaging resource

4 **Submitted manuscript**

“Blood Oxygen Level Dependent (BOLD) and Gd-DTPA dynamic contrast enhanced (DCE) MRI: comparison of two prostate tumor sublines exhibiting different vascular development”, L. Jiang, D. Zhao, E. W. Hahn, A. J. van der Kogel, J. Bussink, P. Peschke, and R. P. Mason

5 **Conference proceedings**

- “Vatuximab™: Optimizing Therapeutic Strategies For Prostate Cancer Based on Dynamic MR Tumor Oximetry”, R. P. Mason; W. Cui; D. Zhao; A. J. van der Kogel; J. Bussink; J. Pacheco Torres; J. McAnally; L. Watkins; P. Peschke; and P. Thorpe. *Innovative Minds in Prostate Cancer Today - IMPaCT* meeting, September 5-8, Atlanta, Georgia, 2007, (poster appended). It may also be viewed at
- “DOCENT-Dynamic Oxygen Challenge Evaluated by NMR T1 and T2* of Tumors”, D. Zhao, J. Pacheco-Torres, P. Peschke and R. P. Mason, Imaging in 2020 2007 Jackson Hole (poster appended). It may also be viewed at

**CONCLUSIONS:** As expected based on previous observations all prostate tumors show considerable hypoxia. However, only HI tumors showed significant acute increased hypoxia following administration of bavituximab. Thus, the hypoxia selective cytotoxin tirapazamine is expected to be effective on the prostate tumors, but in terms of combined effects and potential synergy, we now only expect this for the HI tumors, where additional hypoxia is induced by bavituximab. It appears that the faster growing sublines have a rapidly proliferating edge, which escapes control from bavituximab alone.
References


**APPENDICES:**
1. ABSTRACT

Over the years many techniques have been devised for the measurement of tissue oxygenation (oximetry). Oximetry using polarographic needle electrodes has long been considered a gold standard. Nuclear Magnetic Resonance (NMR) based oximetry uses exogenously administered reporter molecules such as perfluorocarbons to quantitatively interrogate oxygen tension ($pO_2$). This technique has been successfully used in vivo in the preclinical setting and shows promise for clinical applications. NMR $pO_2$ reporter molecules display a linear dependence of the spin lattice relaxation rate on $pO_2$, which forms the basis of this technique. Physical principles of spin lattice relaxation of $pO_2$ reporter molecules and the $pO_2$ dependence of relaxation rate are discussed in this review. Practical considerations for choice of reporter molecules for in vivo measurements, general methodology and new developments are also described.

2. INTRODUCTION

2.1. Tissue oxygenation and hypoxia

Oxygen is essential for tissue health and any reduction in its supply can lead to rapid cellular dysfunction and cell death. It is also an important variable in the treatment of many medical conditions including tumors, peripheral vascular disease, and stroke. In solid tumors, oxygen delivery is impaired by structural abnormalities present in the tumor vasculature such as chaotic vessel architecture. In addition, the altered tumor cell metabolism with elevated metabolic rates contributes to the occurrence of low tissue oxygenation (hypoxia). Hypoxia can adversely affect the efficacy of radiation therapy, chemotherapy, and photodynamic therapy (1). These therapies rely on creation of reactive oxygen species, which can kill cancer cells by damaging DNA and sub cellular organelles (2). Reactive oxygen species are also formed as a natural byproduct of normal metabolism of...
MR Oximetry

oxygen and have important roles in cell signaling (3). Production of reactive oxygen species from molecular oxygen by macrophages and neutrophils probably plays a key role in cell-mediated immunity and microbiocidal activity (4). Measurements of \( pO_2 \) in tumors have been found to have prognostic value and the probability of disease-free survival is significantly lower for patients with hypoxic tumors (5-8). Given the importance of oxygen, the ability to measure tissue oxygen tension non-invasively may have a significant impact in understanding mechanisms of tissue function and in clinical prognosis of disease. Quantitative tissue oximetry remains a challenge, especially in vivo and this review will consider progress in magnetic resonance approaches and the physical foundations underpinning the method.

2.2. Measurement of tissue oxygenation

Many techniques have been used to assess tissue oxygenation in vivo, both qualitative and quantitative as reviewed extensively (1, 9, 10). Direct measurement methods include those using electrodes and fiber-optic probes. These methods have been used for in vivo research and also in the clinical setting, but are invasive and may be unsuitable for routine human use. Indirect methods such as those based on Magnetic Resonance (MR) measure parameters that report on local oxygenation status (see section 3).

Measurements of \( pO_2 \) using polarographic needle electrodes have long been considered a gold standard (1, 11, 12). Typically, an anode is placed on the skin and polarized with a constant voltage. The polarographic needle electrode (cathode) consists of a gold filament embedded within a flexible stainless steel housing with an oxygen permeable membrane covering the opening. The cathode is inserted into the tissue of interest and electrical current is generated at the tip of the electrode, which is proportional to the tissue oxygen pressure. Polarographic electrodes are calibrated in phosphate buffered normal saline, bubbled with gases with a range of \( pO_2 \). Multiple electrodes may be placed at different locations in tissue in order to measure spatial heterogeneity and one can make dynamic measurements to gauge the response to intervention (13). The invasiveness of this technique can be minimized by use of electrode tips as fine as a few microns (14), but these are fragile and are susceptible to stray electromagnetic fields. The Eppendorf Histograph is an improved version of this technique that can make multiple successive measurements along tracks in tissue using a stepwise motion of the needle electrode under computer control (15). It has been successfully used in the clinical setting and revealed hypoxia in many tumor types that are externally accessible (6-8, 12, 16-19). The drawbacks of polarographic electrodes are that measurements can be affected by changes in pH, salinity, and ionic strength. Electrodes also consume oxygen, and thus, may bias readings especially under hypoxic conditions (such as found in tumors) and over long measurement periods.

Another quantitative method for measuring the partial pressure of dissolved or gaseous oxygen utilizes fiber-optic oxygen sensors based on fluorescence. Typically, an optical fiber carries excitation light to the fluorophore coating at the probe tip. Fluorescence generated at the tip is returned by the optical fiber to a spectrometer. When oxygen in the gas or liquid sample diffuses into the fluorophore coating, it quenches the fluorescence. Commercial instruments exploit various parameters such as fluorescence lifetime (OxyLite™) or relative fluorescence intensity (FOXY™), which are correlated with \( pO_2 \) and hence, a calibration curve can be used to measure \( pO_2 \) in vivo. The fluorophores used in commercial systems may be platinum based (OxyLite™) or ruthenium based (FOXY™). This method does not consume oxygen during measurement, but the fluorophore coating may wear off after several measurements and needs to be re-applied to the fiber. Weak detected fluorescence intensity is a clear sign that fluorophore coating needs to be re-applied. Probes can be coated with oxygen permeable coatings to further protect the fluorophore. This usually slows the response time of measurement. Several recent applications have been reported (20-31). Fiber optic probes are more fragile than the Eppendorf Histograph.

Qualitative methods have been used to non-invasively identify tumor regions that are hypoxic based on selective accumulation of specially designed reporter molecules in such regions (32). Following intravenous infusion, these reporter molecules are trapped in tissues in the absence of oxygen, very much like molecules such as pimonidazole and EF5 that are widely used in histological assessment of hypoxia (33). Many such reporter molecules have been developed for different modalities such as NMR (34-36), positron emission tomography (PET) (37-40) and single photon emission computed tomography (SPECT) (41, 42). The red shift of the fluorescence of green fluorescent protein (GFP) under hypoxic conditions has also been used to image hypoxia by fluorescence imaging (43). Exploiting various biochemical pathways that are under oxygen regulation such as induction of hypoxia-inducible factor 1 (HIF-1) or introduction of transgenes with hypoxic response elements (HREs) coupled to reporter genes has enabled the visualization of hypoxia by optical imaging (44-47).

2.3. Magnetic Resonance in Bioscience

In biomedicine, the abundant hydrogen nuclei from tissue water can be utilized to obtain high-resolution anatomical images using Magnetic Resonance Imaging (MRI) to probe living systems non-invasively. Of all medical imaging modalities, MRI provides the best combination of spatial and temporal resolution to yield superb anatomical detail and functional information. It has become an invaluable clinical tool for diagnosis of many diseases. Using tricks of nuclear spin physics it is possible to obtain information beyond structural anatomy. Routinely, one can study diverse aspects of physiology, such as vasculature and blood flow (48-50), cellularity and apparent diffusion (51-54), vascular and tissue oxygenation (9, 55-59) as well as tissue perfusion and endothelial permeability (60, 61). The development of contrast agents and reporter molecules has pushed the limits of detection and established MRI as a tool for molecular imaging (62-64). Assessment of key metabolites such as lactate, choline
MR Oximetry

and N-acetyl aspartate (NAA) by proton NMR has enabled the assessment of metabolic changes at onset of disease (65-71).

Magnetic Resonance (MR) based techniques to measure oxygenation may be divided into quantitative and qualitative methods. Qualitative MR techniques, such as BOLD (Blood Oxygen Level Dependant) contrast use blood oxygenation status as a surrogate marker for tissue oxygenation. BOLD can provide high spatial and temporal resolution and can assess dynamic changes in vascular oxygenation using endogenous deoxyhemoglobin, and is the basis for functional MRI. For large blood vessels where imaging voxels are wholly within a vessel quantitative oximetry has been reported (55, 72, 73). However, since BOLD contrast (changes in T2*) depends on the amount of deoxyhemoglobin it is influenced by hematocrit, vascular volume, pH and flow. While signal changes are sensitive to changes in vascular oxygenation, the relationship with tissue pO2 is neither straightforward nor direct in tissues (58). Quantitative MR oximetry techniques have been developed based on reporter molecules for nuclear magnetic resonance (NMR) (9, 74-76) and electron paramagnetic resonance (EPR) (10, 77-81). EPR is a technique that is very similar to NMR in that they both result from the Zeeman interaction of a spin with an external magnetic field. Unlike NMR where nuclei like protons with non-zero nuclear spin give rise to the signal, EPR relies on unpaired electrons. EPR oximetry, much like NMR oximetry, relies on the indirect methods that exploit the paramagnetic properties of molecular oxygen. Paramagnetic oxygen not only relaxes nuclear spins, but also is effective in electronic T1 and T2 relaxation of other paramagnetic species or radicals. The EPR linewidth of the relaxation rate of PFCs generally results from a magnetic-field strength dependence of R 1d + R 1p, where R 1d is the diamagnetic longitudinal relaxation rate of R 1d, the ones with oxygen in their immediate vicinity have a longitudinal relaxation rate of R 1d + R 1p where R 1p is the paramagnetic contribution of oxygen. Since the oxygen molecules rapidly diffuse in the solvent, the observed relaxation rate for each type of fluorine atom is a molar weighted average:

\[ R_1 = (1-x) R_{1d} + x (R_{1d} + R_{1p}) = R_{1d} + x R_{1p} \]  

where x is the mole fraction of oxygen. Since PFCs behave as essentially ideal liquids, the solubility of oxygen in the PFCs obeys Henry’s law,

\[ pO_2 = k x \]  

where k is a constant that reflects solubility of oxygen in the PFC. It is therefore different for different PFCs. Combining eqs. 1 and 2

\[ R_1 = R_{1d} + pO_2 R_{1p}/k \]  

Thus, the plot of R1 vs. pO2 at a given temperature should be linear, with an intercept of R1d and a slope of R1p/k. R1d is the anoxic relaxation rate, i.e., the relaxation rate in absence of oxygen, and R1p is the relaxation rate due to the paramagnetic contribution of oxygen dissolved in the solution or tissue.

3.2. Diamagnetic contributions to R1

The diamagnetic contribution R1d to the total relaxation rate of PFCs generally results from a combination of 19F-19F dipole-dipole (DD) interactions and 19F chemical-shift anisotropy (CSA) at high magnetic fields. When molecular motions are in the extreme narrowing region the DD contribution to R1d (R1DD) is independent of the magnetic-field strength (86), but the CSA contribution to R1d (R1CSA) varies directly as the square of the magnetic-field strength (87). Thus, at relatively low magnetic fields, the CSA contribution to relaxation is negligible, while at high
magnetic fields it is comparable to the contribution of DD interactions. In general, we can treat DD and CSA interactions as independent and additive contributions to \(R_{1d}\), but they can be correlated in some cases. DD and CSA interactions within a CF2 or CF3 group can interfere with each other because they both are fixed to the same physical structure and this correlation can cause the relaxation curve to be multi exponential by introducing a slow relaxing component (88-90) in some cases. Generally such effects on \(R_{1}\) are negligible. Any inter-molecular DD contribution can be assimilated into the intramolecular DD contribution and represented by an effective \(^{19}\text{F}-^{19}\text{F}\) distance \(r_{FF}\). An exact expression for the DD and CSA relaxation times depends on the structure and the molecular dynamics of the functional group under consideration (i.e., CF4, CF2, or CF) and can be quite complicated. Some knowledge of the molecular dynamics may allow assumptions to compute an exact expression, which can then be compared with experimental observations. For example, internal rotation of the CF3 groups in a linear chain PFC may be sterically hindered and considered to be fixed motionless in a rigid sphere that undergoes isotropic rotational diffusion. For the terminal CF3 group, reorientation results from the same isotropic rotational diffusion of the rigid sphere and random internal 120° jumps about the three-fold symmetry axis fixed in the sphere. It is reasonable to assume that the principle component of the chemical shift tensor lies along the C-F bond and one can use chemical-shielding anisotropy (\(\Delta \sigma\)) and asymmetry (\(\eta_{\sigma}\)) values from literature. Such internal motion will lead to extra terms and the angular dependence in the equations for the CF3 group compared to the CF2 group. Shukla et al. (91) calculated the DD and CSA relaxation rates for the CF2 and CF3 groups of perfluorotributylamine (PFTB) and compared theory with experimental measurements of \(R_{1a}\) (\(=R_{1DD}+R_{1CSA}\)). For the CF2 group,

\[
R_{1DD} = \frac{(N-1)\gamma^2 h^2}{10r_{FF}^2} [j_1(\omega_0) + 4j_2(2\omega_0)] \quad (4)
\]

\[
R_{1CSA} = \frac{2(\gamma B_\sigma \Delta \sigma)^2}{15} (1 + \frac{\eta_{\sigma}^2}{3}) j_1(\omega_0) \quad (5)
\]

while for the CF3 group,

\[
R_{1DD} = \frac{(N-1)\gamma^2 h^2}{10r_{FF}^2} \left[\frac{1}{4} (3\cos^2 \Delta \omega_3 - 1)^2 [j_1(\omega_0) + 4j_2(2\omega_0)] + (1 - \frac{1}{4} (3\cos^2 \Delta \omega_3 - 1)^2 [j_1(\omega_0) + 4j_2(2\omega_0)]\right] \quad (6)
\]

\[
R_{1CSA} = \frac{2(\gamma B_\sigma \Delta \sigma)^2}{15} (1 + \frac{\eta_{\sigma}^2}{3}) \left[\frac{1}{4} (3\cos^2 \Delta \omega_3 - 1)^2 j_1(\omega_0) + (1 - \frac{1}{4} (3\cos^2 \Delta \omega_3 - 1)^2 j_1(\omega_0)\right] \quad (7)
\]

where \(N\) is the number of \(^{19}\text{F}\) nuclei in the group (2 for CF2 and 3 for CF3), \(\gamma\) is the gyromagnetic ratio of \(^{19}\text{F}\), \(B_0\) is the spectrometer magnetic-field strength and \(\omega_0\) is the corresponding \(^{19}\text{F}\) Larmor frequency (\(=\gamma B_0\)). \(\Delta_{DD}\) is the angle between the F-F vector and the internal rotation axis and \(\Delta_{CSA}\) is the angle between the principle axis of the chemical-shift tensor and the internal rotation axis. The spectral density functions \(j_\phi(\omega_0)\) and \(j_\gamma(\omega_0)\) are related to the correlation times of isotropic rotational diffusion of the molecule (\(\tau_c\)) and internal rotation of the CF3 group around the symmetry axis (\(\tau_{ci}\)), respectively, by

\[
j_\phi(\omega_0) = \frac{\tau_c}{1 + (\omega_0 \tau_c)^2} \quad (8)
\]

\[
j_\gamma(\omega_0) = \frac{\tau_{ci}}{1 + (\omega_0 \tau_{ci})^2} \quad (9)
\]

where

\[
1/\tau_c = 1/\tau_{ci} \quad (10)
\]

Assuming that all bond angles for the CF3 groups are tetrahedral (\(\Delta_{DD}=90^\circ\), \(\Delta_{CSA}=71^\circ\)), eqns. 6 and 7 reduce to

\[
R_{1DD} = \frac{3\gamma^2 h^2}{50r_{FF}^2} [0.25j_1(\omega_0) + 4j_2(2\omega_0)] + 0.75[j_2(\omega_0) + 4j_3(2\omega_0)] \quad (11)
\]

\[
R_{1CSA} = \frac{2(\gamma B_\sigma \Delta \sigma)^2}{15} \left[0.11j_1(\omega_0) + 0.89j_3(\omega_0)\right] \quad (12)
\]

In the motional narrowing limit \(j_\phi(\omega_0)\rightarrow \tau_c\) and \(j_\gamma(\omega_0)\rightarrow \tau_{ci}\), and further simplification of the above equations is possible. The relative contributions of DD and CSA to \(R_{1d}\) can vary with temperature and magnetic field. In the case of perfluorotributylamine (PFTB), \(R_{1CSA}\) was found to be greater than \(R_{1DD}\) for CF2 groups at high fields, while \(R_{1DD}\) dominates over \(R_{1CSA}\) for the CF3 group (91). Internal molecular rotation of the CF3 group results in a greater fractional decrease in \(R_{1CSA}\) compared to the fractional decrease in \(R_{1DD}\). From eqns. 4, 5, 11 and 12, in the limit where internal rotation is extremely fast (i.e., \(\tau_{ci}, \tau_{ci} \rightarrow 0\), \(R_{1DD}(CF3) = R_{1DD}(CF2)/2\) and \(R_{1CSA}(CF3) = R_{1CSA}(CF2)/9\).

The anoxic contribution to the relaxation rate, \(R_{1b}\), represents the lower limit of \(R_1\) with respect to pO2 reporter molecules. Accurate determination is essential for calibration, as it represents “0 torr”. In the case of a molecule like hexafluorobenzene (HFB), the expression for \(R_{1DD}\) will be similar to eqn. 4. However, three different F-F distances must be taken into account. Each F nucleus has two ortho (\(r_{FF}\sim2.91\text{Å}\)), two meta (\(r_{FF}\sim5.04\text{Å}\)), and one para (\(r_{FF}\sim5.82\text{Å}\)) F neighbors and the total \(R_{1DD}\) will be a sum of these three components. Due to the strong \(1/r_{FF}^6\) dependence, the para and the meta contributions may be small (1/27 and 1/128 of the ortho...
MR Oximetry

correlation, respectively, accounting for the distances and number of atoms), but this has not been verified. Compared to CF$_3$ (r$_{FF}$ ~2.41Å) and CF$_2$ (r$_{FF}$ ~2.38Å) groups the closest FF distance in HFB is larger, and hence, one might expect R$_{1DD}$ to be smaller. Indeed, the anoxic relaxation rate of HFB (~0.08 s$^{-1}$) is smaller than those of the α-CF$_3$ (~1.35 s$^{-1}$) and CF$_3$ (~0.88 s$^{-1}$) resonances in PFTB (91, 92). Of course, the differences in R$_{1p}$ for different perfluorocarbons cannot be accounted for by considering the F-F distances only; molecular dynamics and CSA contributions play a major role as well.

### 3.3. Paramagnetic contribution of oxygen

The presence of dissolved oxygen affects the chemical shift as well as the relaxation rates of the PFC molecules in their vicinity. The measured paramagnetic chemical shift, $\Delta \sigma_O$, in presence of oxygen results from a Fermi contact interaction between molecular oxygen and PFC nuclei and is given by (86, 93)

$$\Delta \sigma_p = \frac{4Ax_n hS(S+1)\gamma^2 g^2 \beta^2}{g^N \beta^N kT}$$  \hspace{1cm} (13)$$

where $A$ is the hyperfine constant, $x$ is the mole fraction of oxygen, $n_m$ is the number of PFC molecules surrounding an oxygen molecule, $h$ and $k$ are Planck and Boltzmann constants, $\gamma$ is the nuclear gynromagnetic ratio, $g_n\beta_n$ and $g_e\beta_e$ are the electron and nuclear magnetic moments, $S$ is the total electron spin of the paramagnetic species (S = 1 for O$_2$), and $T$ is the absolute temperature. Using eqns. 2 and 13 one could try to measure pO$_2$ from the chemical shift using a predetermined calibration curve. However, $\Delta \sigma_p$ is usually small and is superimposed upon chemical shifts induced by changes in bulk magnetic susceptibility due to the presence of oxygen. Separating the two effects would require the ability to apply $B_0$ perpendicular, as parallel to the sample (93). For in vivo imaging, shimming could also affect the measurement of $\Delta \sigma_p$ and this method has not been used to measure pO$_2$.

The presence of any dissolved oxygen results in a paramagnetic contribution, $R_{1p}$, which is given by (93, 94)

$$R_{1p} = \frac{2S(S+1)\gamma^2 g^2 \beta^2}{15r^B} \left[ \frac{3\tau_e}{1 + \omega_e^2 \tau_e^2} + \frac{7\tau_e}{1 + 9\omega_e^2 \tau_e^2} \right]$$ \hspace{1cm} (14)$$

where $r$ is the distance between the paramagnetic center and the nucleus concerned, $\omega_e$ is the angular frequency of electron resonance, and $\omega_0$ is the angular frequency of nuclear resonance. Here, we ignore the contribution due to contact interaction as oxygen does not form a complex with the PFCs, and hence the hyperfine interaction would be very small. The correlation time for the reorientation of the coupled magnetic moment vectors, $\tau_c$, is given by

$$1/\tau_c = 1/\tau_e + 1/\tau_\rho + 1/\tau_\rho$$ \hspace{1cm} (15)$$

where $\tau_e$ is the electron spin relaxation time, $\tau_\rho$ is the rotational correlation time, and $\tau_\rho$ is the residence time of the paramagnetic species. In the motional narrowing limit, $\omega_0\tau_e << 1$ and $\omega_0\tau_\rho << 1$ so eqn. 11 simplifies to

$$R_{1p} = \frac{8\gamma^2 g^2 \beta^2 \tau_e}{3\rho^6}$$ \hspace{1cm} (16)$$

$R_{1p}$ determines the sensitivity of the PFC spin lattice relaxation rate to the presence of oxygen. PFCs with multiple $^{19}$F atoms (with unique chemical shifts) generally exhibit a different $R_1$ response of each resonance to pO$_2$ (i.e., different slopes on an $R_1$ vs. pO$_2$ graph). These differences are a result of the inverse dependence of $R_{1p}$ on $r^6$ and imply that oxygen has a preferred approach to each PFC molecule. If the average distances between the oxygen molecule and various fluorine atoms in a PFC are different, $R_{1p}$ would be larger for the fluorine nuclei that are closer to the oxygen molecule. Effective spin diffusion within the molecule can lead to the reduction of differences in the slopes. The preferences of the approach of oxygen to different parts of the PFCs are most likely due to steric factors rather than specific binding as formation of complexes or preferential binding would manifest itself as a very high $R_1$ of a particular fluorine atom compared to its neighbors. The oxygen molecule may prefer to approach the ends of the PFCs simply because there is more space available at the ends than in the bridgehead positions or the middle of a chain. This is clearly seen by comparing the slopes of different fluorine atoms of the cis and trans isomers of perfluorodecalin (PFD) (94). In the case of trans-perfluorodecalin, the larger difference in oxygen access to the end chain fluorine atoms compared to bridgehead fluorine atoms leads to a larger variability in the slopes compared to cis-perfluorodecalin. The slope does not vary greatly between terminal CF$_3$ groups of perfluorotributylamine (PFTB), perfluorotripropylamine (PFTP) and perfluoroctyl bromide (PFBO or perfluorobron) (91), and thus, relative pO$_2$ sensitivity of this resonance is determined by R$_{1d}$, which is different in all three cases. The CF$_3$ resonances from these PFCs show high sensitivity to temperature within the temperature range 5-50 °C. The terminal trifluoromethyl groups have greater sensitivity to oxygen and lower sensitivity to temperature (compared to CF$_2$ groups). The CF$_3$ resonance of PFOB exhibits greater sensitivity to pO$_2$ than PFTB or PFTP. Internal motion also aids R$_{1p}$ and hence pO$_2$ sensitivity. For example, the bulky CF$_3$Br group of PFOB is less sensitive to pO$_2$ than the CF$_3$ group on the other end of the molecule.

In general, each contribution (R$_{1d}$ and R$_{1p}$) to R$_1$ is temperature dependent at a given field and exhibits a maximum at a temperature at which the inverse of corresponding correlation time matches the Larmor frequency. The constant $k$, which represents the oxygen solubility of the PFC, is also temperature dependent. On increasing the temperature, oxygen solubility in the PFC decreases and both R$_{1p}$ and R$_{1d}$ decrease for liquids in the motional narrowing regime ($\omega_0\tau_e << 1$). The temperature dependence of these relaxation rates can reveal information of the molecular dynamics that dominate these relaxation processes. In case of both anoxic and oxie PFTB the R$_{1}$ maxima were observed to occur at similar temperatures (91). This implies that in this case the $\tau_c$
determine \( R_{1d} \) and \( R_{1p} \) are approximately equal. Therefore, the residence time of an oxygen molecule near a given PFTB molecule may be comparable to the molecular rotational correlation time of PFTB. This represents a strong influence of residence time on \( R_1 \), possibly as important as the inter-nuclear fluorine-oxygen distance.

### 3.4. Measuring \( pO_2 \)

Although there is no theoretical reason to expect linearity in \( R_{1d} \) and \( R_{1p} \) with temperature, a linear approximation can be made for \( R_{1d} \) and \( R_{1p}/k \) from a purely practical standpoint within the biologically relevant temperature range (e.g., 30-42 °C). If the respective relaxation rate maxima occur in the middle of this range, the slope and intercept may “appear” to be temperature independent. For characterizing the \( pO_2 \) and temperature dependence, the neat PFC or emulsion is typically placed in gas-tight NMR glass tubes, saturated by bubbling for 20-30 minutes with a range of standard gases (e.g., 0%, 5%, 10%, 21% and 100 % \( O_2 \)-balance \( N_2 \)) and sealed. Each sealed tube is inserted in a circulating water bath and the \( T_1 \) is measured as a function of temperature. The data at each temperature is fit to eqn. 3

\[
R_1 \ [s^{-1}] = A' + B' \cdot pO_2 \quad (12)
\]

where \( A' (=R_{1d}) \) and \( B' (=R_{1p}/k) \) are constants at a given temperature. If we assume a linear dependence of \( A' \) and \( B' \) on temperature \( T \), then \( A' = A + C \cdot T \) and \( B' = B + D \cdot T \), giving a temperature-dependent model (95):

\[
R_1 \ [s^{-1}] = A + B \cdot pO_2 + C \cdot T + D \cdot pO_2 \cdot T \quad (13)
\]

where \( A, B, C \) and \( D \) are constants. For PFCs with multiple resonances these constants are usually different for each resonance, discussed earlier. For such PFCs \( pO_2 \) and temperature can be estimated simultaneously by solving two simultaneous equations (corresponding to eqn. 13 for 2 resonances) using the measured values of \( R_1 \) for each resonance (95). In graphical terms, in a 3-dimensional variable space (\( R_1 = f(pO_2, T) \)) the ordinates corresponding to the intersection of \( R_1 \) iso-contours of the two resonances are \( pO_2 \) and \( T \), respectively. Multi resonance PFC spectra can provide multiple estimates of \( pO_2 \), if temperature is known, or \( pO_2 \) and temperature by solving simultaneous equations, as needed.

For imaging, multiple resonances could lead to chemical shift artifacts or reduced signal-to-noise following selective excitation or editing (96, 97). In practice, a PFC such as hexafluorobenzene (HFB) with a single resonance (Figure 1 a, b), high \( pO_2 \) sensitivity and minimal temperature sensitivity is preferable (75). Perfluoro-15-crown-5-ether (15-C-5) also has quite similar characteristics, and shorter absolute \( T_1 \)s making data acquisition potentially faster, but a higher \( R_1 \) sensitivity to temperature and it is less readily available (9, 74). While a smaller \( A' \) value represents greater sensitivity, it also implies that the PFC has longer \( T_1 \) values (smaller \( R_1 \)) under hypoxic conditions, where \( R_1 \) may be close to \( A' \). Indeed, the \( T_1 \) of HFB at 4.7 T may reach 12 s, limiting the current temporal resolution of \( pO_2 \) measurements using HFB to 6 ½ min (98). However, use of echo planar imaging as in the FREDOM (Fluorocarbon Relaxometry using Echo planar imaging for Dynamic Oxygen Mapping) approach allows images, and hence, spatially resolved oxygen distributions to be acquired in the same time as spectroscopy (9). Following a direct intra-tissue injection, dynamic changes in oxygenation in response to hypoxic intervention can be monitored \textit{in vivo} (Figure 2). A further improvement in temporal resolution is possible by using other approaches such as those based on the Look-Locker technique (99, 100). Even then, a complete sampling of the relaxation curve would require at least 1 min (~ 5\* \( T_1 \) for HFB under hypoxic conditions). The slope \( B' \) represents the effect of oxygen and hence a greater slope is desirable for measurement accuracy. A greater slope would result in a wider separation of measured \( T_1 \) values especially at low \( pO_2 \) values. A high slope could result from higher \( R_{1p} \) or a smaller \( k \) (higher \( O_2 \) solubility). From eqn. 2 we can see that for a given \( pO_2 \), a smaller \( k \) reflects a larger \( O_2 \) mole fraction \( x \).

The solubility of oxygen (and gases in general) in perfluorocarbons and hydrofluorocarbons is three to ten times higher than observed in the parent hydrocarbons or in water (101, 102). It was shown that a model of continuous diffusion of oxygen, that accounts for the \( T_1 \) and \( T_2 \) relaxation of benzene, fails in the case of HFB, leading to either impossibly short residence times for oxygen or...
impossibly small distance of closest approach between fluorine and oxygen (93). The presence of the larger fluorine atoms appears to result in the existence of numerous large “vacancies” or “channels” in the liquid “lattice”, which the oxygen molecules occupy successively by random jumps. The oxygen solubility of long chained aliphatic fluorocarbons are observed to be higher than that of cyclic or aromatic fluorocarbons (102), which suggests that aliphatic chains form large channels in the liquid state, which accommodate more oxygen molecules unlike planar aromatic structures that may result in tighter “packing” with smaller vacancies. This exceptionally high solubility motivated the use of perfluorocarbons as blood substitutes for oxygen delivery to tissues (103, 104). Fluosol-DA (Green Cross Corp., Osaka, Japan) a perfluorotripropylamine based emulsion was the first PFC emulsion clinically tested and approved for clinical use as perfusate for percutaneous coronary angioplasty, but was later withdrawn from the market because of low oxygen delivery capacity under physiologic conditions, lack of clear clinical benefit and development of flow-through catheters (105-108). More recently, Oxygent™ (Alliance Corp., San Diego, CA), an emulsion of perfluorooctyl bromide (perfluorobron) with a higher oxygen solubility and improved emulsion stability has been tested in clinical trials (109, 110). In terms of in vivo oximetry, due to their high oxygen solubility and hydrophobicity, PFCs essentially act as molecular amplifiers by displaying extra sensitivity to oxygen and insensitivity to variations in ionic constituents compared to the surrounding tissue water.

19F MR based oximetry has several strengths and a few weaknesses. The nuclear spin ½ 19F nucleus has γ of 40.05 MHz/T (compared to 42.58 MHz/T for 1H) and about 83% NMR sensitivity compared to 1H. It is 100 % abundant (isotopically) and the amount of endogenous fluorine in the body is very small (mostly present in form of solid fluorides in bones and teeth). Due to a very short T2 relaxation time, the NMR signal from endogenous fluorine is undetectable in most biological systems. Given the absence of background signals, the exogenously administered PFC is readily observed. 19F MR oximetry has been used as a research tool for many years (9, 74, 75, 84, 85, 98, 111-136). However, to date the method has not been translated to the routine clinical setting, since most clinical MRI scanners lack a 19F capability. PFCs have been observed in patients following administration as adjuvant to radiotherapy and as residues in the eye, where they are used as tamponades during retinal surgery (127, 137, 138). A 1H pO2 reporter molecule could have greater immediate applicability and higher potential for clinical translation.

3.5. New development: 1H MRI based oximetry using hexamethyldisiloxane

The 1H R1 of tissue water has been shown to be sensitive to tissue oxygenation (139), but many other factors like metal ions, cellularity, pH, ionic strength can also affect relaxation of tissue water. This makes quantitative measurements impossible except in tissues such as the vitreous humor in the eye and cerebrospinal fluid, where ionic and protein content is low or known and constant (140-143). Even then, R1 sensitivity to oxygen is low (B' = 0.0002 s⁻¹/torr) and to temperature is high. We have recently identified hexamethyldisiloxane (HMDSO, Figure 3) as a 1H NMR probe of pO2 (analogous to PFCs) and shown the feasibility of tissue oximetry using 1H-NMR spectroscopic relaxometry (83). We have also implemented
an imaging based method: Proton Imaging of Silanes to map Tissue Oxygenation Levels (PISTOL) for spatial mapping of \( pO_2 \) (144).

HMDSO is a symmetric molecule with a single NMR signal close to that of the chemical shift standard tetramethylsilane (TMS) (83). It is therefore well separated from water and reasonably separated from fat. HMDSO has many characteristics similar to PFCs: it is a highly hydrophobic mobile liquid, non-toxic, with high gas solubility and is readily available and cheap. At a given temperature, \( R_1 \) of HMDSO showed a linear dependence on \( pO_2 \) with constants \( A' = 0.1126 \pm 0.0010 \, [s^{-1}] \) and \( B' = 0.00130 \pm 0.00002 \, [(torr*s)^{-1}] \) at 37 \( ^\circ \)C. The \( T_1 \) values range from 8.7 s \( (pO_2 = 0 \, torr) \) to 1 s \( (pO_2 = 760 \, torr) \) at 37 \( ^\circ \)C. A small temperature dependence was observed in the temperature range 26-46 \( ^\circ \)C. Fitting the calibration data to the temperature–dependant model (eqn. 13) yielded constants \( A = 0.1479 \pm 0.0028 \, s^{-1}, B = (1.79 \pm 0.05) \times 10^{-3} \, (s \, torr)^{-1}, C = (-9.57 \pm 0.81) \times 10^{-5} \, (s \, ^\circ \text{C})^{-1}, \) and \( D = (-1.23 \pm 0.13) \times 10^{-5} \, (s \, ^\circ \text{C})^{-1}. \) In this temperature range, linear approximation resulted in errors < 3%. The \( pO_2 \) and temperature sensitivities of HMDSO are similar to 15-C-5.

Using a spectroscopic approach, \( pO_2 \) was measured in rat thigh muscle and Dunning prostate R3327 AT1 adenocarcinomas in response to an oxygen challenge (83). Changes in relaxation times in response to hyperoxia and differential response in tumor versus healthy thigh muscle can be easily seen from the HMDSO magnetization recovery curves (Figure 4). Clearance of HMDSO from muscle was seen to be slow with a half-life \( \sim 35 \) h, so that minimal change would be observed during typical MR studies of oxygen dynamics in response to acute interventions. HMDSO is quite inert and it has been reported that no treatment-related signs of toxicity or mortality or other statistically significant deleterious effects were noted in studies where Fisher rats were exposed to up to 6000 ppm HMDSO by inhalation (145, 146).

Like PFCs, HMDSO is lipophilic and is essentially immiscible in aqueous solutions. The boiling point and hydrophobicity of HMDSO suggest that it could be emulsified for intravenous delivery, as popular for several PFCs (147) and such an attempt is currently underway. HMDSO is readily and cheaply available from many commercial vendors and easy to store. One key difference in this \(^1\text{H}\) MR approach compared to \(^{19}\text{F}\) oximetry is the need to effectively suppress water and fat signals and perform relaxometry on the silane signal. In PISTOL, we have developed an effective approach using a combination of frequency selective excitation of the silane resonance and CHESS (148) suppression of the water and fat resonances is used followed by EPI detection for measuring \( T_1 \) values (144). As with HFB, ARDVARC (Alternating Relaxation Delays with Variable Acquisitions for Reduction of Clearance effects) protocol (98) is used in conjunction with this sequence to obtain \( T_1 \) values.

Figure 3. Structure of hexamethyldisiloxane (HMDSO).

Figure 4. Dynamic \(^1\text{H}\) oximetry. HMDSO magnetization recovery curves in vivo in response to hyperoxic challenge following direct intra-tissue injection of HMDSO (50 µl) at discrete locations. Chemical shift selective spectroscopy with suppression of fat and water signals permitted relaxometry of HMDSO. On switching breathing gas from air (●) to oxygen for 30 min (●) a larger change in \( T_1 \) (corresponding to a larger change in \( pO_2 \)) is observed in thigh muscle (a) compared to AT1 prostate tumor (b) which is reversed in both cases by switching back to air breathing (□).
MR Oximetry

4. PERSPECTIVE AND CONCLUSION

An important advantage of MR oximetry compared to hypoxia imaging using nuclear and optical imaging agents is that one can quantitatively measure tissue pO2 as opposed to qualitatively labeling hypoxic regions. Thus issues such as hypoxia specificity, oxygen dependency of agent binding and clearance of unbound agents do not come into play and affect interpretation. Dynamic measurements with transient interventions such as hyperoxia (9) or acute effects of vascular targeting (149) are not possible with nuclear and optical techniques. Optical imaging methods to image hypoxia to date rely on transfection to express bioluminescent (45, 47) or fluorescent proteins (44, 46) and are thus inappropriate for clinical application. In any case light penetration in tissue would be a problem for human use.

MR oximetry has found extensive use in pre clinical studies because it provides essentially unique insight into tissue oxygenation- specifically spatial and temporal resolution revealing heterogeneity and dynamic response to intervention. Moreover, precision achieved is appropriate for radiobiological studies of tumors. To date 19F NMR approaches have been used to examine vascular oxygenation following i.v. administration of PFC emulsion or tissue oxygenation following vascular clearance and sequestration in tissue. However, accumulation occurs predominantly in tumor periphery biasing measurements towards well-perfused regions. Moreover, there is substantial uptake by the reticuloendothelial system (RES). While this allows effective measurements of pO2 in liver, spleen and bone marrow, it is less satisfactory for oncological investigations. An alternate approach is direct injection of the reporter molecule into the tissue of interest. The possibility of targeting emulsion to specific antigens such fibrin for cardiovascular imaging opens further possibilities (150).

The development of PISTOL, a quantitative 1H MR method for dynamic imaging of pO2 opens further opportunities for in vivo studies. This method has a high potential of translation to the clinical setting. With current state-of-the-art MR hardware, it would be easy to generate effective water and fat suppression needed for PISTOL as used in detection of metabolites by Magnetic Resonance Spectroscopy (MRS). In both the research and clinical setting, it will now be possible to add quantitative oximetry to a protocol consisting of other 1H-MR based functional techniques such as dynamic contrast enhancement, diffusion measurements, and MRS, but the minimal invasiveness of the technique has to be taken into account. Development of targeted nano-emulsions for intravenous delivery might help circumvent the need for direct intratissue injections, if high targeting specificity is achieved. Other 1H pO2 reporter molecules could be identified or synthesized, which could have higher oxygen sensitivity than HMDSO. We foresee MR oximetry as a valuable tool for assessing tissue oxygenation status in various disease states, helping to evaluate the acute and chronic response of therapeutic interventions and aiding in the screening of new drugs, such as vascular targeting and anti angiogenic agents which can perturb tissue oxygenation.

5. ACKNOWLEDGMENTS

Investigations discussed here have been supported by the Texas Affiliate of the American Heart Association, the Whitaker Foundation, the American Cancer Society, the Department of Defense Breast and Prostate Cancer Initiatives and the National Institute of Health. Most recent funding is from the NCI SAIRP U24 CA126608 and the work in Figure 2 was supported by the Foundation for Anesthesia Education and Research.

6. REFERENCES

39. Lewis, J. S., D. W. McCarthy, T. J. McCarthy, Y. Fujibayashi & M. J. Welch: Evaluation of 64Cu-ATSM in...


130. Mattrey, R. F., D. J. Schumacher, H. T. Tran, Q. Guo & R. B. Buxton: The use of Imagent BP in diagnostic imaging research and 19F magnetic resonance for PO2


Key Words: Oximetry, hypoxia, perfluorocarbons, MRI, $^{19}$F, hexamethyldisiloxane, Review

Send correspondence to: Vikram Kodibagkar, Ph.D., Assistant Professor of Radiology, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9058, Tel: 214-648-7612, Fax: 214-648-4538, E-mail: vikram.kodibagkar@utsouthwestern.edu

http://www.bioscience.org/current/vol13.htm
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine

Marc Jennewein\textsuperscript{1,2}, Matthew A. Lewis\textsuperscript{2,3}, Dawen Zhao\textsuperscript{2}, Edward Tsyganov\textsuperscript{2}, Nikolai Slavine\textsuperscript{2}, Jin He\textsuperscript{3,5}, Linda Watkins\textsuperscript{3,5}, Vikram D. Kodibagkar\textsuperscript{2}, Sean O’Kelly\textsuperscript{6}, Padmakar Kulkarni\textsuperscript{2}, Peter P. Antich\textsuperscript{2}, Alex Hermanne\textsuperscript{4}, Frank Rösch\textsuperscript{1}, Ralph P. Mason\textsuperscript{2,3} and Philip E. Thorpe\textsuperscript{3,5}

\textsuperscript{1}Institute of Nuclear Chemistry, Johannes Gutenberg-University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany
\textsuperscript{2}Cancer Imaging Program, Department of Radiology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
\textsuperscript{3}Simmons Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
\textsuperscript{4}VUB Cyclotron, University of Brussels, Laarbeeklaan 103, 1090 Brussels, Belgium
\textsuperscript{5}Department of Pharmacology and Hamon Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
\textsuperscript{6}Department of Nuclear Engineering, University of Texas at Austin, Pickle Research Campus, Austin, Texas, USA

Running title: Vascular imaging with arsenic-labeled antibody
Key words: tumor microcirculation and microenvironment, new targets, phosphatidylserine, radioactive arsenic, PET

This work was conducted with the support of a grant from the Gillson Longenbaugh Foundation, an NCI SPORE grant in lung cancer research (CA70907), a sponsored research agreement with Peregrine Pharmaceuticals Inc (Tustin, CA), the Boehringer Ingelheim Fonds for Basic Research in Biomedicine, the Deutsche Forschungsgemeinschaft (DFG-Grant Ro 985/17), the NoE ‘European Molecular Imaging Laboratories: EMIL’, DOD Prostate IDEA awards PC050766 (W81XWH-06-1-0149) and PC050301 (W81XWH-06-1-0050), the NCI Pre-ICMIC P20 CA086334 and SAIRP U24 CA126608. MRI was performed at the AIRC an NIH BTRP Facility P41-RR02584.

Address correspondence to: Philip E. Thorpe, Department of Pharmacology and Simmons and Hamon Cancer Centers, University of Texas Southwestern Medical Center at Dallas, 2201 Inwood Road NC7.304, Dallas, Texas 75390-8794, USA. Phone: (214) 648-1499; Fax: (214) 648-1613; E-mail: Philip.Thorpe@utsouthwestern.edu

Abbreviations: (FBS) fetal bovine serum; (MRI) magnetic resonance imaging; (nca) no-carrier-added; (PBS) phosphate buffered saline; (PET) positron emission tomography; (PS) phosphatidylserine; (ROI) region of interest; (T½) half life.
ABSTRACT

Purpose: We recently reported that anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of vascular endothelial cells in tumors, probably in response to oxidative stresses present in the tumor microenvironment. In the present study, we tested the hypothesis that a chimeric monoclonal antibody that binds phosphatidylserine could be labeled with radioactive arsenic isotopes and used for molecular imaging of solid tumors in rats.

Experimental Design: Babivuximab was labeled with $^{74}$As ($\beta^+$, T½ 17.8d) or $^{77}$As ($\beta^-$, T½ 1.6d) using a novel procedure. The radionuclides of arsenic were selected because their long half-lives are consistent with the long biological half lives of antibodies in vivo and because their chemistry permits stable attachment to antibodies. The radiolabeled antibodies were tested for the ability to image subcutaneous Dunning prostate R3227–AT1 tumors in rats. Results: Clear images of the tumors were obtained using planar $\gamma$-scintigraphy and positron emission tomography (PET). Biodistribution studies confirmed the specific localization of babivuximab to the tumors. The tumor to liver ratio 72 h after injection was 22 for babivuximab as compared with 1.5 for an isotype-matched control chimeric antibody of irrelevant specificity. Immunohistochemical studies showed that the babivuximab was labeling the tumor vascular endothelium. Conclusions: These results demonstrate that radioarsenic labeled babivuximab has potential as a new tool for imaging the vasculature of solid tumors.
INTRODUCTION

Imaging offers non-invasive perspective on tumor development and therapy, providing information on receptor expression, targeting, and drug pharmacokinetics. Imaging technologies include PET, SPECT, MRI, ultrasound and optical imaging, as reviewed extensively elsewhere (1, 2). Nuclear medicine approaches are particularly relevant, since extremely low concentrations of tracer/reporter are permissible. Several radionuclides are in clinical use and many more are under development (3-5). However, many isotopes decay rapidly limiting shelf life and preventing investigation of long term biological phenomena. A particular problem arises with antibodies, which usually have a long biological half life and not reach optimal target to background selectivity for several days. For PET, common radionuclides such as $^{64}$Cu (18% $\beta^+$ positron branching, T½ 12.7 h) or $^{86}$Y (32% $\beta^+$, T½ 17.8 h) have too short half-lives for following antibody localization, while $^{124}$I (24% $\beta^+$, T½ 4.18 d) has a suitable T½, but undergoes metabolic dehalogenation and release of iodine.

Arsenic radioisotopes include long lived positron emitters having favorable characteristics for PET: $^{71}$As (T½ 64 h, 30% $\beta^+$, 104 keV average kinetic energy of the positrons), $^{72}$As (T½ 26 h, 88% $\beta^+$, 1024 keV) and $^{74}$As (T½ 17.8 d, 29% $\beta^+$, 128 keV). Other arsenic isotopes are high energy $\beta^-$ emitters that could potentially be used for tumor therapy: $^{77}$As (T½ 38.8 h, $E_{\beta^-}$ 226 keV) and $^{76}$As (T½ 26.3 h, $E_{\beta^-}$ 1068 keV). The decay characteristics of the arsenic isotopes that are most relevant for imaging or therapy are presented as supplementary information in the Table. $^{74}$As was used in some of the earliest radionuclide imaging studies for the development of PET, at that time called positrocephalography (6). However, inefficient isotope production, difficulty in isolating pure nuclides, and lack of effective derivatization processes handicapped
the exploitation of arsenic isotopes. Radiochemistry has now evolved and several isolation procedures for arsenic isotopes have been reported. Most recently, Jennewein and Rösch developed efficient methods for isolating pure radionuclides from irradiated GeO₂ targets on the basis of a solid phase extraction system (7, 8). Moreover, Jennewein and Rösch proposed chemistry for the effective labeling of biologically relevant molecules, as we have now exploited.

Bavituximab, a chimeric antibody targeting exposed vascular phosphatidylserine (PS), was chosen to develop the labeling procedure and demonstrate the first in vivo use of arsenic isotopes for PET imaging of solid tumors. Bavituximab binds to PS by stabilizing a complex of two β2-glycoprotein I molecules attached to PS on the cell surface (9-12). PS is normally tightly segregated to the internal surface of the plasma membrane in most cell types, including the vascular endothelium (10, 11, 13, 14). PS asymmetry is maintained by an ATP-dependent aminophospholipid translocase (a Mg²⁺-ATPase) that catalyzes the transport of aminophospholipids from the external to the internal leaflet of the plasma membrane (15). Loss of PS asymmetry occurs during apoptosis (16), necrosis (17), cell activation (18) and transformation (19), resulting in the exposure of PS on the external surface of the cells. PS exposure occurs when the aminophospholipid translocase becomes inhibited (20) or when transporters such as scramblase (21) and the floppases (22) become activated by Ca²⁺ fluxes into the cytosol (23, 24).

We previously demonstrated that anionic phospholipids become exposed on the vascular endothelium of blood vessels in mice bearing various types of solid tumors probably in response to oxidizing stresses in the tumor (10, 11). There was no detectable exposure on vascular endothelium in normal tissues including the ovary, a site of physiological angiogenesis, and the
pancreas, a site of high vascular permeability. PS is one of the most specific markers of tumor vasculature yet discovered. The murine version of bavituximab, 3G4, retards tumor growth in multiple rodent models, by stimulating host cells to bind to, and destroy tumor blood vessels. Bavituximab is currently in Phase I clinical trials in patients with various solid tumors†. Despite its proven ability to target tumor endothelium, bavituximab has not yet been explored as an imaging agent. The vascular location of PS ensures ready access by radiolabeled antibody in the blood. Imaging techniques could not only enable the detection of tumors and their metastases, but also verify the presence of antigen before bavituximab therapy.

In the present study, we tested the hypothesis that bavituximab can be labeled with radioactive arsenic isotopes and used for vascular targeting and molecular imaging of solid tumors in rats. Doses of bavituximab were used that are ten-fold below the doses that have significant vascular damaging activity (14) in order to prevent occlusion of tumor vasculature from impeding effective imaging. Clear tumor imaging was obtained by planar $\gamma$-scintigraphy and PET.

MATERIALS AND METHODS

Antibodies. Bavituximab was provided by Peregrine Pharmaceuticals Inc. (Tustin, CA). Bavituximab is a chimeric antibody composed of the Fv regions of the mouse antibody 3G4 (14) and the constant regions of human IgG1. Bavituximab binds to PS through a cofactor protein, $\beta$2-glycoprotein I. Bavituximab recognizes rat $\beta$2-glycoprotein I as strongly as it does human $\beta$2-glycoprotein I, avoiding the need for supplementation with exogenous human $\beta$2-glycoprotein I

† Peregrine Pharmaceuticals Inc. See: http://www.clinicaltrials.gov/ct/show/nct00129337
which is necessary in the mouse (14). Bavituximab binds to human β2-glycoprotein I with an affinity of $1.7 \times 10^{-8}$ M (monovalent interaction) and an avidity of approximately $10^{-10}$ M (divalent interaction) in Biacore experiments.

Hamster anti-mouse CD31 monoclonal antibody was from BD Pharmingen (San Diego, CA). Secondary antibodies were from Jackson Immunoresearch Labs (West Grove, PA). Rituximab (Monoclonal antibody Therac®, CD20) was purchased from Roche.

**Isotopes.** \(^{74}\)As for PET imaging was produced by \(^{nat}\)Ge(p,x)\(^{74}\)As reaction \([E_p= 20 \text{ MeV}, 3 \text{ h irradiation at } 15 \mu\text{A}]\) giving a yield of about 370 MBq. \(^{77}\)As for scintigraphy was produced in a no-carrier-added (nca) state via the \(^{76}\)Ge(n,γ)\(^{77}\)Ge, \(T\frac{1}{2} 11.30 \text{ h } \beta^- \rightarrow \gamma \rightarrow \gamma \) processes in a TRIGA reactor \((\Phi = 4.0 \cdot 10^{13} \text{ n/cm}^2\cdot\text{s})\).

**Radiochemical separations.** Nuclear reactions were typically performed on 100 mg of \(^{nat}\)GeO\(_2\) (99.9999 % grade, PURA TREM, Strem Chemicals Inc.). Irradiated germanium oxide targets were dissolved in 5 ml HF\(_{\text{conc.}}\) and extracted, as described in detail previously (7) providing nca \([^{*}\text{As}]\text{AsI}_3\) fixed to the solid phase of the extraction cartridge (Varian BOND ELUT ENV solid phase extraction cartridges with a sorbent mass of 50 mg and a volume of 1 ml). Excess HF\(_{\text{conc.}}\) was removed with a high pressure nitrogen-flow over the cartridge for 5 min. When required for labeling, nca \([^{*}\text{As}]\text{AsI}_3\) was eluted with 500 µl ethanol and concentrated to 50 µl under a gentle \(N_2\)-flow. The radioarsenic separation yield and efficacy of nca \([^{*}\text{As}]\text{AsI}_3\) was >90%. 
Antibody conjugation and testing. Antibodies were SATA-modified according to the protocol of Pierce Endogen (25). Deprotection of the sulphydryl groups of the monoclonal antibody derivative using hydroxylamine was performed directly before the labeling. The number of free thiol groups per antibody molecule was measured using Ellman’s reagent and by comparison with cysteine based standards. Thiolated antibody (100 µg) in PBS (3 ml, pH = 7.5) was combined with the nca [*As]AsI₃ solution at 37°C for 30 min. [*As]AsI₃ couples to one SH functionality with elimination of HI, as illustrated in Fig. 1. Quality control of the antibody labeling was performed by HPLC, using an Agilent 1100 Series HPLC system, with an LDC/Milton Roy UV-Monitor III at 254 nm and a ‘Gabi’ NaI-radiation Monitor from Raytest. The HPLC column was a Bio-Silect Sec 250-5, 300x7.8 mm and PBS + 0.01 M NaN₃ was used as solvent at a flow of 0.8 ml/min. Retention time of the *As[SATA] labeled antibodies was 11.5±0.5 min. To keep the thiols from forming disulfide bridges, all solutions were kept out of contact with air and contained 1 mM EDTA.

In vitro stability. The radioarsenic-labeled bavituximab was tested for possible transfer of radioarsenic to proteins present in blood plasma. This was done by incubating the labeled antibody in fetal bovine serum (FBS) and examining the mixture by HPLC at various time points up to 72 h. Radioarsenic labeled bavituximab (10 µg) in PBS (50 µl) was added to undiluted FBS (500 µl) and incubated at 37°C. Samples (50 µl) were taken at 30 min, 24, 48, and 72 h, diluted with 200 µl water, and examined by HPLC.

Binding of bavituximab antibody to plastic-immobilized phospholipids. Phospholipids were dissolved in n-hexane to a concentration of 50 µg/ml. 100 µl of this solution was added to wells
of 96-well microtiter plates. After evaporation of the solvent in air, the plates were blocked for 2 h with 1% BSA diluted in PBS (binding buffer). Bavitu

ximab was diluted in the binding buffer containing 10% FBS at an initial concentration of 33 nM. Serial two-fold dilutions were prepared in the plates (100 µl per well). The plates were then incubated for 1 h at room temperature. After washing with PBS, HRP goat anti-human IgG (diluted 1:2000) was used to detect bavituximab. Secondary reagents were detected by using chromogenic substrate o-phenyldiamine followed by reading plates at 490 nm using a microplate reader (Molecular Devices, Palo Alto, CA). Binding of \[^{77}\text{As}\]-bavituximab to PS-coated plates was determined using unmodified bavituximab as the positive control and \[^{77}\text{As}\]-rituximab as the negative control. The concentrations of \[^{77}\text{As}\]-bavituximab and unmodified bavituximab that gave half-maximal binding were determined. Since the association rate of bavituximab with PS on the plate is rapid and its dissociation is negligible over the time course of the experiment, the half-maximal binding concentrations allow the antigen-binding capacities of the labeled and unmodified antibodies to be compared under conditions that approximate equilibrium.

**Growth of tumors.** All experiments were conducted in accordance with recommendations of the UTSW Institutional Animal Care and Use Committee. A Dunning prostate R3327-AT1 tumor (originally provided by Dr. Peter Peschke, German Cancer Center, Heidelberg, Germany) was excised from a donor animal (26, 27). Small pieces were implanted subcutaneously into the left thigh of male Copenhagen rats (Charles River, Wilmington, MA) and allowed to grow to a size of 15-25 mm diameter.
**Biodistribution and planar imaging studies.** Three animals each were injected with $[^{74}\text{As}]$-bavituximab or with $[^{74}\text{As}]$-rituximab in PBS (5 MBq in 500 µl) into a tail vein. The animals were sedated using isoflurane (Baxter Healthcare) and imaged on a 25.2 x 30.3 cm phosphor imaging plate (Fuji CR ST-VN, Fuji Photo Film, Tokyo). The photostimulable plates were read on a Molecular Dynamics Storm (Amersham Biosciences) scanner and regions of interest drawn around the tumors and upper body for quantification. In a second study, four animals were injected with 3 MBq of $[^{77}\text{As}]$-bavituximab or $[^{77}\text{As}]$-rituximab were imaged at 48 and 72 h using a 30 min exposure time. Prior studies have established that $[^{74}\text{As}]$-bavituximab and $[^{77}\text{As}]$-bavituximab have identical pharmacological parameters, *i.e.* independent of the isotope of arsenic. In a further study, rats were injected with 3 MBq of $[^{77}\text{As}]$-bavituximab or $[^{77}\text{As}]$-rituximab and were sacrificed without exsanguination 48 or 72 h later. Tumors were excised, frozen and 1mm sections were cut. Tumor sections were autoradiographed with exposure times of 12 h for $[^{77}\text{As}]$-bavituximab and 48 h for $[^{77}\text{As}]$-rituximab to visualize the distribution of radioactivity within the tumors.

**PET studies.** Four animals each were injected with 10 MBq of $[^{74}\text{As}]$-bavituximab or $[^{74}\text{As}]$-rituximab in 500 µl of PBS (pH 7.4, 1 mM EDTA) via a tail vein. The animals were anesthetized with isoflurane and imaged over 2 h after 24, 48, and 72 h using a small animal PET system built at UT Southwestern (28, 29). The images were reconstructed using the maximum Likelihood - Expectation Maximization (ML-EM) algorithm for 3D reconstruction (28) After 72 h, the animals were sacrificed by exsanguination and perfusion via cardiac puncture under general anesthesia and major organs and tumors were collected and their radioactivity measured in a gamma counter.
MRI. T1 weighed spin-echo MR images were obtained from rats with size matched tumors for anatomical comparison. The images were acquired with TR/TE = 450 ms/14 ms. The acquisition matrix was 128x256 zero-filled to 512x1024 with field of view 10 x 20 cm and a slice thickness of 1 mm

Detection of localized bavituximab in tumor bearing rats in vivo. Groups of two male Copenhagen rats (200 g weight) bearing AT1 tumors (s.c., 15 mm diameter) were injected i.v. with 1 mg bavituximab or control antibody (rituximab). Twenty four h later, rats were anesthetized and their blood circulation was perfused with heparinized saline to clear it of free antibody, as described above. Organs and tumors were removed and snap-frozen for preparation of cryosections. Sections were fixed with 4% paraformaldehyde in PBS and blocked with PBS containing 1% BSA. To prevent loss of phospholipids during slide processing, detergents and organic solvents were omitted from blocking and washing buffers. Chimeric IgG was detected using biotinylated goat anti-human IgG followed by Cy2-streptavidin. Vascular endothelium was detected by mouse anti-rat CD31 antibody followed by Cy3-goat anti-mouse antibody (minimally reactive with rat serum). Tumor sections derived from rats injected with rituximab served as negative controls. Single images, taken with appropriate filters for Cy2 (green) and Cy3 (red) fluorescence, respectively, were captured by digital camera and transferred to a computer. Images of 10 random fields (0.317 mm²/field) were merged with the aid of Metaview software. When bavituximab was bound to tumor endothelium, the green and red fluorescence often merged to give a yellow color. The percentage of vessels with localized bavituximab was calculated.
RESULTS

$^{74}\text{As}$ and $^{77}\text{As}$ were produced, radiochemically separated, and transformed into the labeling synthon $^{*}\text{AsI}_3$. Isotopes were chosen depending on the goal of each study, so that $^{74}\text{As}$ was used for ex vivo organ distribution, whole body planar imaging (in vivo and ex vivo), and in vivo PET imaging. $^{77}\text{As}$ was used to develop the radiochemistry and labeling procedures and used to label bavituximab for whole body planar imaging in vivo and biodistribution.

Bavituximab was modified with SATA to introduce an average of 3.5 free thiol groups per molecule of antibody (Fig. 1a). Arsenic has a high affinity for sulfur and $\text{AsI}_3$ is able to bind covalently to sulphydryl groups (7). $^{*}\text{AsI}_3$ conjugation to the SATA-modified antibodies was achieved quantitatively (Fig. 1b). The specific activity of the $[^{\ast}\text{As}]-$labeled antibodies was $> 100$ GBq / µmol. Incubation in serum for up to 72 h did not cause release of radioarsenic from the labeled monoclonal antibody or formation of antibody fragments (Fig. 1c). Complexes of bavituximab and $\beta_2$-glycoprotein I were not observed, probably because the complex is not stable in the absence of an anionic phospholipid surface upon which to dimerize. Immunoreactivity of the labeled bavituximab was verified by ELISA. Little or no loss of PS-binding activity was observed after SATA-modification and subsequent labeling with nca $[^{77}\text{As}]\text{AsI}_3$ (Fig. 1d). The concentration of $[^{77}\text{As}]-$bavituximab giving half-maximal binding was less than twice that for unmodified bavituximab, indicating that the labeling procedure had caused no more than a two-fold reduction in the antigen binding capacity of the antibody.

Rats bearing Dunning R3227-ATI prostate tumors of approximately 15 mm diameter were injected i.v. with $[^{74}\text{As}]-$bavituximab or with the isotype-matched control antibody, $[^{74}\text{As}]$-rituximab. The radioactivity present in various organs was measured 48 and 72 h after injection.
These time points were selected because they gave good tumor localization in the imaging studies below. Tumor to normal tissue ratios were highest for bavituximab at 72 h after injection, consistent with the imaging results. Tumor to liver and tumor to muscle ratios at 72 h were 22 and 470, respectively (Fig. 2a and b). Bavituximab localized to tumors to a greater extent than did the control antibody, rituximab. The ratios of bavituximab to rituximab were 28 and 52 at 48 h and 72 h, respectively (Fig. 2c). The percentage of the injected dose per gram of tumor was 0.25 and 0.65 for $^{74}$As]-bavituximab at 48 and 72 h, respectively. This level of localization is respectable given the inverse relationship between animal weight and %ID/gram in different species. Significant uptake of radioactivity was observed in the stomach 48 h after injection of $^{74}$As]-bavituximab, but had decreased by 72 h. In most organs (heart, liver, kidney, muscle, bone), the two antibodies showed similar low uptake. Uptake of $^{74}$As]-labeled bavituximab and rituximab was observed in the spleen.

Fig. 3a shows the whole body scintigraphy of a representative rat imaged at 72 h after injection with $^{74}$As]-bavituximab. Fig. 3b compares the radioactivity in the tumor to that in the upper organs (liver, lung, heart) at various time points after injection of $^{74}$As]-bavituximab. At 24 h, the tumor was barely distinguishable because of the high body background. At 48 h, the tumor was clearly localized, but some signal attributable to blood pool was observed in the upper organs. At 72 h, labeled bavituximab had substantially cleared from the blood and antibody localization to the tumor was most visible. Thereafter, tumor to background ratios declined. Images are also shown for rats injected with $^{77}$As]-bavituximab or $^{77}$As]-rituximab (Fig. 3c and d) and imaged 72 h after injection. Relatively little $^{77}$As]-rituximab (about one-eighth as much) localized to the tumor as compared with $^{77}$As]-bavituximab, showing that the localization of $^{77}$As]-bavituximab was antigen-specific.
Distribution of radioactivity within the tumor was heterogeneous. Slices of tumors were examined by autoradiography (Fig 4). Extensive localization of $^{77}\text{As}$-bavituximab was observed in the tumor periphery and throughout the central regions, though quite heterogeneously. For rituximab, activity was limited to the tumor periphery. PET images from a 3D data set of a tumor-bearing rat obtained 48 h after injection of $^{74}\text{As}$-bavituximab again showed strong localization to the tumor periphery with similar heterogeneity of activity in central regions (Fig. 5).

Frozen sections of tumor and normal tissues were stained for the presence of human immunoglobulin to identify the cells to which the bavituximab had localized. Sections were counterstained with anti-rat CD31 to detect vascular endothelium (Fig. 6). The images were merged. Coincidence of staining between localized bavituximab and CD31 indicated specific localization of bavituximab to tumor endothelium. (Fig. 6). Coincident staining appeared yellow, unless dominated by a particularly intense green or red fluorescence in that region. Labeled vessels were visible in all regions of the tumors with an average of $40 \pm 10\%$ labeled vessels. Labeled vessels were particularly abundant in and around regions of necrosis. Larger vessels sometimes had regions where the vascular endothelium was positive for localized bavituximab and other regions where it was not, showing heterogeneity of PS exposure within a single vessel. Regions where bavituximab had leaked into the tumor interstitium were also visible around the endothelium of some vessels. Non-vascular staining of dead and dying tumor cells in and around necrotic tumor regions was only occasionally observed. The antigen specificity of bavituximab localization to vessels was confirmed by the lack of endothelial cell staining in tumors from rats injected with rituximab. Localization of bavituximab to vascular endothelium in normal tissues was not detectable in rat heart, lung, liver, pancreas, kidney, spleen, brain, and testis.
DISCUSSION

This study demonstrates the feasibility of using arsenic radioisotopes to label a monoclonal antibody directed against anionic phospholipids on the surface of tumor vascular endothelium. Tumor selective targeting was observed in vivo and confirmed by biodistribution analysis and histology.

The two isotopes we selected for the present studies were $^{74}$As, a potential clinical PET imaging isotope, and $^{77}$As, a potential therapeutic isotope. $^{74}$As ($\beta^+$, T½ 17.8 d) has a long half life that allows imaging several days after administration of labeled antibody. Optimal tumor imaging in humans is often achieved three or more days after administration of a labeled antibody, when the levels of free antibody have declined relative to those specifically bound or retained by the tumor (30, 31). $^{77}$As ($\beta^-$, T½ 38.8) has a high energy $\beta^-$ emission suitable for anti-tumor therapy. Both isotopes, like other isotopes of arsenic, can be attached through stable covalent linkages to antibodies. In addition, arsenic does not accumulate in the thyroid or undergo transchelation to metal-binding blood and tissue proteins.

Jennewein and Rösch have developed efficient methods for isolating arsenic from irradiated germanium oxide targets to provide arsenic in a form that is useful for labeling sensitive biomolecules (7, 8). They have also developed novel methods for linking arsenic to biomolecules. Here, we demonstrate that monoclonal antibodies can be labeled efficiently with $^{74}$As or $^{77}$As to produce radioimmunoconjugates having full antigen-binding activity and high in vitro and in vivo stability. [*As]-bavituximab was stable for several days when incubated in serum. Very little non-specific uptake of radioactivity by the liver was seen in rats injected with [*As]-bavituximab or [*As]-rituximab, indicating that the labeled antibodies have high in vivo
stability and that transfer of *As to serum proteins and uptake by the liver is minimal. This contrasts with the use of radioiodine for antibody labeling, where dehalogenation and high thyroid uptake are considerable. Instability is less of a problem for antibodies labeled with metal ions (e.g. $^{64}$Cu) since the advent of improved chelating agents.

Biodistribution studies showed high selectivity of bavituximab toward tumor tissue. Within 48 h, the tumor to muscle ratio approached 10 and reached almost 500 by 72 h (Fig. 2). The tumor to liver ratio exceeded 20 by 72 h. $^{74}$As]-bavituximab showed 30 to 50-fold higher absolute uptake in tumor than did the control antibody, $^{74}$As]-rituximab. The ex vivo biodistribution matches the tumor uptake observed by imaging, with higher localization of bavituximab being seen in the tumor than in any normal tissues. Both *As-labeled bavituximab and rituximab accumulated in the spleen, possibly due to non-specific capture of immunoglobulin or metabolites by the reticuloendothelial system. We did not observe preferential accumulation of [*As]-bavituximab in the liver or spleen, which would be expected if bavituximab bound to PS-expressing blood cells being cleared by these organs.

The PET and planar scintigraphy studies showed pronounced localization of bavituximab to solid Dunning prostate R3227-AT1 tumors. Localization was seen in the periphery of the tumor and in various central regions, in agreement with prior PET studies with FDG or perfusion MRI (32-34). We have previously observed that PS positive vessels are present in both the periphery and the core of tumors. It is likely that the peripheral location of the radioactivity seen with [*As]-bavituximab in the present study is because this is the region of tumors that typically has the most abundant and functional blood supply. Some of the bavituximab was probably free in the blood of peripheral vessels, or had diffused into peripheral tumor regions, because a similar peripheral distribution was seen with the non-binding rituximab control antibody.
Heterogeneous localization of bavituximab was also observed throughout the central regions of the tumor. This central localization was antigen-specific since relatively little localization was seen in central tumor regions with the rituximab control antibody. Immunohistochemical examination confirmed that the bavituximab was bound to the endothelium of the central tumor regions with little staining of necrotic regions being visible. The heterogeneous staining with bavituximab is probably because some tumor regions have more hypoxia, acidity or inflammatory cytokines than others, leading to variable levels of PS exposure on the tumor endothelium. We have previously examined multiple different types of mouse and human tumors growing in mice and all have PS-expressing tumor vascular endothelium (10, 14, 35, 36). The percentage of PS-positive vessels ranged from 16 to 41%. Thus, we anticipate that vascular imaging observed with bavituximab in the present studies will extend to other tumor types. The Dunning prostate R3227-AT1 tumor has small areas of focal necrosis scattered throughout the tumor (37). The lack of strong localization of bavituximab to these necrotic regions could be related to difficulties of access associated with high interstitial pressure and inadequate lymphatic drainage. However, in a previous study using a different anti-PS antibody (9D2) and different tumors, staining of necrotic tumor tissue was observed in addition to the endothelium at later time points (10). The apparent difference in the ability of the two antibodies to localize to necrotic regions may relate to idiosyncrasies of the tumor models or to differences in the ability of the two antibodies to resist proteolysis after binding. It is also possible that the cofactor protein, β2-glycoprotein I, which is needed for PS binding by bavituximab but not 9D2, does not efficiently penetrate into extravascular tissues or is degraded rapidly by proteolytic enzymes within the tumor interstitium.
The present labeling chemistry can also be applied to other radioarsenic isotopes. $^{72}\text{As}$ has a half life of 26 h, suitable for imaging with antibody Fab’ and F(ab’)2 fragments and other biomolecules having intermediate half lives. The abundance of positrons for $^{72}\text{As}$ is 88%, which is higher than for other commonly-used positron emitters, such as $^{64}\text{Cu}$ (18.0 % $\beta^+$, T$_{1/2}$ 12.7 h) or $^{124}\text{I}$ (23.0 % $\beta^+$, T$_{1/2}$ 4.2 d). Arsenic provides two potentially therapeutic isotopes: $^{77}\text{As}$ (T$_{1/2}$ 38.8 h, $E_{\beta^-}$ 226 keV), as used in the present study, and $^{76}\text{As}$ (T$_{1/2}$ 26.3 h, $E_{\beta^-}$ 1068 keV) (see Table in supplementary information). The multiple isotopes of arsenic potentially offer additional applications such as combined imaging/dosimetry and radioimmunotherapy. Another advantage of arsenic is that, unlike iodine, it does not subject the thyroid to high irradiation. The doses of arsenic used for imaging with $^{74}\text{As}$-bavituximab are also several orders of magnitude below toxic levels, so that even if $^{74}\text{As}$ were released from the antibody no toxicity would be expected. However, the arsenic isotopes do not include alpha emitters, which, because of their short path length, could be advantageous for vascular targeted therapies.

In conclusion, we have exploited the unique properties of arsenic radioisotopes to achieve clear imaging of tumors with an antibody, bavituximab, directed against a tumor vessel marker. Radioarsenic-labeled bavituximab shows promise as a vascular imaging agent for tumor detection and dosimetry in man.
LEGENDS

Figure 1.

a) Reaction scheme for the labeling of S[ATA]-modified antibody with radioactive arsenic isotopes.  
b) Quality control of bavituximab labeling with radioactive arsenic. After a labeling time of 30 min, a sample of \(^{74}\text{As}\)-bavituximab (20 µl) was resolved on a size-exclusion column for radio-HPLC. The UV-spectrum (upper trace) and corresponding radioactivity-progression (lower trace) confirm the absence of aggregates and of free \(^{74}\text{As}\). Labeling yield is > 99.9 %.  
c) In vitro stability of \(^{74}\text{As}\)-bavituximab. \(^{74}\text{As}\)-bavituximab was incubated in undiluted FBS for 24, 48, and 72 h. Size exclusion radio-HPLC was performed. The UV spectrum (upper graph) shows a typical FBS profile because the amount of \(^{74}\text{As}\)-bavituximab is too small to detect. The lower graphs show the corresponding radioactivity peak. Aggregates and breakdown products were not observed, indicating that the product is stable in serum.  
d) Immunoreactivity. ELISA was used to analyze the immunoreactivity of \(^{77}\text{As}\)-bavituximab (●). Unlabeled and unmodified bavituximab was used as the positive control (○) and \(^{77}\text{As}\)-rituximab as the negative control (▼). Little or no reduction of immunoreactivity was detected following S[ATA]-modification and radioarsenic labeling.

Figure 2.

Biodistribution. Dunning prostate R3327-AT1 tumor bearing rats were injected with 185 kBq of \(^{74}\text{As}\)-bavituximab or \(^{74}\text{As}\)-rituximab i.v. Groups of four animals were sacrificed by exsanguination and perfusion 48 h or 72 h after injection.  
a) Tumor to liver ratios for rats sacrificed after 48 and 72 h after injection with \(^{74}\text{As}\)-rituximab (black) or \(^{74}\text{As}\)-bavituximab (dots).  
b) Corresponding tumor to muscle ratios.  
c) Specific localization of bavituximab:
rituximab in major organs after 48 h (narrow hatched) and 72 h (broad hatched). Specific localization is calculated as the ratio of the %ID/g for $[^{74}\text{As}]$-bavituximab to the %ID/g for $[^{74}\text{As}]$-rituximab in tumor and normal tissues. At 72 h the uptake of bavituximab was significantly higher in tumor than liver or muscle (p<0.001).

**Figure 3.**

**Whole-body planar scintigraphy of Dunning prostate R3227-AT1 tumor bearing rats.**

a) Rats bearing approximately 20 mm diameter tumors were injected i.v. with 5 MBq of $[^{74}\text{As}]$-bavituximab. The rats were imaged on a phosphor plate at various time points after injection. The Figure shows a representative image 72 h after injection. The image is overlaid on an X-ray picture to provide anatomical correlation. b) Ratio of uptake of $[^{74}\text{As}]$-bavituximab in tumor versus upper organs (liver, lung, heart) at various time points after injection. ●, outer tumor regions; ○, entire tumor. At 24 h after injection, no obvious contrast was observed, but at 48 h the tumor became clearly visible and by 72 h, the tumor to organ ratio was the highest. c-d) Scintigraphy of rats injected with 3 MBq $[^{77}\text{As}]$-bavituximab or $[^{77}\text{As}]$-rituximab (negative control). Images acquired with 30 min exposure time at 72 h. Eight-fold higher uptake of bavituximab than of the control antibody was observed in the tumor.

**Figure 4.**

**Autoradiography of excised tumor sections.** a-b) Autoradiographs of 1mm sections of Dunning prostate R3227-AT1 tumors from rats 48 h or 72 h after injection with $[^{77}\text{As}]$-bavituximab. Localization of bavituximab was observed in the tumor periphery and heterogeneously throughout the tumor core. c) $[^{77}\text{As}]$-rituximab showed relatively little
accumulation in the tumor, particularly in the central regions. The autoradiograph was exposed for 4 times longer with $^{77}$As-rituximab to visualize the distribution. Scale shows arbitrary storage phosphor units.

**Figure 5.**

**Small Animal PET.** a-b) Small animal PET images obtained from a Dunning prostate R3227-AT1 tumor-bearing rat 48 h after injection of 10 MBq of $^{74}$As-bavituximab a) coronal; b) transaxial. PET intensity is overlaid on slices obtained by 3D MRI. $^{74}$As-bavituximab localized to the tumor (arrows) and was also visible in the blood pool of normal organs. The PET field of view (FOV) is indicated by the bracket. c) Images of 1mm sequential tumor slices from the 3D data sets.

**Figure 6.**

**Localization of bavituximab to tumor vessels after injection into rats bearing syngeneic Dunning R3227-AT1 prostate tumors.** Rats were injected i.v. with bavituximab or rituximab. After 24 h the rats were exsanguinated and their tumors were removed. Panels a, b and c show blood vessels in a frozen section of tumor at low magnification. a) Stained with biotinylated goat anti-human IgG followed by Cy2-streptavidin (green) to detect localized bavituximab; b) Stained with mouse anti-rat CD31 followed by Cy3-labeled goat anti-mouse IgG (red) to detect vascular endothelium. c) A merged image of bavituximab localized on CD31 positive endothelium (thick arrows). d) A merged image of blood vessels in the tumor of a rat injected with rituximab. No binding of rituximab was detected. e-f) Higher magnification merged images of blood vessels in
tumors from rats injected with rituximab (e) or bavituximab (f). Bars in the panels represent 100 µm.
References


a) SATA-labeled antibody

\[ \text{SATA-labeled antibody} \xrightarrow{\text{Hydroxylamine}} \]

\[ \text{Sulfhydryl-labeled antibody} \]

\[ \xrightarrow{\text{AsI}} \]

b) OD_{280}

\[ \text{Concentration (µg/ml)} \]

0 0.05 0.10 0.15 0.20

0 0.2 0.4 0.6 0.8 1.0 1.2

0 200 400 600 800

0 2 4 6

c) UV

\[ \text{Time (min)} \]

0 5 10 15 20 25

0 30 60 90 120

0 1.5

0 1.0 0.5 0.0

d) OD_{280}

\[ \text{Concentration (µg/ml)} \]

0 0.05 0.10 0.15 0.20

0 0.2 0.4 0.6 0.8 1.0 1.2 1.4

0 100 200 300 400

0 2 4 6 8 10
% ID/g bavituximab/%ID/g rituximab

- Heart
- Liver
- Kidney
- Spleen
- Upper intestine
- Stomach
- Tumor
- Muscle
- Bone

Tumor : Liver ratio
0 5 10 15 20 30
48 h 72 h

Tumor : Muscle ratio
0 100 200 300 400 500 600
48 h 72 h
a)  

b)  

c) bavituximab  
d) rituximab
a) $[^{77}\text{As}]$-bavituximab, 48 hours

b) $[^{77}\text{As}]$-bavituximab, 72 hours

c) $[^{77}\text{As}]$-rituximab, 72 hours
### Supplementary Information

#### Table 1:

Decay characteristics of the most relevant arsenic isotopes for molecular imaging or therapy

<table>
<thead>
<tr>
<th></th>
<th>$^{71}$As</th>
<th>$^{72}$As</th>
<th>$^{73}$As</th>
<th>$^{74}$As</th>
<th>$^{76}$As</th>
<th>$^{77}$As</th>
</tr>
</thead>
<tbody>
<tr>
<td>$T\frac{1}{2}$ [d]</td>
<td>2.70</td>
<td>1.08</td>
<td>80.3</td>
<td>17.78</td>
<td>1.1</td>
<td>1.62</td>
</tr>
<tr>
<td>Mode of decay (%)</td>
<td>EC (70)</td>
<td>EC (12)</td>
<td>EC(100)</td>
<td>EC (42)</td>
<td>$\beta^-$ (100)</td>
<td>$\beta^-$ (100)</td>
</tr>
<tr>
<td>Most abundant $\gamma$-lines [keV]</td>
<td>175.0</td>
<td>834.0</td>
<td>53.4</td>
<td>595.9</td>
<td>559.1</td>
<td>239.0</td>
</tr>
<tr>
<td></td>
<td>(83.1%)</td>
<td>(79.5%)</td>
<td>(10.5%)</td>
<td>(60.2%)</td>
<td>(45.0%)</td>
<td>(1.6%)</td>
</tr>
<tr>
<td></td>
<td>630.0</td>
<td>634.8</td>
<td>657.1</td>
<td>520.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(7.9%)</td>
<td>(15.4%)</td>
<td>(6.2%)</td>
<td>(0.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean particle energies [keV]</td>
<td>$\beta^+$: 104</td>
<td>$\beta^+$: 1024</td>
<td>$\beta^+$: 128</td>
<td>$\beta^-$: 1068</td>
<td>$\beta^-$: 226</td>
<td></td>
</tr>
<tr>
<td>Application</td>
<td>PET</td>
<td>PET</td>
<td>PET</td>
<td>SPECT</td>
<td>SPECT</td>
<td>Therapy</td>
</tr>
</tbody>
</table>

EC electron capture
CHAPTER 5

Non-Invasive Physiology and Pharmacology Using $^{19}$F Magnetic Resonance

Jian-Xin Yu, Weina Cui, Dawen Zhao, and Ralph P. Mason

Laboratory of Prognostic Radiology, Department of Radiology, The University of Texas Southwestern Medical Center at Dallas, TX 75390, USA

Contents
1. Introduction 198
   1.1. Context and perspective 199
   1.2. $^{19}$F as an in vivo NMR probe 201
2. $^{19}$F NMR for pharmacology 215
   2.1. Cancer chemotherapeutics 216
      2.1.1. Fluoropyrimidines 216
      2.1.2. Other anticancer drugs 217
   2.2. Other drugs 218
3. Active reporter molecules 220
   3.1. Physical interactions 220
      3.1.1. in vivo oximetry 220
      3.1.2. pH 231
      3.1.3. Metal ions 235
      3.1.4. Caveats 242
   3.2. Chemical interactions 243
      3.2.1. Metabolism of FDG 243
      3.2.2. Hypoxia 244
      3.2.3. Enzyme reporters 245
4. Passive reporter molecules 252
5. Potential innovations and improvements 253
6. Conclusions 253
References 254

Abstract
$^{19}$F provides a powerful tool for nuclear magnetic resonance (NMR) investigations. It has been widely exploited for both spectroscopic studies and increasingly for magnetic resonance imaging (MRI). The $^{19}$F atom has high NMR sensitivity while there is essentially no background signal in the body. Many diverse reporter molecules have been designed, which exploit the unique sensitivity of the fluorine atom to its microenvironment and these

*Corresponding author. Tel.: +1-(214)-648-8926; Fax: +1-(214)-648-2991; E-mail: Ralph.Mason@UTSouthwestern.edu
cover such diverse aspects as $pO_2$, pH, metal ion concentrations (e.g., calcium, magnesium), gene reporter molecules, hypoxia reporters, vascular flow, and volume. There are also numerous drugs in clinical use (e.g., the cancer chemotherapeutics 5-fluorouracil and gemcitabine, anesthetics, and psychoactive drugs such as fluoxetine) and agrochemicals, which include a fluorine atom. This review examines the properties of the fluorine atom that make it an ideal tool for NMR, consider the many properties that are available for interrogation and examine applications. NMR is a particularly flexible technology, since it can provide information through multiple parameters including chemical shift, relaxation processes ($R_1$ and $R_2$), scalar coupling, and chemical exchange. Moreover, fluorine NMR has a very large chemical shift range ($\approx 300$ ppm) allowing multiple agents to be examined simultaneously.

1. INTRODUCTION

MRI has become the technology of choice for radiology and detection of many diseases. Today, clinical MRI uses almost exclusively the proton nucleus of the hydrogen atom, which occurs naturally in tissue water. Thus, there is a particularly strong signal, which is sensitive to tissue status and provides exquisite indicators of soft tissue anatomy. Increasingly, the development of specific contrast agents and selective pulse sequences allows more detailed analysis of tissue properties such as diffusion, flow, and changes in vascular oxygenation [1,2]. Much information may also be obtained from metabolites; however, these typically occur at millimolar concentrations (or less) requiring prodigious water suppression [3]. Heteronuclei can provide metabolic tracers and physiological reporters while avoiding the intense water and lipid signals. The $^{19}$F atom has sensitivity of the order of 80% of that of proton, but there is essentially no endogenous signal from tissues. Most of the fluorine in the body is in the form of solid state fluoride ions, which give very broad lines, essentially undetectable using standard NMR equipment. There are also a few fluorine containing molecules that occur in nature, but these are almost exclusively in plants, are highly toxic, and thought to be part of inherent defense mechanisms [4]. Thus, any molecular fluorine introduced into the body in the form of reporter molecules or drugs is readily detected with high sensitivity.

The importance of fluorine in the Life Sciences continues to be recognized in journals such as the *Journal of Fluorine Chemistry*, reviews in regular journals devoted to technology, and the current series *Advances in Fluorine Science*. Many reviews beginning in the 1980s were devoted to fluorine NMR with seminal work from Thomas, Selinsky and Burt, Prior, and London [5–8]. More recently, Mason reviewed the use of perfluorocarbons (PFCs) for measuring tissue oxygenation [9,10] and fluorinated derivatives of vitamin B6 as probes of pH *in vivo* [11]. McSheehy *et al.* [12] discussed applications of fluorine NMR to oncology, Menon [13] examined fluorinated anesthetics, and Passe *et al.* [14] reviewed neuropsychiatric applications. Several reviews have concerned the pharmacokinetics of
fluoropyrimidine drugs based on fluorine NMR including notable contributions from Bachert, Martino, and Wolf [15–17] and, indeed, Wolf et al. contributed the succeeding article in this volume. Use of fluorine NMR to investigate physiology and pharmacology from an organic chemical perspective was the focus of a review by us [18]. Given the continuing appearance of novel applications in the field and developing interest in fluorine NMR, this current article will provide both a historical perspective and review state of the art. Readers are also directed to many relevant reviews that consider pharmacology, organic chemistry, or synthetic methods relating to fluorine [19–30]. Examples include recent reviews from Jescke [26]: on the unique role of fluorine in the design of active ingredients for modern crop protection, Dolbie: a review of fluorine chemistry at the millennium [21], Shimizu and Hiyama [24]: examining modern synthetic methods for fluorine substituted target molecules, Isanbor and O’Hagan [28]: reviewing fluorinated anticancer agents, Jäckel and Koksch [23]: on fluorine in peptide design approaching engineering, and Plenio: on the coordination chemistry of fluorine in fluorocarbons [25].

1.1. Context and perspective

In many disciplines, investigators have a deep understanding of their own speciality, but lack perspective of competing technologies. Historically, NMR investigators were physicists, who could develop sophisticated pulse sequences to manipulate nuclear spins, or radiofrequency engineers specialized in wave propagation and coil design. Alternatively, NMR investigators were chemists who could design new reporter molecules and assess metabolic processes. Today, the field is far more diverse. Beyond the integration of multiple disciplines into NMR, increasingly, there is recognition that often no single technology will optimally solve a problem, but multidisciplinary teams need to understand the strengths and weakness of diverse technologies and exploit multiple modalities. This review will promote the virtues and unique capabilities of 19F NMR, but it is important to recognize competing technologies. In the United States, increased emphasis on multimodality imaging and cross-disciplinary research is now driven by the formation of the National Institute for Biomedical Imaging and Bioengineering (NIBIB) [31] and Cancer Imaging Program (CIP) of the NCI [32]. Moreover, new learned societies are dedicated to imaging in general, for example, Society of Molecular Imaging (SMI) [33], as opposed to being devoted to a specific modality (e.g., International Society of Magnetic Resonance in Medicine (ISMRM) [34] or Society of Nuclear Medicine [35]) and many journals have published issues reviewing diverse imaging methods [36–39].

Proton MRI has the great advantage of using spin physics to interrogate tissue water revealing anatomy and pathophysiology based on cellular and tissue properties. Nonetheless, it is often enhanced by the introduction of paramagnetic contrast agents at micromolar concentrations. Fluorine MRI typically requires
millimolar concentrations of reporter molecules. In this respect, radionuclide and optical imaging techniques can offer far superior sensitivity, potentially with picomolar to nanomolar requirements. Fluorescence imaging is becoming more attractive with the commercial availability of many labeling kits [40] and new instrumentation, which allows spectral deconvolution [41]. However, fluorescence imaging can suffer from signal quenching and is generally a two-dimensional technique. Recently, 3D fluorescence is becoming feasible in small animals [42,43]. Nanoparticles (quantum dots) offer particularly high sensitivity although current generations would be inappropriate for human application, since they use highly toxic elements, such as cadmium and mercury [44]. Fluorescent proteins can also be generated in situ; cellular transfection can generate green fluorescent protein (GFP) or longer wavelength proteins [45]. Alternatively, cells may be transfected with a bioluminescent imaging (BLI) reporter such as luciferase, which emits light upon interaction with luciferin substrate [38,46]. Again, this is becoming feasible in three dimensions in small animals [47]. Generally, optical imaging technologies can use relatively cheap instrumentation.

Radionuclide imaging has similar sensitivity to optical imaging and is routinely used for studies of biodistribution, planar \( \gamma \)-scintigraphy, positron emission tomography (PET), and single photon emission computed tomography (SPECT) [48,49]. A major drawback with radionuclides is the limited shelf life of substrates, which may either decay (short half-life) or be subject to long-term radiolysis. Radioactivity also poses specific safety issues during production, reagent preparation, and ultimate disposal. Nonetheless, several PET and SPECT agents are in routine clinical use (e.g., fluorodeoxyglucose [FDG], Prostascint, \(^{99m}\)Tc [50–52]). Other materials are effective for tracing the pharmacokinetics of labeled substrates. A major problem is ensuring that the label remains part of the molecule, since radioactivity provides no molecular characterization and unless specific analytical techniques such as high performance liquid chromatography (HPLC) are applied, only experience can indicate whether metabolic transformation has occurred.

Ultrasound and X-ray imaging are routine in the clinic and examine endogenous molecules based on signal reflection and/or absorption. These are starting to find application in small animal research [53]. Currently, they provide primarily anatomical information, although addition of contrast agents promises new applications [54].

Relatively, \(^{19}\)F NMR has multiple strengths and virtues as described in the following sections. Briefly, fluorine containing molecules tend to be metabolically stable and have indefinite shelf life. The fluorine nucleus offers sufficient sensitivity for imaging, but also provides a very large chemical shift range immediately revealing metabolic transformations and allowing multiple molecules to be observed and identified simultaneously with potential applications to metabolomics. Fluorine MRI is readily combined with anatomical proton MRI providing high spatial resolution anatomy.
1.2. $^{19}$F as an *in vivo* NMR probe

$^{19}$F is 100% naturally abundant and the only stable isotope of fluorine. The nucleus has a nuclear spin $I = \frac{1}{2}$ and a gyromagnetic ratio of 40.05 MHz/T, providing a sensitivity approximately 83% that of protons. The high gyromagnetic ratio generally allows the use of existing proton NMR instrumentation with the minimum of component adjustments. NMR has multiple strengths and virtues. Modern NMR instrumentation can be user friendly allowing a well-trained technician to undertake studies. However, NMR is intrinsically a complex tool providing potentially a multitude of information based on diverse parameters including signal intensity (SI), chemical shift ($\delta$), and changes of chemical shift ($\Delta\delta$). In addition, signals are characterized by the transverse dephasing rate ($R_2 = 1/T_2$), spin–spin or transverse relaxation rate ($R_2 = 1/T_2$) and spin–lattice or longitudinal relaxation rate ($R_1 = 1/T_1$). Indeed, each of these parameters have been exploited for specific $^{19}$F NMR reporter molecules (Table 1). With care, the NMR signal can be quantitative, so that the integral (area under the peak) of a signal is directly proportional to the amount of material being interrogated. However, NMR may be considered relatively insensitive compared with some other modalities. Typically, millimolar concentrations are required to achieve a good signal in a reasonable amount of time. The precise detection sensitivity is governed by numerous parameters including the volume of interrogation, the required spatial resolution, and relaxation properties of the molecule, and its tendency to accumulate or disperse from a region of interest. Perhaps, most important is the temporal resolution since signals may be averaged over many hours. Increasingly, there are attempts to target fluorinated agents to accumulate at a site of interest, for example, using specific antibodies [55,56] and low-molecular weight ligands [57].

The simplest concept of NMR is that of chemical shift. In this context, $^{19}$F is exceptionally sensitive to molecular and microenvironmental changes. Fluorine NMR has a chemical shift range of approximately 300 ppm, as opposed to approximately 10 ppm for proton. Multiple different fluorinated agents may readily be detected simultaneously with minimal danger of signal overlap. To allow comparison between data from different molecules and different investigators, chemical shifts must be referred to a standard. The International Union of Pure and Applied Chemistry (IUPAC) $^{19}$F NMR chemical shift standard is fluorotrichloromethane (CFCl₃) [58]. Using this agent, the range of chemical shifts of most organic fluorinated compounds is 0–250 ppm. However, this volatile solvent is not convenient for most biomedical applications and thus, secondary standards are usually preferred. We favor sodium trifluoroacetate (CF₃CO₂Na or NaTFA). This has the advantage of being readily available, quite nontoxic, and may be used as either an external, or indeed, internal chemical shift standard in biological investigations. It should be noted that fluorine chemical shifts can be strongly solvent dependent and vary with dilution [59]. Fluorine may ultimately be described on a $\phi$ scale, extrapolated to infinite dilution, under which...
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Indicator (example)</th>
<th>NMR parameter</th>
<th>References (representative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical interactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$\rho$O$_2$</td>
<td>Perfluorocarbons</td>
<td>$R_1$ ($R_2$)</td>
<td>[9,10,222,351,407]</td>
</tr>
<tr>
<td>For example, hexafluorobenzene</td>
<td>$\Delta\delta$</td>
<td></td>
<td>[408]</td>
</tr>
<tr>
<td>pH</td>
<td>FPOL, DFMO, ZK150471</td>
<td>$\Delta\delta$, J</td>
<td>[11,280,301,303,409]</td>
</tr>
<tr>
<td>$[\text{Na}^+]$</td>
<td>F-cryp-1</td>
<td>$\delta$, ratio</td>
<td>[410]</td>
</tr>
<tr>
<td>$[\text{Ca}^{2+}]$</td>
<td>5F-BAPTA</td>
<td>$\delta$, ratio</td>
<td>[8,295,311]</td>
</tr>
<tr>
<td>$[\text{Mg}^{2+}]$</td>
<td>5F-APTRA</td>
<td>$\delta$, ratio</td>
<td>[321]</td>
</tr>
<tr>
<td>Membrane/chloride potential</td>
<td>TFA</td>
<td>ratio</td>
<td>[287,411]</td>
</tr>
<tr>
<td>Chemical interactions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene activity</td>
<td>PFONPG, 5FC</td>
<td>$\Delta\delta$</td>
<td>[147,294,374,378]</td>
</tr>
<tr>
<td>Nitric oxide</td>
<td>NN$^a$</td>
<td>$\Delta\delta$</td>
<td>[412]</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>F-misonidazoles</td>
<td>Integral</td>
<td>[351,413]</td>
</tr>
<tr>
<td>Glycolysis</td>
<td>FDG</td>
<td>Integral</td>
<td>[331]</td>
</tr>
<tr>
<td>Drug metabolism</td>
<td>5FU, gemcitabine</td>
<td>Integral</td>
<td>[17,63]</td>
</tr>
<tr>
<td>Protein catabolism</td>
<td>DLBA</td>
<td>Integral</td>
<td>[414]</td>
</tr>
<tr>
<td>Disease specific receptors</td>
<td>Nanoparticles</td>
<td>Integral</td>
<td>[56,57]</td>
</tr>
<tr>
<td>Passive reporters</td>
<td></td>
<td>Ratio</td>
<td>[5,207,415]</td>
</tr>
<tr>
<td>Temperature</td>
<td>PFCs</td>
<td>Integral</td>
<td>[401]</td>
</tr>
<tr>
<td>Blood flow</td>
<td>Freon FC-23</td>
<td>Integral</td>
<td>[287]</td>
</tr>
<tr>
<td>Cell volume</td>
<td>TFM</td>
<td>integral</td>
<td>[416]</td>
</tr>
<tr>
<td>Diffusion</td>
<td>FDG</td>
<td>ADC</td>
<td></td>
</tr>
<tr>
<td>Vascular volume</td>
<td>Fluorocarbon emulsion</td>
<td>Integral</td>
<td>[398,417]</td>
</tr>
<tr>
<td>Lung function</td>
<td>PFC; SF$_6$</td>
<td>Integral</td>
<td>[384,386,387]</td>
</tr>
<tr>
<td>GI function</td>
<td>PFC</td>
<td>Integral</td>
<td>[69,392]</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>MP-312</td>
<td>Integral</td>
<td>[418]</td>
</tr>
</tbody>
</table>

$^a$ 2-(2,6-Difluorophenyl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazol-3-oxide-1-oxyl.
conditions CF₃CO₂H is quoted as −76.530 ppm. For precise measurements, it may be critical for both the chemical shift standard and molecule of investigation to be under precisely the same conditions (necessitating an internal standard). External standards, for example, in glass capillaries, may be subject to small susceptibility effects causing errors in estimation of absolute chemical shift. However, they provide more reliable quantitation standards for SI. Chemical shift is the mainstay of detecting and classifying molecules and detecting and identifying metabolic products of agents. While there have been many theoretical exercises on fluorine chemical shift it can often be quite unpredictable and occurs across an exceptionally large range. In 1971, Emsley and Phillips [60] published a 520-page review of the theory relating to $^{19}$F NMR chemical shifts followed by a 673 page compilation of coupling constants [61].

Scalar coupling constants of fluorine are typically much larger than proton. For geminal fluorine atoms, $^2J_{FF}$ may be in the range of 200–800 Hz, while $^3J_{FF}$ is often less than 1 Hz, yet $^4J_{FF}$ may reach 20 Hz: such nonmonotonicity can be confusing and large long range couplings $^6$ or $^7$ are also encountered [18,59,61,62]. Proton fluorine coupling constants are $^2J_{FH}$ ~ 45–90 Hz and $^3J_{FH}$: 0–53 Hz. While fluorine carbon coupling is typically large ($^1J_{CF}$ > 200 Hz), it generally not observed unless the carbon is enriched with $^{13}$C. However, as a corollary, fluorine coupling is observed clearly and extensively in $^{13}$C NMR spectra. To avoid complexity of fluorine–fluorine coupling, it may be important to include fluorine as a symmetrical moiety, for example, a trifluoromethyl group, as opposed to asymmetric geminal fluorine atoms or a single fluorine atom. Likewise, a CF₃ moiety will generally avoid fluorine–hydrogen couplings. Since $^{19}$F NMR is often detected by retuning a proton channel, proton decoupling may not be available.

Representative drugs, which include fluorine atoms and for which in vivo NMR has been reported are shown in Fig. 1 [17,63–73]. Furthermore, many drugs in early preclinical testing include fluorine atoms: the prevalence of fluorine atoms may reach 20% of all candidate agents [19]. Introduction of fluorine requires care. While the carbon fluorine bond is particularly strong, any release of fluoride or metabolites such as mono- or difluoroacetate can lead to exceedingly toxic products. For reporter molecules or pharmacological drugs, it is clearly important to minimize inadvertent toxicity. In this respect, the trifluoromethyl (CF₃) group is particularly suitable, since it resists degradation and for NMR avoids fluorine–fluorine couplings. In pharmaceuticals and agrochemicals, fluorine occurs in many forms ranging from a single fluorine atom to as many as six or nine identical fluorines (Table 2). In terms of NMR detection, the more equivalent fluorines, the stronger the signal. However, fluorine will modulate the properties of a molecule, since the fluorine atom is exceedingly electronegative and the CF bond strongly polarized. While the van der Waals radius of a fluorine atom is quite similar to a proton, the electronegativity alters electronic configuration modulating $pK_a$. For the series of acetic acids $pK_a(CH₃CO₂H) = 4.76$, $pK_a(CH₂FCO₂H) = 2.59$, $pK_a(CHF₂CO₂H) = 1.24$, and $pK_a(CF₃CO₂H) = 0.23$ [19]. Similar changes have been reported for a
series of fluoromethyl alanines (Table 3) [74]. The trifluoromethyl group is often considered to be equivalent to the introduction of an isopropyl group. Fluorine not only perturbs the electronic structure of a molecule, but also alters the hydrophobicity [75]. Indeed, in many cases, particularly for agrochemicals, fluorine is specifically added to reduce the water solubility of molecules, so they are retained more effectively on the waxy cuticle of plants [26]. Fluorine modifies lipophilicity and ability to cross membranes, such as the blood–brain barrier, which is pertinent to the extensive applications in anesthetics and psychiatric drugs [76].
Fluorine chemistry has made major progress over the last 10–15 years and now many reagents are available for derivatization [24]. However, many require quite severe conditions using such materials as hydrogen fluoride [77], various metal halides such as SeF₄ [78], WF₆ [79], XeF₂ [80], and SbF₅ [81], or fluorine itself [82]. In some cases, a fluorine moiety may be introduced with S-ethyl trifluoroacetate (SETFA) [83] or trifluoroacetic anhydride [84]. It is often preferable to use a starting material that already includes a fluorine or multiple fluorine atoms, which may be introduced using relatively mild conditions, as explored extensively in the generation of fluorinated peptides [23].

While only a single isotope of fluorine is available for NMR, fluorine is finding increasing use as ¹⁹F for PET (see other articles in this volume). While ¹⁸F has a limited half-life (t½ = 110 min), it has found major application in the detection of tumors including Medicare reimbursed studies with FDG within the last 5 years. There is active interest in the pursuit of other ¹⁸F agents to detect parameters such as hypoxia or mitosis [85–90]. The greatest strength of PET is that it may use nano to femtomolar concentrations, as opposed to the milli to micromolar concentrations required for NMR. However, ¹⁸F simply provides a count of molecular concentration, that is, detecting radioactive decay with no indication of multiple substrates or metabolites. Thus, it may require rigorous HPLC or other analyses to strictly determine the fate of a drug. Meanwhile, ¹⁹F can allow the detection of multiple agents, and metabolites simultaneously based on chemical shift. ¹⁹F is indefinitely stable and the lack of radioactivity provides not only a long shelf life, but minimizes any issues of disposal of hazardous waste. Moreover, any fluorine MRI detection is readily correlated with the exquisite anatomy provided by routine proton MRI.

---

**Fig. 1.** (a) Representative fluorinated molecules. Pharmaceuticals for which clinical or preclinical in vivo NMR studies have been reported: 5-fluorouracil (5FU) [16,17,63], gemcitabine [65], and capecitabine [73] are anticancer drugs; fluoxetine [162] and dexfenfluramine [72] have neurological activity, sitafloxacin [66] is an antimicrobial, niflumic acid [67] is a nonsteroidal anti-inflammatory, tecastemzole [68] is an experimental antihistamine and perfluorononane has been proposed for Gl imaging [69]. (b) Published ¹⁹F NMR reporter molecules: 6-FPOL (6-fluoropyridoxol) is a pH reporter [11], hexafluorobenzene (HFB) is used for oximetry [10], PFONPG is a gene reporter for β-gal [294], and 5FBAPTA measures [Ca²⁺] [295]. (c) Natural products incorporating fluorine atoms: fluoroacetate, fluorocitrate, fluoroacetone, and fluorooleic acid [4].
Table 2. Fluorine-containing pharmaceuticals and agrochemicals [22,26,28]

<table>
<thead>
<tr>
<th>Number of equivalent F-atoms</th>
<th>Relevant references</th>
<th>Use</th>
<th>Name</th>
<th>Molecular structure</th>
<th>ProjectAcronym:bs:AFS Volume:00005</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>[419,420]</td>
<td>Anticancer drug</td>
<td>Gefitinib</td>
<td>ZD1839</td>
<td>Iressa®</td>
</tr>
<tr>
<td>3</td>
<td>[181,421]</td>
<td>Anti-androgen drug</td>
<td>Flutamide</td>
<td>Flucarbazone</td>
<td>Herbicide</td>
</tr>
<tr>
<td>3</td>
<td>[422]</td>
<td>Herbicide</td>
<td>Flucarbazone</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**19F NMR Reporter Molecules**

1. Bistrifluron
2. Roflumilast
3. Hexaflumuron
4. Fulvestrant Faslodex®

**Chemical Structures:**

- **Bistrifluron**
- **Roflumilast**
- **Hexaflumuron**
- **Fulvestrant**

**Chemical Formulas:**

- Bistrifluron: 
  \( \text{OCF}_2\text{CHF}_2 \)
  \( \text{Cl} \)
  \( \text{CF}_3 \)

- Roflumilast: 
  \( \text{O} \)
  \( \text{O} \)
  \( \text{Cl} \)
  \( \text{Cl} \)
  \( \text{OCF}_2\text{CHF}_2 \)

- Hexaflumuron: 
  \( \text{OH} \)
  \( \text{OH} \)
  \( (\text{CH}_2)_9\text{SON(CH}_2)_3\text{CF}_2\text{CF}_3 \)

- Fulvestrant Faslodex®: 
  \( \text{CH}_3\text{SO}\text{CH}_2\text{SOCH}_2\text{CH}_3 \)
  \( \text{CF}_3 \)
  \( \text{CF}_3 \)
\[ \begin{align*}
3 + 2 + 2 + 1 &= 8 \\
6 + 3 &= 9
\end{align*} \]

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 |

427 | 183 | 428 | 429 | 430 | J.-X. Yu et al. | Lufenuron | Anticancer drug | Topoisomerase inhibitor | Fungicide | Toxicant | T 0901317 | Fludarabine | Flutriafol | Sarin | OCF2CHCF3 | Cl | Cl | Cl | NH2 | F | F | OH | OH | OH | OH | iso-PrO | P | Me | UNCORRECTED PROOF
### Table 3. 19F NMR pH indicators

<table>
<thead>
<tr>
<th>Reporter</th>
<th>Structure</th>
<th>pK(_a) (ppm)</th>
<th>(\Delta\delta) (ppm)</th>
<th>(\delta_F(\text{acid})) (ppm)</th>
<th>Reported applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-Fluoro-2-methyl alanine</td>
<td><img src="image1" alt="Structure 1" /></td>
<td>8.5</td>
<td>2.05</td>
<td>143.2</td>
<td>Intracellular pH, perfused liver, lymphocytes [74]</td>
</tr>
<tr>
<td>3,3-Difluoro-2-methyl alanine</td>
<td><img src="image2" alt="Structure 2" /></td>
<td>7.3</td>
<td>2.00</td>
<td>53.95</td>
<td>Figure 8 [74]</td>
</tr>
<tr>
<td>3,3,3-Trifluoro-2-methyl alanine</td>
<td><img src="image3" alt="Structure 3" /></td>
<td>5.9</td>
<td>2.10</td>
<td>0.25</td>
<td>[74]</td>
</tr>
<tr>
<td>DFMO</td>
<td><img src="image4" alt="Structure 4" /></td>
<td>6.4</td>
<td>0.30</td>
<td>4.60</td>
<td>Transmembrane pH gradient, blood, heart, tumor [11,290]</td>
</tr>
<tr>
<td>6-FPOL</td>
<td><img src="image5" alt="Structure 5" /></td>
<td>8.2</td>
<td>9.72</td>
<td>9.84</td>
<td>0.30</td>
</tr>
</tbody>
</table>

**Reported applications:**
- Transmembrane pH gradient, blood, heart, tumor [11,290]
- Intracellular pH, perfused liver, lymphocytes [74]
- Figure 8 [74]
Transmembrane pH gradient, blood, heart, tumor [11,291]

6-FPAM

\[
\begin{array}{ccc}
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\end{array}
\]


6-FPOL-5-NH₂

\[
\begin{array}{ccc}
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\end{array}
\]


6-FPOL-5-α-CF₃

\[
\begin{array}{ccc}
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\text{CH}_2\text{OH} & \text{N} & \text{F} \\
\end{array}
\]

7.05 8.0 7.6 6.9 [291] 5.76 [291] 4.45 [291] 3.64 [291]

PFONP

\[
\begin{array}{ccc}
\text{OH} & \text{NO}_2 & \text{F} \\
\text{OH} & \text{NO}_2 & \text{F} \\
\text{OH} & \text{NO}_2 & \text{F} \\
\text{OH} & \text{NO}_2 & \text{F} \\
\end{array}
\]

6.9 6.0 58.77 61.01 2.24 [294]

Extracellular pH [294]

Transmembrane pH gradient, blood, heart, tumor [294,374]

OFPNP

\[
\begin{array}{ccc}
\text{OH} & \text{NO}_2 & \text{F} \\
\text{OH} & \text{NO}_2 & \text{F} \\
\text{OH} & \text{NO}_2 & \text{F} \\
\text{OH} & \text{NO}_2 & \text{F} \\
\end{array}
\]

6.0 58.77 61.01 2.24 [294]

J.-X. Yu et al.
19F NMR Reporter Molecules

- **5FNEAP-1**: N-(methyl-2-carboxyisopropyl)-4-fluoroaniline
- **Fquene**: 4-Fluoro benzene boronate (FBA)

**In vivo pH measurement agents** [297, 296, 298]

- Extracellular pH: 10.90
- In vivo pH: 6.85
- Intracellular pH, liver of rats: 6.7

**In vivo pH measurement agents** [298, 431]

- 4-Fluoro benzene boronate (FBA): 8.73
- Fquene: 11.82
PCF$_3$ONP  
\[
\begin{array}{cccc}
5.6 & 13.49 & 14.52 & 1.03 \\
\end{array}
\] Extracellular pH [299]

CF$_3$POL  
\[
\begin{array}{cccc}
6.8 & 15.15 & 16.76 & 1.7 \\
\end{array}
\] Extracellular pH [18]

ZK 150471  
\[
\begin{array}{cccc}
7.16 & -52.74^{* * * *} & -62.87^{* * * *} & -10.13 \\
\end{array}
\] In vivo pHe probe, tumor and tissue [301,303, 304]

Unless otherwise noted, dilute CF$_3$CO$_2$H was used as chemical shift reference
** tetrafluoroterephthalic acid was used as standard, though variously in the experimental section NaF and hexafluorobenzene were used as standards
*** chemicals shifts quoted with respect to 5FBAPTA
**** intramolecular chemical shift difference.
NMR is a particularly facile approach to analysis requiring minimal sample preparation: mixtures, turbid media, and organisms including biopsy specimens or living plants and animals or even patients may be examined directly. Feasibility is governed by sample volume and the need for appropriate magnetic resonance systems and radio frequency (RF) coils [91,92]. For small specimens (<1 ml), magnetic fields exceed 22 T (950 MHz proton) and routine analysis is available at and above 7 T. These high field systems usually use vertical narrow bore magnets which can accommodate small samples of solutions (analytical and in vitro investigations) and sometimes mice. Small animal studies are most commonly performed in horizontal bore systems at 4.7 T, but increasingly systems are available at 7 and 9.4 T. Humans are now routinely studied at 3 T with research systems up to 12 T. Figure 1 shows representative drugs, which have been studied by $^{19}$F NMR in clinical trials.

Proton NMR is potentially more versatile, since protons are essentially ubiquitous. However, this also provides a major drawback—crowded signals across limited chemical shift dispersion. Moreover, the water component of tissues can approach 70% water leading to signals approaching 80 M, as compared with mM metabolites. Elegant water suppression methods have evolved over the years, but often obliterate extended spectral windows around water or are limited to specific molecular structures exhibiting multiquantum detectability [93–95]. Lipid signals may also interfere with detection. Samples may be subjected to D$_2$O exchange, but this is perturbing. Deuterium enrichment is feasible providing up to 6,400-fold amplification [96], but the gyromagnetic ratio (γ) is much lower reducing ultimate sensitivity. Carbon is also ubiquitous in biological systems, but only 1.1% is NMR active as $^{13}$C. This does provide the opportunity for selective isotopic enrichment and has proven fruitful for many studies [97], though $^{13}$C can be expensive. Again, the gyromagnetic ratio is relatively low, precluding effective clinical studies at low fields.

The virtues of $^{19}$F have led to the design and use of many reporter molecules in preclinical investigations (Table 1 and Fig. 1b). Since, there are few naturally occurring compounds containing fluorine, fluorinated molecules do not have to compete with background signal. Fluorine does occur extensively in bones and teeth, but the solid matrix causes very short $T_2$ values providing exceedingly broad signals, which can either be removed by deconvolution or electronic timing. Indeed, special rapid electronics are required for detecting solid state $^{19}$F [98]. The spin lattice relaxation time $T_1$ can be quite long, but efficient use of rapid pulsing at the Ernst angle can accelerate spectral acquisition [99]. For aqueous solutions, relaxation agents, such as Gd-DTPA, can be added to accelerate relaxation [100–102], and indeed, this has been used to identify cellular compartmentation based on the ability of the contrast agent to relax extracellular material, but not intracellularly [103]. Data acquisition efficiency can also be enhanced by interleaving or acquiring simultaneously $^1$H and $^{19}$F NMR providing both anatomical and pharmacological/physiological data simultaneously.

19F NMR Reporter Molecules

1
NMR is a particularly facile approach to analysis requiring minimal sample preparation: mixtures, turbid media, and organisms including biopsy specimens or living plants and animals or even patients may be examined directly. Feasibility is governed by sample volume and the need for appropriate magnetic resonance systems and radio frequency (RF) coils [91,92]. For small specimens (<1 ml), magnetic fields exceed 22 T (950 MHz proton) and routine analysis is available at and above 7 T. These high field systems usually use vertical narrow bore magnets which can accommodate small samples of solutions (analytical and in vitro investigations) and sometimes mice. Small animal studies are most commonly performed in horizontal bore systems at 4.7 T, but increasingly systems are available at 7 and 9.4 T. Humans are now routinely studied at 3 T with research systems up to 12 T. Figure 1 shows representative drugs, which have been studied by $^{19}$F NMR in clinical trials.

Proton NMR is potentially more versatile, since protons are essentially ubiquitous. However, this also provides a major drawback—crowded signals across limited chemical shift dispersion. Moreover, the water component of tissues can approach 70% water leading to signals approaching 80 M, as compared with mM metabolites. Elegant water suppression methods have evolved over the years, but often obliterate extended spectral windows around water or are limited to specific molecular structures exhibiting multiquantum detectability [93–95]. Lipid signals may also interfere with detection. Samples may be subjected to D$_2$O exchange, but this is perturbing. Deuterium enrichment is feasible providing up to 6,400-fold amplification [96], but the gyromagnetic ratio (γ) is much lower reducing ultimate sensitivity. Carbon is also ubiquitous in biological systems, but only 1.1% is NMR active as $^{13}$C. This does provide the opportunity for selective isotopic enrichment and has proven fruitful for many studies [97], though $^{13}$C can be expensive. Again, the gyromagnetic ratio is relatively low, precluding effective clinical studies at low fields.

The virtues of $^{19}$F have led to the design and use of many reporter molecules in preclinical investigations (Table 1 and Fig. 1b). Since, there are few naturally occurring compounds containing fluorine, fluorinated molecules do not have to compete with background signal. Fluorine does occur extensively in bones and teeth, but the solid matrix causes very short $T_2$ values providing exceedingly broad signals, which can either be removed by deconvolution or electronic timing. Indeed, special rapid electronics are required for detecting solid state $^{19}$F [98]. The spin lattice relaxation time $T_1$ can be quite long, but efficient use of rapid pulsing at the Ernst angle can accelerate spectral acquisition [99]. For aqueous solutions, relaxation agents, such as Gd-DTPA, can be added to accelerate relaxation [100–102], and indeed, this has been used to identify cellular compartmentation based on the ability of the contrast agent to relax extracellular material, but not intracellularly [103]. Data acquisition efficiency can also be enhanced by interleaving or acquiring simultaneously $^1$H and $^{19}$F NMR providing both anatomical and pharmacological/physiological data simultaneously.
[91,92,104,105]. $T_1$ relaxation is extensively exploited with PFCs to measure $pO_2$, as described in detail in Section 3.1.1.

A few natural organofluorine compounds exist, most notably in plants (Fig. 1c). These are generally noted for their toxicity; most importantly, fluoroacetate enters the tricarboxylic acid (TCA) cycle and as fluorocitrate inhibits cis-aconitase [4,106,107]. Of course, toxicity provides an opportunity to generate specific poisons and fluoroacetate is widely used as a rodenticide providing opportunities for NMR [108]. $^{19}$F NMR has been used for extensive studies of body fluids such as milk and urine with respect to xenobiotica [109–115].

Fluorine is increasingly used in industrial products ranging from fluoropolymers (e.g., Teflon) and liquid crystal components to anesthetics (e.g., isoflurane) to refrigerants and fire suppressants (halocarbons), numerous agrochemicals and several medicines [21,22,26,28]. While application of fluoro molecules will lead to increasingly crowded spectra, the large chemical shift range ensures that multiple molecules may be detected simultaneously. For example, in a study to investigate influence of tumor pH, on the anticancer drug 5FU in rat breast tumors, four molecules were detectable simultaneously (Fig. 2, the drug 5FU at $-93.6$ ppm, the extracellular pH reporter CF$_3$POL at $-16.69$ ppm, a chemical shift standard NaTFA (0 ppm) and two signals for the gaseous veterinary anesthetic isoflurane ($-5.1$, $-10.99$ ppm)). As noted above, we favor NaTFA as an internal standard for biological investigation, as compared with the IUPAC

![Fig. 2. Simultaneous detection of multiple fluorinated molecules in vivo.](image)

To explore the hypothesis that uptake of the anticancer drug 5FU by tumors is pH dependant, we infused 5FU (0.4 ml (50 mg/ml) IV), the extracellular pH reporter CF$_3$POL (400 mg/kg IP), and the chemical shift standard NaTFA (200 mg/kg IP) into an anesthetized rat (1% isoflurane) with a subcutaneous 13762NF breast tumor (1.4 $\times$ 1.5 $\times$ 1.1 cm). Thirty minutes after administration, all four molecules were detectable simultaneously in 17 min. At this stage, no metabolites of 5FU were detected.
standard (CFCl3). In principle, the NaTFA was unnecessary here, since the iso-
flurane signals could have served as a secondary standard. However, it is impor-
tant to note that the signals from anesthetics tend to have very short T2 [116–
118], and thus, while they are visible in this pulse-acquire spectrum, they will 
tend to be “lost” in spin echo investigations, such as chemical shift imaging 
(CSI). While 19F NMR investigations can generally be performed using existing 
1H equipment, some care is required, since probe and RF components may 
include fluorinated material which can give rise to spurious signals [119].

In the following sections, this review will separately consider industrial pharma-
cological and agrochemical agents (Section 2) followed by active (Section 3) 
and passive (Section 4) reporter molecules. Active reporter molecules may fur-
ther be differentiated as those based on physical interaction with a substrate 
(Section 3.1) or those that undergo a chemical reaction (Section 3.2).

2. 19F NMR FOR PHARMACOLOGY

Fluorine is often added to modulate biological activity of pharmaceuticals. 

Numerous reports describe changes in pK_a [74,75] (see also Table 3), lipophili-
city [19,26,75], retention, resistance to degradation [22], enhanced binding 
[19,120] induced by selective incorporation of F atom or atoms. In other cases, 
F atoms have been used to probe molecular interactions or binding sites in order 
to enhance drug design, even if fluorine is ultimately not included in the drugs. 

It has been recognized that 19F chemical shift is not only highly dependant 
on molecular structure and ionization, but also on the microenvironment. In 
early works, Dwark [121] and Gerig [122] reported the use of F moieties to 
probe interactions of oxy- and deoxyhemoglobin with cofactors such as dipho-
sphoglycerate (DPG) under differential protonation [123]. Trifluoroacetylated chit-
otriose and N-trifluoroacetylglucosamine were used to probe active sites in 
lysozyme [124]. Many fluoro sugars have been used to study enzyme specificity, 
substrates, or inhibitors of enzymes such as glycogen phosphorylase and gluco-
sidases [125–127].

Essentially, no background 19F signal occurs and the sensitivity is sufficient to 
examine biological mixtures, for example, body fluids such as urine, blood, or 
milk for fluorinated metabolites [109–115,128,129]. This is being used both by 
avademic laboratories and pharmaceutical companies to examine the fate of 
xenobiotics. In some cases, metabolites (degradation products or excretory bio-
conjugates) are derived from fluorine containing drugs; in other cases, 19F labels 
may be added for the ADMET (absorption, distribution, metabolism, and excre-
tion toxicity) process to learn about pathways, even though the labels are not 
included in the ultimate pharmaceuticals. In several cases, glucuronides have 
been identified as key detoxification products [130–132].
2.1. Cancer chemotherapeutics

2.1.1. Fluoropyrimidines

With the significant developments in fluorination technology, inclusion of F atoms into pharmaceuticals and agrochemicals is becoming more feasible and popular [26,28]. Fluorine can yield subtle, but significant changes in drug activity [19,22,28]. The F atom is generally considered to have a structural size between H and OH, while CF₃ is similar to an isopropyl group [75]. The strong electronegativity can modulate electronic distributions influencing pKₐ, particularly in proximity to delocalized aromatic structures [19,75]. F may be involved in hydrogen bonding altering binding and entry into enzyme pockets [23]. Many new industrial pharmaceuticals and agrochemicals incorporate a fluorine group providing a tool for NMR investigations. Figure 1 shows drugs, which have been examined by ¹⁹F NMR in clinical or advanced preclinical studies, while Table 2 shows diverse molecules including pharmaceuticals and agrochemicals, which could be strong candidates for ¹⁹F NMR investigations, but for which reports are lacking in the public domain. Most studies to date have examined pharmacokinetics and metabolism of fluoropyrimidines, particularly 5-fluorouracil (5FU). 5FU was first developed in the 1950s and remains a primary drug in treatment of many cancers, but it has a narrow range of efficacy/toxicity [28,63,133]. Presumably, both response and toxicity are related to pharmacokinetics and there is interest in assessing dynamics of uptake, biodistribution, and metabolism. Patients with enhanced tumor retention of 5FU ("trappers") may be expected to exhibit better response [134]. Such trapping is apparently a requisite, though not in itself sufficient for efficacy [17].

Given the importance and prevalence of 5FU, over 200 studies have reported ¹⁹F NMR investigations in clinical trials and evaluation in animal models. Several detailed reviews consider metabolism, pharmacokinetics, and detectability of 5FU and its metabolites and the reader is referred to these [15–17,63]. 5FU requires anabolic conversion to nucleosides (e.g., FdUrd, FdUmp) and nucleotides for cytostatic activity, requiring the activity of various kinases and phosphorylases [17]. However, competing catabolic reactions convert 5FU to 5,6-dihydrofluorouracil (DHFU) and α-fluoro β-alanine (FBAL) in liver, in addition to several other molecules offering little toxicity [15,17,135]. FBAL is excreted by the kidneys. Localized NMR spectroscopy and low resolution CSI have examined pharmacokinetics [103,136–138]. NMR of excised tissue and body fluids has also provided insight into metabolism and can provide much higher sensitivity (e.g., μM). While studies in vivo are most attractive, studies of cultured cells can also provide important information.

The pharmacokinetics of 5FU are reported to be pH sensitive and thus, measurements of tumor pH may have prognostic value for drug efficacy. In tumors with lower pH, the retention of 5FU is considerably enhanced [139–141]. This has prompted
investigations of the ability to alter pharmacokinetics by modulation of tumor pH to increase activity, for example, by breathing carbogen [142,143]. 5FU, its metabolites, and fluorinated pH reporter molecules can all be detected simultaneously by 19F NMR (Fig. 2). Intriguingly, fluoronucleotides derived in vivo from 5FU exhibit sensitivity to changes in pH and could be used to measure intracellular pH (pHi), although the presence of a mixture of products may complicate interpretation [141,144,145].

Given the inherent dose-limiting toxicity of 5FU, various prodrugs and mixture formulations have been developed (e.g., capcitabine (Xeloda), Tegafur-uracil (Uftoral®, emitefur (3-(3-(6-benzoyloxy-3-cyano-2-pyridloxycarbonyl)benzoyl)-1-ethoxymethyl-5-fluorouracil)) and 19F NMR has played a role in analysis and development [16,63]. A new and potentially exciting application is assessment of prodrug therapy in conjunction with gene therapy; specifically, the use of cytosine deaminase (CD), to convert the relatively innocuous 5-fluorocytosine (5FC) to 5FU [146–150]. Several investigations have now reported 19F NMR of the conversion of 5FC to 5FU based on the 19F NMR chemical shift, $\Delta \delta = 2$ ppm [18,147,150,151].

Gemcitabine (Gemzar®) is a newer anticancer drug with a more favorable toxicity profile than 5FU. It comprises both sugar and pyrimidine moieties. In cells, it is phosphorylated and incorporated into DNA and to a lesser extent RNA, where it can inhibit DNA polymerases. It can also inhibit thymidine synthase. Given the significant clinical results and successful combination with radiotherapy, there is interest in optimizing activity based on 19F NMR. Unlike 5FU, fluorine is now on the deoxyribosyl ring and the two geminal fluorines give rise to an AB quartet at −42 ppm ($\delta_{TFA} = 0$ ppm). This has been detected in human tumor xenografts by 19F NMR following IP injection and kinetics have been investigated with respect to vasoactive drugs [65,152]. Metabolite signals have been observed in liver and bladder using CSI [153]. At low pH, the signals appear as an AB quartet, but they appear to collapse and broaden to a single signal at pH 8 (Fig. 3).

2.1.2. Other anticancer drugs

McSheehy et al. [154] presented a preliminary report of a novel thymidine synthase inhibitor, ZD9331, where both parent and metabolite peaks were detected at 4.7 T. Brix et al. [155] evaluated a trifluoromethylated derivative of 3-aminobenzamide, an inhibitor of poly(ADP-ribo) polymerase1 (PARP-1), as a potential radio sensitizer in Dunning prostate rat tumors and using CSI, detected separate signals from liver, muscle, and tumor revealing maximum tissue signals after 2 days. Spees et al. [156] followed pharmacokinetics of fluorine-labeled methotrexate in sensitive and resistant tumor xenografts in mice and found an inverse correlation between surviving fraction and area under the curve.
2.2. Other drugs

Recognizing the exquisite sensitivity of $^{19}$F NMR to microenvironment, inclusion of fluorine atoms in libraries of ligands has been used to probe molecular interactions based on changes in line width and chemical shift [157–160].

Following cancer chemotherapeutics, most in vivo $^{19}$F NMR has examined psychiatric agents [14,161]. These can be particularly favorable when they incorporate a CF$_3$ moiety. Several reports investigated fluoxetine (Prozac) with studies ranging from biopsy tissue extracts to preclinical animal models and human volunteers [70,71,162]. The primary goal has been correlation of concentration with efficacy, for example, Henry et al. [70] explored the relative brain concentrations of $R$ and $S$ enantiomers versus a racemic mixture of fluoxetine in separate groups of patients. Other studies have examined fluvoxamine (a selective serotonin reuptake inhibitor—SSRI) to counter a possessive compulsive disorder [71,163].

Dexfenfluramine has been observed at brain concentrations <10 $\mu$M [72]. $^{19}$F NMR of trifluoperazine revealed multiple metabolites in rat brain extracts, but these were too weak and unresolved in vivo at 4.7 T [164]. Such studies have provided a single unlocalized spectrum corresponding to whole brain volume and lines are generally quite broad (2–3 ppm). Sassa et al. [165] used $^{19}$F chemical shift imaging to detect haloperidol decanoate in schizophrenic patients.

![Fig. 3. $^{19}$F NMR of gemcitabine. Lower spectrum shows a solution of gemcitabine hydrochloride at pH 3.2. For comparison, the upper spectrum was obtained in the presence of sodium hydroxide at pH 8.4. Each spectrum required about 1 min at 376 MHz (9.4 T) (data acquired in collaboration with Dr. Peter Peschke, DKFZ, Heidelberg, Germany).](image)
Other studies have examined fluoroquinolone antibiotics (floxacin) [166], antimicrobials (sitafoxacin) [66], nonsteroidal anti-inflammatory (niflumic acid [67]), and anti-histamines (tecastemizole [68]). However, the tecastemizole was only detected from 3 of 23 patients and the retention was found to be much shorter than the psychotropic drugs such as fluoxetine. Attempts to detect dexamethasone in the eye at 1.5 T failed [167]. PFCs have been used as a tampo-nade in eye surgery and residual PFC has been detected in patients at 1.5 T [168,169]. Indeed, this allowed $pO_2$ measurements based on spin lattice relaxation, as discussed in detail in Section 3.1.1.1. The PFC emulsion synthetic blood substitute Fluosol was proposed as a method of modulating tumor oxygenation [170] and it could be detected from surrounding tissues as long as 1 year after administration and tumor resection [171]. Perfluorononane has been used to explore GI tract in man and mice at 1.5 T [69]. This may provide insight into GI function or serve as a model for all drug delivery.

Many gaseous anesthetics are fluorinated, for example, halothane, enflurane isoflurane, sevoflurane, and desflurane. NMR studies of fluorinated anesthetics form some of the earliest in vivo applications of $^{19}$F NMR [172–174]. Issues regarding the use of anesthetics are site of anesthetic action, duration of residence in the brain, and toxicity of metabolic byproducts. The results have been a source of debate and controversy. Wyrwicz and coworkers [175] addressed the issue of residence times of anesthetics in the brain and observed signals for prolonged durations after cessation of anesthesia. Global spectroscopy is straightforward, but anesthetics have a short transverse relaxation time ($T_2^*$) and signals may be lost in localized spectroscopy or imaging approaches. Very few clinical studies have reported $^{19}$F NMR of anesthetics in the brain, though Menon et al. [13] demonstrated the feasibility of such studies and found halothane signal up to 90 min after the withdrawal of anesthetic. Lockwood et al. [176] studied isoflurane kinetics and showed biphasic elimination with decay half-times of 9.5 and 130 min. Selinsky et al. [177,178] have studied the metabolism of volatile anesthetics showing generation of potentially toxic metabolites such as methoxydifluoroacetate, dichloroacetate, and fluoride ion from methoxyflurane.

The ability to detect drugs in vivo depends on multiple considerations. Obviously, the concentration at which drugs are administered is important together with the tendency to localize or clear from tissues. One would also expect multiple fluorine atoms to provide enhanced signal-to-noise over a single fluorine atom. Of course, they must be spectrally equivalent. Table 2 shows multiple diverse commercial molecules from the pharmaceutical and agrochemical fields, each of which has one or more fluorine atoms. Although no particular in vivo fluorine NMR has been reported, they are clearly prime candidates. Indeed, $^{19}$F NMR has been exploited to assess pesticides as contaminants in food [179]: in oils and wine levels $>$1 mg/l, while in food extracts detection levels may approach parts per billion [180]. In particular, we note that some agents have multiple equivalent fluorine atoms. Flutamide [181] has a trifluoromethyl
group and while there appear to be no references to in vivo NMR, $^{19}\text{F}$ NMR has been used to investigate drug formulation [181, 182]. Bistrifluoron has two trifluoromethyl groups, but they are spectrally nonequivalent. By contrast, T009317 [183] has a hydroxyditrifluoromethylisopropyl group and would be expected to give high NMR sensitivity.

To obtain detectable signals (spectra, or images), sufficient fluorinated probe must be administered, though the concentration of probe in studies of living organisms should be as low as possible to avoid physiological perturbations or toxic side effects. For pharmaceuticals, fluorine labels are added for development, but their ultimate presence depends on optimal drug activity. By contrast, for reporter molecules, the fluorine atom is the key to efficacy and design is optimized for NMR detectability.

3. ACTIVE REPORTER MOLECULES

Many reporter molecules have been designed specifically to exploit fluorine chemical shift, coupling, or relaxation to reveal physiological parameters. Active agents typically fall into three categories: (i) molecules which enjoy a physical interaction, for example, PFCs, which exhibit exceptional gas solubility and reveal oxygen tension based on modification of relaxation parameters (Section 3.1.1); (ii) ligands designed to trap/bind specific entities, such as ions, specifically, but reversibly, for example, $\text{H}^+$ (pH) (Section 3.1.2), metal ions (Ca$^{2+}$, Mg$^{2+}$) (Section 3.1.3); and (iii) molecules which undergo irreversible chemical interaction modifying their structure, as revealed by a change in chemical shift (Section 3.2). These are represented by gene reporter molecules (Section 3.2.3), where substrates are cleaved by specific enzyme activity, and hypoxia agents (Section 3.2.2), which are modified by reductases and trapped. There are also passive agents, which occupy and hence reveal a space, compartment, or volume, for example, tumor blood volume (Section 4).

3.1. Physical interactions

3.1.1. In vivo oximetry

Oxygen is vital to the well being of normal mammalian tissues and deficits are associated with myocardial infarct, stroke, diabetic neuropathy, and cancer. In each case, lack of oxygen is associated with poor prognosis and a clinical goal is often to enhance tissue oxygenation. There is increasing evidence that hypoxia influences such critical characteristics as angiogenesis, tumor invasion, and metastasis [184–187]. Moreover, it has long been appreciated that hypoxic tumor cells are more resistant to radiotherapy [188]. Given that hypoxic tumors are more resistant to certain therapies, it becomes important to assess tumor oxygenation as part of therapeutic planning [189]. Patients could be stratified...
according to baseline hypoxia to receive adjuvant interventions designed to modulate $pO_2$, or more intense therapy as facilitated by intensity modulated radiation therapy (IMRT). Tumors, which do not respond to interventions, may be ideal candidates for hypoxia selective cytotoxins (e.g., tirapazamine [190]).

Thus, there is a vital need to be able to measure tissue $pO_2$ and many diverse technologies have been presented, as reviewed previously [10,191,192]. Some, such as near infrared spectroscopy and blood oxygen level dependent (BOLD) contrast MRI provide an indication of vascular oxygenation [2,193,194]. PET has been used to examine oxygen extraction fraction and hence metabolic activity based on uptake of $^{15}$O$_2$, but the half-life of oxygen-15 is exceedingly short ($t_{1/2} \approx 2$ min) [195,196]. Other modalities provide an indication of hypoxia [197,198]. In many cases, there is a desire to measure $pO_2$ directly and this may be achieved using polarographic electrodes [199,200], fiber optic probes [201], free radical probes with electron spin resonance (ESR) [191,202], or PFC probes with NMR [9,10], as described below.

### 3.1.1.1. PFC $pO_2$ reporters

NMR oximetry is based on the paramagnetic influence of dissolved oxygen on the $^{19}$F NMR spin lattice relaxation rate of a PFC, as reviewed previously [10]. The solubility of gas, notably oxygen, in PFCs occurs as an ideal gas liquid mixture and thus, $R_1$ varies linearly with $pO_2$, as predicted by Henry’s Law [5,10,203]. $R_1$ is sensitive to temperature, and magnetic field, but importantly, $R_1$ of PFCs is essentially unresponsive to pH, CO$_2$, charged paramagnetic ions, mixing with blood, or emulsification [204–206] and for the PFC emulsion of perfluorotributylamine (PFTB) (Oxypherol), we have shown that calibration curves obtained in solution are valid in vivo [207]. At any given magnetic field ($B_0$) and temperature ($T$)

$$R_1 = A + B \ pO_2, \quad (1)$$

where $A$ is the anoxic relaxation rate and $B$ represents the sensitivity of the reporter molecule to the paramagnetic contribution of oxygen and the ratio $\eta = B/A$ has been proposed as a sensitivity index [208]. Several PFCs have been used successfully for NMR oximetry and characteristics are summarized in Table 4. A particular PFC molecule may have multiple $^{19}$F NMR resonances, and each resonance has a characteristic $R_1$ response to $pO_2$ and temperature [9,62]. Many PFCs (e.g., PFTB, perfluoron (often referred to as perfluoroocetylbro- mide [PFOB]) and Therox™ (F44-E)) have several $^{19}$F NMR resonances, which can be exploited to provide additional information in spectroscopic studies, but complicate effective imaging [209–211]. PFCs with a single resonance provide optimal signal-to-noise ratio (SNR) and simplify imaging: two agents hexafluoro- benzene (HFB) [10,36,200,212–217], and perfluoro-15-crown-5-ether (15C5) [218–221] have found extensive use. While most $pO_2$ investigations have exploited the $R_1$ sensitivity, $R_2$ is also sensitive as reported by Girard et al. [222].
Table 4. $^{19}$F NMR characteristics and applications of PFCs for tissue oximetry

<table>
<thead>
<tr>
<th>Name</th>
<th>Structure</th>
<th>Sensitivity to $pO_2$</th>
<th>Number of $^{19}$F resonances</th>
<th>Applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFB</td>
<td><img src="image" alt="HFB Structure" /></td>
<td>$A = 0.0835$; $B = 0.001876$</td>
<td>1</td>
<td>Rat breast tumor, prostate tumor, human lymphoma xenograft [10,214, 215,217,267,270] (Fig. 7)</td>
</tr>
<tr>
<td>Perfluoro-15-crown-5-ether</td>
<td><img src="image" alt="Perfluoro-15-crown-5-ether Structure" /></td>
<td>$A = 0.345$; $B = 0.0034$</td>
<td>1</td>
<td>Tumor cells, mouse tumor, spleen, liver, rat breast tumor, rat brain [218,247,254]</td>
</tr>
<tr>
<td>FC-43 (Oxypherol)</td>
<td><img src="image" alt="FC-43 (Oxypherol) Structure" /></td>
<td>$A = 1.09$; $B = 0.00623$</td>
<td>4</td>
<td>Liver, spleen, lung, eye, tumors, heart [5,243,244,256]</td>
</tr>
<tr>
<td>PFTP (Fluosol)</td>
<td><img src="image" alt="PFTP (Fluosol) Structure" /></td>
<td>$A = 0.301$; $B = 0.00312$</td>
<td>3</td>
<td>Rat spleen, lung, tumors, cells [232,252,406]</td>
</tr>
</tbody>
</table>
\( F-44E \) (Therox) \[ \text{CF}_3\text{(CF}_2\text){}_3\text{CH=CH(CF}_2\text){}_3\text{CF}_3 \]
\[ A = 0.2525; \quad B = 0.16527 \]
Rat spleen, liver, aorta, mouse Tumors [235, 253]

\( \text{PFOB (Imagent, Oxygen)} \) \[ \text{Br(CF}_2\text){}_7\text{CF}_3 \]
\[ A = 0.2677; \quad B = 0.12259 \]
Rat heart, rat prostate tumor, rabbit liver, pig lungs, phantom [241, 250, 432, 433]

\( \text{PTBD} \)
\[ A = 0.50104; \quad B = 0.1672 \]
Phantom [434]

\( a \quad R_1 \,(s^{-1}) = A + B \, pO_2 \,(\text{Torr}) \)  
HFB, hexafluorobenzene.
$R_1$ is sensitive to temperature and even a relatively small error in temperature estimate can introduce a sizable discrepancy into the apparent $pO_2$ based on some PFCs. The relative error introduced into a $pO_2$ determination by a 1 °C error in temperature estimate ranges from 8 Torr/°C for PFTB [207] to 3 Torr/°C for PFOB (perfluorobron) [223] or 15-Crown-5-ether [218] when $pO_2$ is actually 5 Torr. HFB exhibits remarkable lack of temperature dependence and the comparative error would be 0.1 Torr/°C [224]. Recognizing differential sensitivity of pairs of resonances within a single molecule to $pO_2$ and temperature, Mason et al. [207,225] patented a method to simultaneously determine both parameters by solving simultaneous equations. However, generally it is preferable for a $pO_2$ sensor to exhibit minimal response to temperature, since this is not always known precisely in vivo and temperature gradients may occur across tumors.

PFCs are extremely hydrophobic and do not dissolve in blood directly, but may be formulated as biocompatible emulsions for intravenous (IV) infusion. PFC emulsions have been developed commercially both as potential synthetic blood substitutes [226–229] and as ultrasound contrast agents [230,231]. Following IV infusion, a typical blood substitute emulsion circulates in the vasculature with a half-life of 12 h providing substantial clearance within 2 days [227]. Some investigators have examined tissue vascular $pO_2$, while PFC remained in the blood [206,232–235]. Flow can generate artifacts and correction algorithms have been proposed [236,237]. Primary clearance is by macrophage activity leading to extensive accumulation in the liver, spleen, and bone marrow [238,239]. This is ideal for investigating $pO_2$ in the liver or spleen, but a major shortcoming for other tissues, since animals may exhibit extensive hepatomegaly or splenomegaly though there is no apparent toxicity [227,238,240]. Long-term retention in tissues allows $pO_2$ measurements to be made in vivo and extensive studies have been reported in liver, spleen, abscess, perfused heart, and tumors [5,9,62,218,241–254].

### 3.1.1.2. Myocardial oxygenation

Due to motion, the heart is a particularly complex organ for measuring $pO_2$, yet understanding myocardial physiology with respect to infarcts has important implications for the clinical practice. Sponsored by the American Heart Association, we sought to develop a noninvasive approach for monitoring dynamic changes in myocardial oxygenation [243]. In Figs. 4 and 5, we present a case study demonstrating the ability to evaluate dynamic changes in myocardial oxygenation. Following IV or IP administration of PFC, some becomes sequestered in heart tissue. This is detectable using a surface coil placed over the heart of an open-chest rabbit, but for proof of principle investigations, we examined excised crystalloid perfused Langendorff rat hearts [243]. To achieve effective $^{19}$F NMR signal, Sprague–Dawley rats were loaded with PFTB (Oxypherol: 1 ml/100g/day) for 9 days via tail vein injections. Hearts containing the sequestered PFC
Fig. 4. Monitoring myocardial oxygenation using $^{19}$F NMR of sequestered perfluorotributylamine. (a) Spin lattice relaxation ($R_1$) recovery curve obtained in 2 min for the CF$_3$ resonance from an isolated Langendorff perfused rat heart that had sequestered oxypherol. $R_1 = 2.11 \pm 0.08$ s$^{-1}$ indicates 510 $\pm$ 30 Torr at 37°C. Inset shows partial $^{19}$F NMR spectrum with resolved downfield CF$_3$ and CF$_2$ resonances. (b) Steady-state $R_1$-measured $pO_2$ values of perfused rat hearts as percentage of normalized initial tissue $pO_2$ with respect to interventions. Hearts in Group A (▲) showed $pO_2$ equivalent to 0 Torr during total global ischemia (TGI), but returned to 100% upon reperfusion. KCl arrest resulted in increased tissue $pO_2$ from the excess available oxygen. Elevated $pO_2$ was observed in hearts in both Group B ( ▲) (experiencing immediate arrest) and those in Group A (experiencing prior TGI). The previous ischemia experienced by Group A did not “condition” the hearts in terms of the...
were excised and retrograde perfused by the Langendorff method at a pressure of 70 cm H2O with modified Krebs–Henseleit buffer. A fluid-filled latex balloon was inserted into the left ventricle and connected to a pressure transducer to monitor developed pressure. Total global ischemia (TGI) was induced by halting flow to the aorta *in situ*. Cardiac arrest was induced by increasing the KCl in the perfusate to 20 mM.

In the absence of spatial selection, a 19F NMR signal of PFTB could be obtained representing the whole heart in one pulse at 7 T using a volume coil [243]. Using a full T1 relaxation sequence (e.g., Fig. 4), precise pO2 values could be obtained. Global R1 measurements provided an accuracy of 20–40 mmHg (Torr) and showed significant differences in cardiac tissue before and during ischemia (p < 0.001) and before and during KCl-induced cardiac arrest (p < 0.001, Fig. 4b). However, it was apparent that pO2 changes occurred far more rapidly than could be assessed using a full T1 curve. More rapid T1 estimates are feasible using fewer recovery time delays on the relaxation curve, and indeed, a two-point comparison based on partial saturation allowed dynamic changes in pO2 to be assessed with 1-s time resolution [243]. While any individual pO2 estimate is less precise, the dynamics are apparent (Fig. 5). The decline in myocardial tissue pO2 in KCl-arrested hearts undergoing ischemia was four to eight times slower than that of the normally beating hearts. Following the onset of ischemia, there was close correlation (R = 0.93) between the decline of pO2 and developed pressure (Fig. 5e).

Global measurements related to TGI have some value, but clinical infarction is more likely to generate regional ischemia requiring spatial resolution for useful models. We have undertaken 19F MRI of arrested hearts with respect to regional ischemia induced by ligation of the lower anterior descending (LAD) artery and found spatial heterogeneity of hypoxia [246]. However, acquisition times for the images were excessive (hours), so that monitoring pO2 dynamics in the heart is restricted to preclinical studies. Use of a PFC with a single resonance could improve SNR and reduce imaging times. Targeting cardiac tissue directly could also improve SNR and this has been a goal of Wickline *et al*. [56].

3.1.1.3. Tumor oxygenation

The most extensive use of 19F NMR oximetry has been to investigate tumor oxygenation with both acute studies of interventions and chronic studies of growth. Many investigations, including our own initial studies, used PFC emulsions to probe tumor oxygenation. Uptake and deposition of PFC emulsions in tumors is highly variable and heterogeneous with most signal occurring in well-perfused R1-measured pO2. Global ischemia showed complete hypoxia for both groups with or without KCl arrest. Error bars represent one standard deviation of measurements from multiple hearts (data adapted from Ph.D. thesis of Himu Shukla, UT Southwestern 1994) [405].
Fig. 5. Correlation of myocardial oxygenation and developed pressure in excised Langendorff perfused rat hearts. (a) When NMR signals are acquired more rapidly than the time required for full relaxation, there is signal loss due to partial saturation. Comparing the
regions [242,254]. Indeed, \( pO_2 \) values measured soon after intravenous infusion, but following vascular clearance (typically 2 days), are generally high, approaching arterial \( pO_2 \) [242]. Thus, physiological measurements with respect to intervention are biased towards the well-perfused, well-oxygenated regions, which are often less important than hypoxic regions. Interestingly, following sequestration, PFC does not seem to redistribute within tissue, but remains associated with specific locations. Figure 6 shows residual PFC in the center of a tumor 18 days after systemic administration of Oxypherol. This was found to be essentially hypoxic tissue. When fresh PFC emulsion was administered and allowed to clear for two days, the original signal was still clearly delineated in shape, form, and intensity. However, a new signal was detected around the tumor periphery indicating the newly well-perfused regions. Such long-term tissue marking has been proposed as a form of noninvasive histology [255]. Long tissue retention has the advantage of facilitating chronic studies during tumor development and progressive tumor hypoxiation has been observed over many days [242,245].

To avoid the bias towards well-perfused regions and need to await vascular clearance, we developed an approach using direct intratumoral (IT) injection of neat PFC, which allows any region of interest in a tumor to be interrogated immediately [10]. Use of a fine needle ensures minimal tissue damage. Direct injection of neat PFC has been used by others to investigate retinal oxygenation [256–258] and cerebral oxygenation in the interstitial and ventricular spaces [221] and for the first time here, we show results in rat thigh muscle (Fig. 7).

We have identified HFB as an ideal reporter molecule [224]. Symmetry provides a single narrow \(^{19}\)F NMR signal and the spin lattice relaxation rate is highly sensitive to changes in the local rate of tissue oxygenation. The intensity of a partially saturated signal to fully relaxed signal indicates \( R_1 \) and hence, \( pO_2 \). In (a), the larger CF\(_3\) signal shows a decrease of about 15% compared with baseline under fully perfused, well-oxygenated conditions. Induction of TGI caused rapid loss of signal commensurate with increasing \( T_1 \) and reduced \( pO_2 \). Individual spectra were acquired in 1.1 s. The transition was complete within about 40 s. \( T_1 \) of the CF\(_3\) resonance increased from 540–1240 ms causing the signal to decline from 86% to 68% accompanying TGI. The CF\(_2\) resonance only changed from about 390 to 570 ms and this had minimal effect on signal intensity (SI) under these partial saturation conditions. (b) Dynamic data (the partial saturation spectra quantified using decay of the CF\(_3\) resonance) from hearts made globally ischemic showed that an arrested heart (▲) consumed residual oxygen in the heart more slowly than a beating heart (○). Note that the arrested heart started from a higher state of tissue oxygenation due to reduced oxygen demand. The monoexponential rate constants representing the loss of tissue \( pO_2 \) are: beating \( L = 0.11 \, \text{s}^{-1} \), arrested \( L = 0.02 \, \text{s}^{-1} \). (c) The pressure tracing of a perfused rat heart based on an intraventricular balloon catheter was digitized to quantitate the rate of ventricular pressure failure during ischemia. For this heart, a monoexponential curve fit to the pressure amplitude yielded a decay rate constant \( P = 0.085 \, \text{s}^{-1} \). (d) Reperfusion following 5 min TGI led to rapid reoxygenation of the rat hearts, revealed by increase in the CF\(_3\) signal corresponding to shortening of \( T_1 \). (e) A strong linear relationship was found between the rate of heart tissue hypoxiation and ventricular pressure failure for rat hearts upon acute TGI (\( r > 0.9 \)).
sensitive to changes in $pO_2$, yet minimally responsive to temperature [224,259,260]. HFB also has a long spin–spin relaxation time ($T_2$), which is particularly important for imaging investigations. HFB is well characterized in terms of lack of toxicity [261,262], exhibiting no mutagenicity [263], teratogenicity or fetotoxicity [264], and the manufacturer’s material data safety sheet indicates LD50 > 25 g/kg (oral-rat) and LC50 95 g/m$^3$/2 h (inhalation-mouse). HFB had been proposed as a veterinary anesthetic and has been used in many species including ponies, sheep, cats, dogs, rats, and mice, but was abandoned due to its flammability [265]. Flammability is not a problem for NMR oximetry, where small quantities of liquid (typically, 50 $\mu$l) are injected directly into the tumor.

Initial studies used 10–20 $\mu$l HFB injected directly into the center or periphery of a tumor and $pO_2$ measurements indicated tumor heterogeneity [224,266]. Although data were acquired using nonlocalized spectroscopy, the highly localized signal ensured that regional $pO_2$ was measured. Subsequently, we developed an imaging approach: \textit{FREDOM} (Fluorocarbon Relaxometry using Echo planar imaging for Dynamic Oxygen Mapping) [10], which typically provides
50–150 individual $pO_2$ measurements across a tumor simultaneously in about 6.5 min with a precision of 1–3 Torr in relatively hypoxic regions based on 50 $\mu$l injected dose (Fig. 7). In both muscle and tumor tissues, $pO_2$ heterogeneity is apparent when rats breathe air ($pO_2$ ranged from 0 to 100 Torr). Upon challenge with oxygen breathing, essentially all muscle regions showed a significant increase in oxygenation. Many tumors show little response to hyperoxic gas, but the 13762NF mammary tumor generally shows extensive response [217].
as seen in Fig. 7. We have used FREDOM to examine the effects of vascular targeting agents [36,267], vasoactive agents [215] and hyperoxic gases [10,200, 212–217,268–270]. We have shown that measurements are consistent with sequential determinations made using electrodes [271,272] and fiber optic probes (FOXY™ and OxyLite®) [201,216]. Repeat measurements are highly reproducible and generally quite stable in tumors under baseline conditions. Results are also consistent with hypoxia estimates using the histological marker pimonidazole [212]. Most significantly, estimates of $pO_2$ and modulation of tumor hypoxia are found to be consistent with modified tumor response to irradiation [213,273]. Such prognostic capability could be important in the clinic, since it is known that relatively hypoxic tumors tend to be more aggressive and respond less well to radiation therapy [274–276]. Hitherto, we have lacked a $^{19}$F MRI capability in our human systems in Dallas. However, Philips is promoting dual $^{19}$F MRI capabilities on the new 3 T human systems [91,277] and we expect to be able to pursue translation of the FREDOM approach in the near future.

3.1.2. pH

$pH$ is an important indicator of tissue health and acidosis may reflect ischemia and hypoxia. Historically, tumors were believed to be acidic (Warburg hypothesis) and the detection of neutral or basic environments by NMR led to initial controversy [278]. It was ultimately realized that $^{31}$P NMR of endogenous inorganic phosphate (Pi) reflects primarily the cytosolic pH, which is often in the range 7.0–7.4, whereas tumor interstitial (pHe) may indeed be acidic, as previously observed using polarographic electrodes. This reversed pH gradient has important implications for partitioning of weak acid or base drugs, and thus, considerable effort has been applied to developing robust reporter molecules. $^{19}$F NMR pH indicators (Table 3) represent three strategies: (i) development of molecules specifically designed for $^{19}$F NMR, (ii) fluorinated analogues of existing fluorescent indicators, and (iii) exploitation of the $^{19}$F NMR chemical shift sensitivity inherent in cytotoxic drugs. Many molecules exhibit chemical shift response to changes in pH, for example, the $^{19}$F NMR resonance of 6-fluoropyridoxol (6-FPOL) [11,279]. On the NMR timescale, protonated and deprotonated moieties are generally in fast exchange, so that a single signal is observed representing the amplitude weighted mean of acid and base forms. $pH$ is measured using the Henderson–Hasselbalch equation:

$$pH = pK_a + \log_{10}\left(\frac{\delta_{\text{obs}} - \delta_{\text{acid}}}{\delta_{\text{base}} - \delta_{\text{obs}}}\right)$$

where $\delta_{\text{acid}}$ is the limiting chemical shift in acid, $\delta_{\text{base}}$ is the limiting chemical shift in base, and $\delta_{\text{obs}}$ is the chemical shift observed at a given pH. Due to the nonlinear form of the equation, greatest sensitivity is found close to the $pK_a$. 

19F NMR Reporter Molecules 231
Reporter molecules may readily access the interstitial compartment, but intracellular measurements are more difficult. Deutsch et al. [74,280] championed the use of $^{19}$F NMR to measure intracellular pH primarily based on the series of agents 3-monofluoro-, 3,3-difluoro-, and 3,3,3-trifluoro-2-amino-2-methyl propionic acid (Table 3). pH sensitivity is predicated on protonation of the amino group and it is immediately apparent that additional fluorine atoms influence the $pK_a$. These molecules have been successfully applied to pH measurements in cells [74,281–283] and isolated organs [74,284]. A significant problem is loading indicators into cells, but esters are relatively permeable, stable in water, and undergo nonspecific enzymatic hydrolysis intracellularly, liberating the pH-sensitive molecules [280]. This approach can lead to complex spectra including overlapping multiline ester and liberated free acid resonances from both intra- and extracellular compartments (Fig. 8) [285]. Widespread use of these molecules has been hindered by the problem of loading the indicators into cells and the relatively small chemical shift range approximately 2 ppm. Difluoromethyl ornithine (DFMO) represents another $^{19}$F NMR sensitive amino acid, which is also a

Fig. 8. pH measurement in cells. $^{19}$F NMR of difluoromethylalanine para-chlorophenyl ester (1 mM) added to suspension of RINm5F cells (4% cytocrit). Spectra were taken at 4-min intervals (1,600 scans, 30° pulse, repetition rate = 5/s) with broadband proton decoupling. The resonances marked “e” arise from the ester form of the amino acid. The resonances in the lower spectrum marked “o” arise from extracellular free amino acid, whereas those marked “i” arise from intracellular free amino acid. Spectrum (a) 1–5 min; (b) 5–9 min after addition of ester to the cell suspension. The ester quartet (e) lines decreased in intensity, while the quartets of lines from the product of ester hydrolysis, intracellular difluoromethylalanine (CF$_2$) and extracellular difluoromethylalanine (CF$_2$e), increased with time [partial figure reproduced from J. Taylor and C.J. Deutsch, $^{19}$F nuclear magnetic resonance: measurements of [O$_2$] and pH in biological systems. Biophys. J. 1988; 53: 227–233 [406] with permission of the Biophysical Society].
therapeutic drug. Unfortunately, its chemical shift response is even smaller and the chemical response is not monotonic, going though a reversal above the pKₐ [286]. A large chemical shift range is important to ensure precise measurements of pH. When multiple cellular compartments are present there is less problem with signal overlap. Perhaps more importantly, any chemical shift perturbations due to other factors, such as susceptibility become less important [287–289]. Furthermore, the pKₐ should be matched to the pH range of interest since the largest chemical shift response occurs close to the pKₐ [74].

Aromatic reporter molecules tend to have a much larger chemical shift pH response. Analogs of vitamin B6, for example, 6-FPOL are highly sensitive to pH [11,279,290–292]. We showed that 6-FPOL itself readily enters cells and provides well-resolved resonances reporting both intra- and extracellular pH (pHi and pHe), simultaneously, in whole blood (Fig. 9) [279] and the perfused rat heart [290]. Ease of entry into blood cells may be related to facilitated transport, since vitamin B6 is naturally stored, transported, and redistributed by erythrocytes [293]. Intriguingly, most tumors cells show a single resonance only, suggesting that 6-FPOL does not enter. The somewhat basic pKₐ = 8.2 is appropriate for investigations of cellular alkalosis, but it is not ideal for studies in the normal physiological range (6.5–7.5) [290].

Ring substitution allowed us to alter the pKₐ and 6-fluoropyridoxamine (6-FPAM) offered superior characteristics with pKₐ 7.05 [291]. As for 6-FPOL, we have observed intra- and extracellular signals in whole blood and perfused rat hearts [11,291] and in addition, specific tumor cells (Morris hepatoma...
MH-Tk) showed uptake [18]. While modification of the 4-hydroxymethyl group to aminomethyl altered the $pK_a$ favorably, the 5-isomer was minimally changed (Table 3) [291].

Noting the large chemical shift response of pyridines, we also explored fluoro-phenols as pH indicators. Like 6-FPOL, $p$-fluorophenols show a large chemical shift response $\Delta \delta$ 6.4–11.3 ppm, whereas $o$-fluorophenols have a smaller chemical shift range ($\sim$0.3–2.2 ppm) (Table 3) [294]. For comparison both 6-FPOL and PFONP ($p$-fluoro-$o$-nitrophenol) are shown to reveal pH gradients in whole blood giving comparable results and consistent with electrode measurements (Fig. 9). Fluorophenols must be used cautiously, since PFONP appears cytolytic for certain tumor cells and may act as an ionophore, by analogy with dinitrophenol.

Other aromatic pH reporters have been presented including analogs of fluorescent pH indicators. FQuene, a $^{19}$F NMR sensitive analog of the fluorescent pH indicator quene-1, was used to measure intracellular pH in a perfused heart [295] and liver [296]. $o$-Methoxy-$N$-(2-carboxyisopropyl)-4-fluoroaniline has a chemical shift range approximately 17 ppm, but the $pK_a$ (5.8) is less suitable for in vivo investigations. Modification to $N,N$-(methyl-2-carboxyisopropyl)-4-fluoroaniline [297] retained a substantial chemical shift range ($\Delta \delta$ 12 ppm) and produced a physiologically suitable $pK_a$ (6.8), however, no biological studies have been reported. Metafluoro isomers showed considerably smaller chemical shift response to changes in pH. $N$-ethylaminophenol (NEAP) has been described with various analogs to detect pH or metal ions [298].

To enhance SNR, or reduce the required dose, a pH sensitive CF$_3$ moiety could be introduced in place of the F-atom. Trifluoromethylphenols show titration response, though by comparison with the fluorophenols (Table 3), the chemical shift response is typically smaller $\Delta \delta = 1.25$ ppm ($p$-CF$_3$ArOH, $pK_a$ 8.5) to 0.4 ppm ($o$-CF$_3$-Ar, $pK_a$ 7.92), as expected since electronic sensing must be transmitted through an additional C–C bond [299]. Importantly, the $^{19}$F NMR signal occurs downfield from NaTFA, so that unlike 6-FPOL there is no interference from isoflurane signals [18]. While FPOL and FPAM provide both intracellular and extracellular signals with varying ratios depending on cell type, 6-trifluoromethylpyridoxol (CF$_3$POL) is found to occur exclusively in the extracellular compartment, and thus reports pHe, or interstitial pH [18,300]. Frenzel et al. [301] have described a fluoroaniline sulfonamide (ZK150471) and its use has been demonstrated in mice and rats to investigate tumor pH [302,303]. This molecule is restricted to the extracellular compartment only [301,304], but combination with $31$P NMR of Pi to determine pH$_i$ has been used to reveal the transmembrane pH gradient in mouse tumors [141]. A distinct problem with ZK150471 is that the $pK_a$ differs in saline and plasma [304]. Most indicators require an additional chemical shift reference standard, for example, sodium trifluoroacetate, but NEAP [298], 6-FPOL-$5\alpha$-CF$_3$ [291], and ZK150471 [301] all have nontitrating intramolecular chemical shift references. pH measurements using 2-amino-3,3-difluoro-2-methyl propanoic acid is based on changes in the
splitting of the AB quartet and this again avoids need for a chemical shift reference, but the splitting increases the complexity of the spectrum and reduces SNR (Fig. 8).

### 3.1.3. Metal ions

Since metal ions play key roles in cellular physiological processes many specific reporter molecules have been developed, mostly as fluorescent indicators incorporating extended aromatic and conjugated structures, where the wavelength of fluorescence depends upon specific binding of a metal ion. Several $^{19}$F NMR reporters have been created by addition of fluorine atoms (Table 5).

Tsien [305] made an important breakthrough by establishing an approach for loading fluorescent metal ion chelators into cells using acetoxymethyl esters. He demonstrated 1,2-bis(o-aminophenoxy)ethane-$N,N,N,N^0$-tetraacetic acid (BAPTA) for detecting intracellular calcium ions and subsequently Metcalfe et al. [295] added para-fluoro atoms to the aromatic ring yielding a $^{19}$F NMR responsive agent (5,5-difluoro-1,2-bis(o-aminophenoxy)ethane-$N,N,N,N^0$-tetraacetic acid (5FBAPTA)) (Table 5). Upon binding calcium, there is a change in chemical shift (Fig. 10).

Ideally, such a reporter molecule would have high specificity for the metal ion of interest. In fact, the F-BAPTA agents are found to bind several divalent metal ions, including Ca$^{2+}$, Zn$^{2+}$, Pb$^{2+}$, Fe$^{2+}$, and Mn$^{2+}$ (Fig. 10) [306,307], but importantly, each metal ion chelate has an individual chemical shift, so that they can be detected simultaneously [308]. 5FBAPTA includes two fluorine atoms symmetrically placed to provide a single signal. Upon binding, there is slow exchange of Ca$^{2+}$, on and off the indicator, on the NMR timescale, so that separate signals are seen for the free and metal ion bound moieties, with chemical shifts of several ppm. Measurements are based on the signal ratio, avoiding the need for a chemical shift reference, in contrast to pH reporters, which are usually in the fast exchange regimen. Calcium concentration may be calculated from the formula [308]

$$[\text{Ca}^{2+}] = K_D \frac{[\text{Ca} - \text{FBAPTA}]}{[\text{FBAPTA}]}$$ (3)

However, the dissociation constant ($K_D$) does depend on pH, ionic strength, and the concentration of free Mg$^{2+}$, which need to be estimated independently. 5FBAPTA has been used extensively [308] in studies of cells [306,309,310], and the perfused beating heart, revealing calcium transients during the myocardial cycle (Fig. 11) [311–313]. Kirschenlohr et al. [313] reported that developed pressure in the perfused heart was reduced after addition of 5FBAPTA, but this could be reversed by including 50 μM ZnCl$_2$ in the perfusion medium.
Table 5. $^{19}$F NMR metal ions indicators$^{a}$

<table>
<thead>
<tr>
<th>Detected Ion</th>
<th>Agent</th>
<th>Structure</th>
<th>$\delta_{F(Ligand)}$ (ppm)</th>
<th>$\Delta \delta$ (ppm)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Ca$^{2+}$]</td>
<td>5FBAPTA</td>
<td><img src="image" alt="Structure of 5FBAPTA" /></td>
<td>2.08$^{b}$</td>
<td>5.8</td>
<td>[307]</td>
</tr>
<tr>
<td>[Zn$^{2+}$]</td>
<td></td>
<td></td>
<td>3.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Pb$^{2+}$]</td>
<td></td>
<td></td>
<td>4.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Cd$^{2+}$]</td>
<td></td>
<td></td>
<td>4.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Hg$^{2+}$]</td>
<td></td>
<td></td>
<td>5.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Co$^{2+}$]</td>
<td></td>
<td></td>
<td>28.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Ni$^{2+}$]</td>
<td></td>
<td></td>
<td>32.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Fe$^{2+}$]</td>
<td></td>
<td></td>
<td>31.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>[Mg$^{2+}$]</td>
<td>5FAPTRA</td>
<td><img src="image" alt="Structure of 5FAPTRA" /></td>
<td>0.80$^{b}$</td>
<td>8.00</td>
<td>[322]</td>
</tr>
</tbody>
</table>

$^{a}$ Data compiled by J.-X. Yu et al.
**19F NMR Reporter Molecules**

- **F-crpy-1**
- **F₄-Cage**
- **F₂-[2.1.1]-Cryptand**
- **F₂-[3.1.1]-Cryptand**

**Chemical Formulas:**

- **[Na⁺]**
- **[Li⁺]**
- **[K⁺]**
- **[Rb⁺]**
- **[Li⁺]**
- **[Na⁺]**
J.-X. Yu et al.

\[
\begin{align*}
\text{F}_6\text{-Carcerand} & \quad [325] \\
\text{[F(N_2O)_2]} & \quad [25,314] \\
\text{F(NO}_3\text{)}_2 & \quad [25,314] \\
\text{F}[2.2.1]\text{-Cryptand} & \quad [25,314] \\
\text{[K}^+] & \quad 110.50 \\
\text{[Rb}^+] & \quad 15.76 \\
\text{[Cs}^+] & \quad 5.40 \\
\text{[Ca}_2^+] & \quad 5.50 \\
\end{align*}
\]


\[ \text{[Sr}^{2+}] \text{HF-[3.1.1]-Cryptand} \]

\[ \text{[Ba}^{2+}] \text{F(NO}_3\text{)}_2 \]

Unless otherwise noted, CFCl₃ was used as a chemical shift standard, solvent: CH₃CN.

6-Fluorotryptophan was used as a chemical shift standard.

\[ ^{19}\text{F NMR Reporter Molecules} \]
In an effort to find an optimal reporter, isomers and derivatives were developed (Fig. 10). 4FBAPTA has a somewhat lower binding constant $K_D = 0.7 \, \mu M$, but exhibits fast exchange [308], so that the signals from the bound and unbound forms are averaged, and it is the absolute chemical shift, which is related to the ratio of the two components (Fig. 10).

Plenio and Diodone have also reported fluorocrown ethers (Table 5), which exhibit chemical shift response upon binding Ca$^{2+}$ [314]. Of course, calcium could potentially be analyzed directly by $^{43}$Ca NMR, however, its natural abundance is <0.2%, its sensitivity is <1% that of $^1$H, and being quadrupolar, it is liable to extensive line broadening [59]. Thus, the application of $^{19}$F NMR with appropriately designed reporter molecules gives insight into cytosolic Ca$^{2+}$.

Magnesium ions are also involved in biological processes and occur in cells at millimolar concentrations [315]. Magnesium can be estimated based on the chemical shift difference of the resonances of adenosine triphosphate (ATP) using $^{31}$P NMR [316–318], though $^{31}$P NMR has intrinsically low signal-to-noise, exacerbated under many pathophysiological conditions, such as ischemia.

**Fig. 10.** Detection of [Ca$^{2+}$] using $^{19}$F NMR of F-BAPTA. Left: molecular structures of three F-BAPTA isomers with Ca$^{2+}$ binding constants. Top right: chemical shifts of F-BAPTA isomers upon binding divalent metal ions with respect to F-tryptophan. Bottom right: $^{19}$F NMR spectra of F-BAPTA in presence of Ca$^{2+}$. 5F-BAPTA is in slow exchange showing response for free and bound forms, whereas 4F-BAPTA is in fast exchange showing weighted average (modified from Smith et al., Proc. Natl. Acad. Sci. (USA) Biological Sciences 80, 7178–7182 (1983)—with permission [306]).
There are many fluorescent indicators for detection of $[\text{Mg}^{2+}]$ [319] and fluorinated NMR reporter have been proposed. The simplest is fluorocitrate [313], which shows a change in chemical shift upon binding $\text{Mg}^{2+}$. However, it is critical that the reporter molecule be used as the $\pm$ isomer only, which has relatively little toxicity [320]. Levy et al. [8,321] developed the $\alpha$-aminophenol-$N,N,O$-triacetic acid (APTRA) structure both for fluorescent application and by incorporation of fluorine atoms for $^{19}$F NMR, which have been used in the perfused rat heart [322].

**Fig. 11.** Changes in gated NMR spectra during the cardiac cycle. Top panel: isovolumic left ventricular pressure in a ferret heart paced at 0.99 Hz in 8 mM $[\text{Ca}^{2+}]$. NMR spectra were acquired at the two times indicated on the pressure record: (a) 10 ms prior to stimulation; (b) 75 ms after stimulation. Middle panel shows gated $^{19}$F NMR spectra (each from 800 acquisitions) recorded at (a) and (b), as indicated. The bound (B) and free (F) peaks of 5F-BAPTA exhibit distinct chemical shifts at approximately 8 and 2 ppm, respectively, downfield from a standard of 1 mM 6-Ftryptophan at 0 ppm. It appears that the free $[\text{Ca}^{2+}]$ varied during the cardiac cycle. Bottom panel shows gated $^{31}$P spectra (400 scans) acquired at times a and b in the same heart. The major peaks correspond to phosphocreatine (0 ppm), ATP (the three peaks upfield from phosphocreatine), and inorganic phosphate (the small peak at 4–5 ppm) (Reproduced from Marban et al. Circ. Res. 1988; 63: 673–678 [311] with permission of Lippincott, Williams & Wilkins).
While indicators are normally designed for a specific ion they often also interact with other ions, for example, FBAPTA provides a unique chemical shift with many divalent metal ions (Fig. 10) [306,307] and has been used to estimate \([\text{Zn}^{2+}], [\text{Pb}^{2+}]\) [323], and \([\text{Cd}^{2+}]\) [307]. Plenio and Diodone [314,324] have developed series of fluorocyclophanes and fluoro crown ethers to explore specific cation binding (e.g., \(\text{K}^+\), \(\text{Li}^+\), \(\text{Na}^+\), \(\text{Ba}^{2+}\), \(\text{Sr}^{2+}\), \(\text{Ca}^{2+}\)) though in many cases, multiple ions may be bound (Table 5 and Fig. 12). Takemura [325] reported macrocycles designed to bind \(\text{K}^+, \text{NH}_4^+, \text{and Ag}^+\). In addition to the metal binding ligands shown in Table 5, many others have been reported, but these were selected since they exhibit particularly large chemical shift responses.

While most reporter molecules have been designed to interact with cations, Plenio and Diodone [326] reported fluorine containing cryptands, which interact with perchlorate. London and Gabel [327] reported fluorobenzene boronic acid, which interacted with specific sugars.

### 3.1.4. Caveats

A number of criteria are pertinent to the development and exploitation of reporter molecules. The fluorine NMR spectrum must respond to interaction with the ion of interest, for example, through the formation of a second signal, as in the slow...
exchange regime, or chemical shift in a fast exchange regime. For many ions, agents should be water soluble, although a degree of lipophilicity may help in transport. The reporter molecule must reach the cellular compartment of interest. Some molecules penetrate cells directly, while for others, this is facilitated using acetoxyethyl esters. A critical issue for intracellular interrogation is loading the reporter molecule into cells. The tetra-carboxylates do not penetrate cells, however, derivatization as acetoxyethyl esters, which has been very widely used in association with analogous fluorescent indicators provides a more lipophilic entity, which can equilibrate across cell membranes [305]. These esters are specifically designed so that intracellular esterases cleave the acetoxyethyl ester, releasing the charged reporter molecule, which is then essentially trapped in the intracellular compartment. The release of acetic acid and formaldehyde are considered to be relatively innocuous. In other cases, specific cellular exclusion is important, so that any signal can unambiguously be attributed to the extracellular or interstitial compartment in a tissue. Such measurements would be analogous to electrode measurements.

It is critical that the reporter molecule not perturb the system under investigation. For ions, there is inevitably some binding and complexation. Provided there is sufficient reservoir of the ions, there can be rapid re-equilibration, and the concentration may give a realistic indication of the free concentration. In unregulated systems, this may be less reliable. The binding constant must be compatible with the typical concentration encountered in vivo. Ideally, the reporter ligand is highly selective for the ion of interest and of course the molecule should exhibit minimal toxicity. Signals should be narrow to enhance both the signal-to-noise and spectral resolution.

3.2. Chemical interactions

In the previous section, we considered reporter molecules, which interact reversibly in a physical sense, for example, solvation of gas, protonation, or binding of metal ion by a ligand. Other reporter molecules reveal activity based on irreversible bond cleavage to release a distinct product. This may be more akin to the metabolism of drugs, but these reporters can be tailored to interrogate specific biological processes.

3.2.1. Metabolism of FDG

Steric and electrostatic considerations allow a fluorine atom to replace a hydroxyl group in many sugars, while retaining enzyme substrate activity. Many tumors are characterized by a high glycolytic rate and FDG is a fluorinated glucose analogue used in PET to measure metabolic activity [328]. It is particularly useful for staging tumors and monitoring metastases. FDG is recognized by glucose transporters and enters cells where it is effectively phosphorylated, trapping it...
intracellularly, but phosphorylated FDG (FDG-6-P) is not a substrate for phosphofructose isomerase. FDG accumulates in metabolically active cells, such as tumors, brain, and myocardium. FDG PET is currently the method of choice for detecting many cancer metastases and differentiating recurrent disease from scar tissue. While PET can assess retention with great sensitivity, it provides no metabolic information, whereas $^{19}$F NMR can be used to differentiate individual metabolites from anabolic and catabolic processes. Of course, NMR studies typically require mM concentrations as opposed to nM/μM for PET and thus, metabolic fates may differ, but 2-FDG has been used in metabolic studies using $^{19}$F NMR [329–332]. The 3-fluoro-3-deoxy-D-glucose isomer (3-FDG) has also been used in the eye, particularly with respect to exploring onset of cataracts [333,334]. It is a poor substrate for hexokinase and the binding affinity of phosphohexose isomerase is low relative to glucose, but it has been used to probe aldose reductase activity in brain [335].

NMR not only provides spectral resolution for a given nucleus allowing multiple fluorine-labeled substrates to be observed simultaneously together with metabolic products, but other nuclei may also be detected. In particular, $^{13}$C and $^2$H NMR have been used extensively to probe metabolism, both confirming well-known pathways (e.g., glycolysis) and revealing novel detoxification products of xenobiotica [96,97,336,337]. $^{13}$C NMR may be considered preferable for such studies since isotopic enrichment is less perturbing than introduction of a fluorine label. As for $^{19}$F NMR, $^{13}$C NMR normally has minimal background signal, since the natural abundance of $^{13}$C is only 1.1% allowing almost 100-fold enrichment. Isotopomer analysis can reveal substrate preferences and mechanisms of enzyme activity and kinetic isotope effects are minimal for $^{13}$C, though may be sizable for $^2$H-examined substrates [338].

3.2.2. Hypoxia

While FDG has a role in detecting tumors, a new thrust is characterizing tumors so as to individualize therapy and optimize outcome. To this end, hypoxia is recognized as a critical characteristic. In Section 3.1.1, we described $^{19}$F NMR methods for measuring $pO_2$. As an alternative approach, fluoronitroimidazoles have been used to detect hypoxia. Nitroimidazoles are bioreductive agents that are reduced by intracellular reductases to generate reactive intermediates. In the presence of oxygen, the intermediates are rapidly reoxidised and may clear from cells, but under hypoxic conditions they become covalently bound to cellular constituents, indicating the presence of cellular hypoxia. Nitroimidazoles have been used extensively in the past as hypoxic cell radiosensitizers [339] and more recently have gained a role as markers of tumor hypoxia [85,340–344]. EF5 and pimonidazole are widely used to assess hypoxia in histological analysis of biopsy specimens [198,345–347], but noninvasive approaches would be preferable for therapeutic prognosis. Retention of $^{18}$F misonidazole in hypoxic tumors has been...
observed using PET. Given the importance of hypoxia other PET and SPECT sensitive agents have been proposed and tested (e.g., Cu-ATSM [348,349] and iodinated azomycin galactoside (IAZG) [350]), but nonradioactive approaches would be preferable.

Fluorine-19 labels have been introduced into the nitroimidazole structure providing NMR-sensitive agents [351,352]. Studies have reported the fluorinated nitroimidazoles CCI-103F [353], Ro 07–0741 [354], and SR4554 [351,355,356], which contain 6, 1, and 3 fluorine atoms per molecule, respectively (Table 6). Subsequent to administration, a washout period sufficient for elimination of unbound marker is required, since there is apparently no difference detectable in vivo in the chemical shifts of the parent molecule and the metabolites [351]. Li et al. [357] investigated the predictive potential of CCI-103F retention as an indicator of tumor radiosensitivity and found a weak correlation indicating that factors other than hypoxia are involved and glutathione concentration may be pertinent [351].

Aboagye et al. [358] found increased retention of SR4554 in hypoxic tumors, but no linear correlation with \( pO_2 \). Lack of correlation with \( pO_2 \) measurements [355,358] and pimonidazole uptake [351] suggest that additional factors influence hypoxia marker retention and indeed blood flow/perfusion has been implicated [351]. Robinson and Griffiths found differential uptake of SR4554 in diverse tumors known to exhibit different levels of hypoxia. Surprisingly, there was no retention detected in C6 gliomas, which are widely reported to have extensive hypoxia (Fig. 13). Trapping is predicated on nitroreductase activity, which may be lacking in some tumors. Unlike radiochemical approaches, which detect all labeled molecules, NMR offers potential benefits, but added complexity. Diverse adducts, and metabolites may exhibit multiple chemical shifts, each at very low concentration. There is also concern that polymeric adducts may have exceedingly short \( T_2 \), so that they become essentially invisible for many NMR sequences [359]. The biggest problem with \(^{19}\)F hypoxia agents is that they merely provide a qualitative impression of hypoxia rather than a definitive \( pO_2 \). Seddon et al. [356] reported a correlation between retention of SR4554 and \( pO_2 \), but a Phase I clinical \(^{19}\)F NMR study [356] required infusion at doses of 400–1600 mg/m\(^2\), which could have adverse side effects.

### 3.2.3. Enzyme reporters

A \(^{19}\)F atom can be substituted for a hydroxyl group in sugars with little overall structural perturbation. As such, fluorosugars were widely used to explore mechanisms of enzyme activity [124,126,360]. We adopted a different strategy by including \(^{19}\)F into the aglycon moiety of a substrate to detect \( \beta \)-galactosidase activity (Figs. 1 and 14 and Table 7) [294]. This provides insight into activity of the lacZ gene, which has historically been the most popular reporter gene in molecular biology.
### Table 6. $^{19}$F NMR hypoxia indicators

<table>
<thead>
<tr>
<th>Name</th>
<th>Structure</th>
<th>Number of F atoms</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCI 103F</td>
<td><img src="image" alt="Structure" /></td>
<td>6</td>
<td>Tumors, cells [353,413]</td>
</tr>
<tr>
<td>RO 070741</td>
<td><img src="image" alt="Structure" /></td>
<td>1</td>
<td>Tumors, cells [354]</td>
</tr>
<tr>
<td>SR4554</td>
<td><img src="image" alt="Structure" /></td>
<td>3</td>
<td>Tumors, cells [355,356,351]</td>
</tr>
<tr>
<td>NLTQ-1</td>
<td><img src="image" alt="Structure" /></td>
<td>3</td>
<td>Tumors, cells [435]</td>
</tr>
<tr>
<td>3,3-Difluorochlorambucil</td>
<td><img src="image" alt="Structure" /></td>
<td>2 ABq</td>
<td>Tumors, cells [354]</td>
</tr>
</tbody>
</table>
Gene therapy holds great promise for the treatment of diverse diseases. However, widespread implementation is hindered by difficulties in assessing the success of transfection in terms of spatial extent, gene expression, and longevity of expression. The development of noninvasive reporter techniques based on appropriate molecules and imaging modalities may help to assay gene expression and this is often achieved by including a reporter gene in tandem with the

**Fig. 13.** $^{19}$F NMR of hypoxia reporter SR4554 in tumors. $^{19}$F NMR spectra obtained from (a) a vial containing 6 mg/ml SR4554 resonating at ca. 45 ppm relative to a 5-fluorotryptophan (5-FTP) external standard; (b) a wild-type C6 glioma; (c) a RIF-1 fibrosarcoma; and (d) an HT29 colon adenocarcinoma all acquired 45 min after administration of 180 mg/kg SR4554 IP. The degree of retention of the reduced adducts of SR4554, measured by $^{19}$F MRS, affords a noninvasive assessment of tumor hypoxia. No $^{19}$F resonance was detected in C6 gliomas, although they are expected to exhibit considerable hypoxia. The RIF-1 fibrosarcoma grown in C3H mice and HT29 colon adenocarcinoma grown in nude mice showed clear $^{19}$F resonances from SR4554 (reproduced with permission from Robinson and Griffiths, *Phil. Trans. R. Soc. London B Biol. Sci.* 359, 987–996, Fig. 6 (2004) [351]).
therapeutic gene [38,361]. Currently, reporter genes associated with optical imaging are most popular (e.g., BLI of luciferase [38,362] and fluorescent imaging of GFP and longer wavelength variants [45], since they are cheap modalities, and highly sensitive results are rapidly available. These techniques are very useful in superficial tissues and have extensive applications in mice, but application to larger bodies is limited by depth of light penetration. For deeper tissues and larger animals, nuclear medicine approaches based on thymidine kinase or the sodium iodine symporter (hNIS) have been used [49,363]. For cancer, thymidine kinase has the advantage that the gene serves not only as a reporter, but gene products can themselves have therapeutic value [146]. CD activates the minimally toxic 5-fluorocytosine (5FC) to the highly toxic 5-fluorouracil (5FU) [146,147]. The conversion of 5FC to 5FU causes a $^{19}$F NMR chemical shift approximately 1.5 ppm, hence, revealing gene activity, which has been demonstrated in a number of systems in vivo [147,150].

We have focused on substrates for lacZ, recognizing its popularity as a reporter gene. Given the popularity of lacZ [364–366] diverse reporter agents are commercially available, but mostly for optical and histological applications (e.g., X-gal, o-nitrophenylgalactopyranoside (ONPG), S-Gal$^{\text{TM}}$, and S-Galacton-Star$^{\text{TM}}$) [367–369]. Recently, $^1$H MRI [370], fluorescent [371], and radionuclide [372] substrates have been presented for in vivo work, prompting us to consider $^{19}$F NMR active analogs. It appeared that introduction of a fluorine atom into the popular colorimetric biochemical indicator ortho-nitrophenyl $\beta$-galactopyranoside (ONPG) could produce a strong candidate molecule. Fluoronitrophenol galactosides were used by Yoon et al. [373], to explore $\beta$-gal activity, but they placed the fluorine atom on the sugar moiety, which would be expected to provide much
<table>
<thead>
<tr>
<th>Reporter</th>
<th>Structure</th>
<th>$\delta_F$ (Substrate) (ppm)</th>
<th>$\delta_F$ (aglycone) (ppm)</th>
<th>$\Delta\delta$ (ppm)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFONPG</td>
<td><img src="image" alt="PFONPG Structure" /></td>
<td>-42.87</td>
<td>-52.71</td>
<td>-9.84</td>
<td>[294,374]</td>
</tr>
<tr>
<td>OFPNPG</td>
<td><img src="image" alt="OFPNPG Structure" /></td>
<td>-54.93</td>
<td>-61.04</td>
<td>-6.11</td>
<td>[294,375]</td>
</tr>
<tr>
<td>OFONPG</td>
<td><img src="image" alt="OFONPG Structure" /></td>
<td>-50.67</td>
<td>-58.67</td>
<td>-8.00</td>
<td>[294]</td>
</tr>
<tr>
<td>PCF$_3$ONPG</td>
<td><img src="image" alt="PCF$_3$ONPG Structure" /></td>
<td>13.40</td>
<td>14.54</td>
<td>1.14</td>
<td>[299]</td>
</tr>
</tbody>
</table>
NaTFA was used as a chemical shift standard in PBS (0.1 M, pH 7.4) buffer at 37°C.
ess chemical shift response to cleavage and they do not appear to have used $^{19}$F NMR in these investigations.

Our prototype molecule 4-fluoro-2-nitrophenyl $\beta$-D-galactopyranoside (PFONPG, Table 7) proved effective as a substrate for $\beta$-galactosidase [374]. It provides a single $^{19}$F NMR signal with a narrow line width and good stability in solution. It is stable in normal wild-type cells and whole blood, but exposure to the enzyme or cells transfected to express $\beta$-galactosidase causes rapid cleavage in line with anticipated levels of transfection [374]. Upon cleavage of the glycosidic bond, a chemical shift difference $\Delta \delta > 3.6$ ppm is observed, though the chemical shift of the product may have a range of about 9 ppm, since the released aglycone is pH sensitive and the p$Ka$ is in the physiological range. Significantly, there is no overlap between the chemical shift of the substrate and the product and the chemical shift difference is sufficient to permit chemical shift selective imaging to reveal distribution of each entity separately [375].

To seek optimal $^{19}$F NMR reporters, we synthesized diverse agents and the broad range of substrate structures is consistent with enzyme promiscuity (lack of substrate specificity) (Table 7). The released aglycone PFONP is somewhat toxic and can cause lysis of fragile cells. We have synthesized series of analogues with the fluorine atom placed at various locations on the phenolic ring and incorporating alternate substituents, such as Cl and Br [294]. Each adduct and aglycone provides a unique chemical shift allowing ready comparison of susceptibility to enzyme activity. The chemical shift accompanying cleavage depends strongly on the orientation of the F-atom with largest response for para-F and less for ortho-F. The rate of cleavage was closely related to the p$Ka$ of the aglycone [294] commensurate with enzyme studies reported previously [376].

One approach to reducing toxicity is introduction of a trifluoromethyl (CF$_3$) reporter group, as opposed to the single F-atom to enhance signal-to-noise. The chemical shift response is much smaller (Table 7), due to transmission of the electron density redistribution through an additional carbon–carbon bond [299]. Spectroscopic detection is still feasible in vivo and deconvolution allows CSI, but it is unlikely to be feasible in vivo [299]. Toxicity may also be altered by using alternate aglycons, such as the pH reporter 6-FPOL [11]. 3-O-($\beta$-D-galactopyranosyl)-6-fluoropyridoxol (GFPOL) is found to be a much less good substrate and reactivity is much slower [377]. It is also less water soluble. However, we have found that water solubility may be enhanced by polyglycosylation of the hydroxymethyl arms [378]. The polyglycosylated substrate was also highly reactive for $\beta$-gal, but when galactose was used for all sugar residues multiple products were rapidly generated causing complex spectra. Differential glycosylation using glucose or mannose as the secondary sugars overcame this problem [378].

Given the different chemical shifts of individual substrates and products, we believe there will be opportunities to use multiple reporters simultaneously. Indeed, we have investigated using 4-fluoro-2-nitrophenyl $\beta$-D-galactopyranoside (PFONPG) and 2-fluorine-4-nitrophenyl $\beta$-D-galactopyranoside (OPNPG) as...
substrates simultaneously to differentiate wild type and lacZ expressing tumors in mice [379].

4. PASSIVE REPORTER MOLECULES

Many active \(^{19}\)F NMR reporter molecules have been designed, developed, and exploited, but other methods use a passive approach. In essence, fluorinated molecules occupy a space and a signal magnitude provides an indication of anatomical properties such as lung volume, bowel function, vascular volume, or flow. PFCs exhibit remarkable gas solubility, and based on the high carrying capacity for oxygen and carbon dioxide, have been developed in emulsion form as synthetic blood substitutes [231]. PFCs may also be relevant as pure liquids.

In a classic experiment, Clark and Gollan [380] submersed a living mouse in PFC liquid and far from drowning, it inhaled the PFC facilitating effective oxygen transport to the lungs. Thus, PFCs have potential application as surfactants to aid breathing in extremely premature infants, as explored in clinical trials [381]. PFC may be administered as liquid or aerosols. Thomas et al. [382,383] applied \(^{19}\)F MRI to show the extent of lung filling. Further, by applying relaxation measurements (as described in Section 3.1), they could estimate regional \(pO_2\) in the lungs of mice, rats, dogs, and pigs [208,383]. Various PFCs and PFC emulsions have been introduced into the lung as aerosols, sometimes with animals under forced ventilation, following thorocotomy [383]. The \(^{19}\)F signal provides an opportunity to image lungs. By contrast \(^1\)H MRI is handicapped by lack of water signal. In a novel approach, Huang et al. [384] applied \(^1\)H MRI to the water in a PFC emulsion and found considerably enhanced structural information. Liquid and aerosol ventilation can be stressful, whereas inhalation of inert gas may be more practical, as shown by proof of principal using CF\(_4\) or C\(_2\)F\(_6\) [385]. More recent studies used SF\(_6\) with potential application for detection of lung cancer, emphysema, or allograft rejection [386,387]. Gas detection does require special MR instrumentation, due to the exceedingly short \(T_1\) and \(T_2\) relaxation.

Increasing awareness of colon cancer demands improved screening. Traditional barium meals provide contrast in CT, and virtual colonoscopy is competing with traditional fiber optic probes [388]. MR procedures have lagged behind CT, but several potential contrast agents have been presented, ranging from paramagnetic zeolite formulations [389] and ferric ammonium citrate [390] to PFC emulsions [391,392] and recently images were shown in mice based on perfluorononane [69].

Angiogenesis is associated with tumor development and many clinical trials have found correlations between vascular density and prognosis. Traditional analysis required biopsy and histology, with CD31 antibodies to provide blood vessel counts [393], and dyes such as India ink or Hoechst 33342 to reveal
perfusion [394]. 19F NMR provides a robust indication of vascular volume in vivo based on intravenous PFC emulsions, which are retained in the vasculature for a period of hours [395,396]. Noninvasive measurements revealed acute modulation of tumor blood volume and have provided validation of noninvasive NIR methods [397,398]. This approach has also been applied to other organs and tissues, for example, demonstrating reactive hyperemia in muscles [399]. Studies have validated signal using traditional radioisotope-labeled approaches and dyes [400].

Fluorinated gases (e.g., trifluoromethane (FC-23) and chlorofluoromethane (FC-22)) have been used to examine cerebral blood flow based on inflow and outflow kinetics, sometimes with pulsed delivery to facilitate compartmental analysis [401,402]. The observation that HFB clears from tumors over a period of hours suggests this could provide insight into tissue perfusion [224,266].

5. POTENTIAL INNOVATIONS AND IMPROVEMENTS

Implementation and application of 19F MRI in the clinic awaits further developments. As described above, many reporter molecules have been presented and are undergoing further refinement and evaluation. Sensitivity can be enhanced incrementally by exploiting molecular symmetry as emphasized in Table 2: bis-fluorine atoms can enhance SNR twofold, a CF3 group threefold, a bis-CF3 sixfold and tris-CF3 ninefold. Perhaps the most satisfying increase in SNR is gained by better targetability and localization following systemic delivery. Widespread utility of agents will depend on ready commercial availability. Other sensitivity gains can arise from enhanced radiofrequency coils and parallel imaging (e.g., SMASH or SENSE technologies [403,404]) and higher magnetic field. While 19F MRI on human NMR systems is feasible, it still remains to be established as part of a routine commercial inventory. Clearly, use and need will stimulate widespread provision and availability which could occur quite rapidly.

6. CONCLUSIONS

Since there is essentially no 19F NMR background signal in tissues, fluorinated drugs, and reporter molecules may be detected without interference. Huge diversity of application has been demonstrated in the biochemical and small animal areas, with some limited clinical application. To date, clinical application is hindered by the lack of availability of clinical 19F NMR, but manufacturers are increasingly recognizing the value of including such capability. Given that 19F NMR offers the potential to investigate many diverse parameters (Table 1), it will become increasingly available and useful in the future.
ACKNOWLEDGMENTS

Supported in part by the Cancer Imaging Program, NCI Pre-ICMIC P20 CA086354, and IDEA awards from the DOD Breast Cancer Initiative DAMD 17-99-1-9381, and 17-03-1-0343 and Prostate Cancer Initiative W81XWH-06-1-0149. NMR experiments were conducted at the Mary Nell and Ralph B. Rogers NMR Center, an NIH BTRP facility #P41-RR02584. We are grateful to Drs. Mark Jeffrey, Himu Shukla, and Peter Peschke, for collegial support and allowing us to include unpublished collaborative studies here. Melody Simmons provided expert assistance in preparing this manuscript. Over the past 15 years, our development of expertise in $^{19}$F NMR has been supported by the NIH, Department of Defense Breast and Prostate Cancer Initiatives, the American Cancer Society, the American Heart Association, and The Whitaker Foundation.

REFERENCES

19F NMR Reporter Molecules


19F NMR Reporter Molecules

267

tension measurements in human glioma xenografts by 19F-MR relaxometry, Int. J.

imaging technique to measure intracellular pO2 in vivo using perfluorobron, Acad.

[249] K.G. Helmer, S. Han, C.H. Sotak, On the correlation between the water diffusion


tumor oxygenation: Combined fluorine-19 and proton MRI measurements, Int. J.


[253] P.S. Hees, C.H. Sotak, Assessment of changes in murine tumor oxygenation in
response to nicotinamide using 19F NMR relaxometry of a perfluorocarbon emulsion,

[254] D.J.O. McIntyre, C.L. McCoy, J.R. Griffiths, Tumour oxygenation measurements by

Med. 35(5) (1994) 216P.

[256] B.A. Berkowitz, C.A. Wilson, D.L. Hatchell, Oxygen kinetics in the vitreous substitute

[257] C.A. Wilson, B.A. Berkowitz, D.L. Hatchell, Oxygen kinetics in preretinal perfluoro-

[258] W. Zhang, Y. Ito, E. Berlin, R. Roberts, B.A. Berkowitz, Role of hypoxia during normal
retinal vessel development and in experimental retinopathy of prematurity, Invest.


3733–3738.

[261] I.M.C.M. Rietjens, A. Steensma, C. den Besten, G. van Tintelen, J. Haas, B. van
Ommen, P.J. van Bladeren, Comparative biotransformation of hexachlorobenzene

[262] Y.S. Gorsman, T.A. Kapitonenko, Pharmacology and toxicology of hexafluorobenzene,

[263] K.M. Mortelmans, V.F. Simmon, “In vitro” microbiological mutagenicity assays of
2555–2587.

[264] K.D. Courtney, J.E. Andrews, Teratogenic evaluation and fetal deposition of hexab-
romobenzene (HBB) and hexafluorobenzene (HFB) in CD-1 mice, J. Environ. Sci.

[265] L.W. Hall, S.R.K. Jackson, G.M. Massey, A. Arias, R. Llaurado, M.A. Nalda,
J.N. Lunn (Eds.), Hexafluorobenzene in veterinary anaesthesia, Excerpta Medica,
Oxford, 1975, pp. 201–204.

Regional tumor oximetry: 19F NMR spectroscopy of hexafluorobenzene, Int. J.


J.-X. Yu et al.


[400] S.M. Eleff, M.D. Schnall, L. Ligeti, M. Osbakken, V.H. Subramanian, B. Chance, J.S. Leigh, concurrent measurements of cerebral blood-flow, sodium, lactate, and


[405] H.P. Shukla, Application of Perfluorocarbon Emulsions as Fluorine-19 Nuclear Magnetic Resonance Molecular Probes of Cardiac Tissue Oxygen Tension, University of Texas Southwestern Graduate School of Biomedical Sciences, 1994Ph.D.


J.-X. Yu et al.


Blood Oxygen Level Dependent (BOLD) and Gd-DTPA
dynamic contrast enhanced (DCE) MRI: comparison of two prostate
tumor sublines exhibiting different vascular development

Lan Jiang¹, Dawen Zhao¹, Eric W. Hahn¹, Albert J. van der Kogel², Johan Bussink², Peter Peschke³, and Ralph P. Mason¹

¹Department of Radiology, UT Southwestern Medical Center, Dallas, TX
²Department of Radiation Oncology, University Medical Center Nijmegen, Netherlands,
³German Cancer Research Center, Heidelberg, Germany

Running title: BOLD and DCE MRI assessment of prostate tumors

Contact information:
Ralph P Mason, Ph.D., CSci, CChem
Department of Radiology
UT Southwestern Medical Center at Dallas
5323 Harry Hines Blvd
Dallas, TX 75390-9058 USA
Email: Ralph.Mason@UTSouthwestern.edu
Tel: 214-648-8926
FAX: 214-648-2991

Key Words: BOLD, DCE, prostate tumor, oxygen, hypoxia
Abstract

Background: Tumor microcirculation and oxygenation play important roles in the responsiveness of tumors to cytotoxic treatment. Dynamic Contrast-Enhanced (DCE) MRI based on the transport properties of Gd-DTPA provides an indication of vascular perfusion and permeability. Blood Oxygenation Level Dependent (BOLD) MRI contrast in response to challenge with hyperoxic gas is sensitive to tumor vascular oxygenation, blood flow, and vascular volume.

Methods: This study investigates correlations and differences between BOLD and DCE MRI acquired in immediate succession in two Dunning prostate R3327 rat tumor sublines (AT1 and H) noted for their different growth rates and vascular maturity. Tumors were imaged serially during respiratory oxygen challenges and Gd-DTPA injection at 4.7 Tesla using echo planar imaging (EPI). Both BOLD and DCE revealed intra and inter tumor heterogeneity. A pharmacokinetic model and histology were used to assess characteristics of the tumor vasculature.

Results: The mean permeability, $K_{ep}$, showed no significant difference between tumor regions or types. However, the regional semi-quantitative response ($\Delta SI$) accompanying BOLD or DCE MRI in the two sublines was markedly different in accord with histology.

Conclusion: This study further validates the use of DCE and BOLD MRI for characterizing the vascular compartments and differentiating tumors with diverse vascular characteristics.
Introduction

Imaging provides the opportunity to non-invasively characterize tumors with three primary goals: identification of tumors, prognosis of potential tumor development, and the longitudinal response to therapy. Tumors comprise heterogeneous populations of stromal and tumor cells that differ in their growth rates and sensitivity to therapeutic agents. Owing to this diversity, marked regional differences are also observed in microenvironmental characteristics, such as oxygenation status and microcirculation. Heterogeneity may be spatial and temporal and imaging allows non-invasive repeat assessment. It may be particularly valuable in prostate cancer, which is often a heterogeneous multi-focal disease with the potential development ranging from aggressive metastatic spread to indolent stasis. A major goal of Urology/Radiology is to be able to differentiate patients who need immediate aggressive therapy from those better served by watchful waiting.

Proton MRI not only provides non-invasive assessment of detailed tumor anatomy, but specific MRI techniques may give an indication of tumor angiogenesis and pathophysiological state (1-4). Dynamic Contrast Enhanced MRI based on the transport properties of small paramagnetic contrast agents, such as Gd-DTPA, provides an indication of tumor perfusion and vessel permeability. There have been many semi quantitative reports together with increasingly sophisticated pharmacokinetic models to monitor tumor vascular function (5-8). Another approach exploits intrinsic contrast based on Blood Oxygenation Level Dependent (BOLD) signal in response to inhaling hyperoxic gas, such as oxygen or carbogen (5% CO₂, 95% O₂). The conversion of paramagnetic deoxyhemoglobin to diamagnetic oxyhemoglobin influences the MR signal, particularly in T₂* weighted images (9). However, the BOLD effect is also
sensitive to changes in blood flow and vascular volume, and hence, the term FLOOD (Flow and oxygen level dependent) has been introduced (10). To date, there have been limited reports of the use of the BOLD effect to characterize tumors (11-20). Still fewer reports have examined BOLD and DCE together in the same tumors consecutively or in conjunction with histology (13,21).

We hypothesize that the combined application of BOLD and DCE MRI can provide additional insight into tumor pathophysiology. In this study, we test this notion in two syngeneic rat prostate tumor sublines noted for their differences in growth rates and vascular maturity.

Materials and Methods

Experiments were approved by the UT-Southwestern Institutional Animal Care and Use Committee.

Animal model

Two sublines of the Dunning prostate R3327 adenocarcinoma were selected: H, a well-differentiated, hormone dependent slow-growing tumor with a volume doubling time (VDT) of 16 days, and the AT1, an anaplastic and faster-growing subline with a VDT of 5 days (22-24). Tumor tissues were originally obtained from Dr. J. T. Isaacs (Johns Hopkins University, Baltimore, MD). Eight tumors of each subline were implanted in a skin pedicle surgically created on the foreback of adult male syngeneic Copenhagen-2331 rats, as described in detail previously (25). Tumors were allowed to grow to about 1 cm³ and were investigated by MRI. The rats were anesthetized with ketamine hydrochloride 200 μl (100 mg/ml) IP, and maintained with air and isoflurane (1.3%; 1 dm³/min). A heparin tipped catheter (27 G butterfly, Abbott Labs, Chicago, IL)
was placed in the right tail vein. The body temperature of rats was maintained with a circulating warm-water blanket. A reference capillary phantom containing saline was placed adjacent to selected tumors.

**MRI technique**

A size-matched single turn solenoid volume coil was placed around the tumor and MR experiments were performed using a 4.7 T horizontal bore system with actively shielded gradients (GE Omega with Acustar®, Bruker, Fremont, CA). Vascular oxygen dynamics were assessed using BOLD contrast $^1$H MRI in a coronal section parallel to the rat body acquired using a series of spin echo planar images sensitive to both T$_1$ and T$_2^*$ with a field of view 40×40 mm, matrix 32×32, and thickness 2 mm. We previously used this pulse burst saturation recovery MBEST sequence for both $^{19}$F MRI oximetry and $^1$H contrast studies (15,26). Initial saturation is non-slice selective, thereby saturating signal throughout the tumor and minimizing in-flow effects. Here, we used a constant recovery time $\tau = 500$ ms (≡ TR) and TE = 33.5 ms. Each experiment included a series of fifty-six consecutive echo planar images obtained at 5 s intervals. Baseline stability was measured for up to 5 mins, while the rat breathed air. For BOLD contrast measurements, baseline was assessed for 25 s (images 1 to 5) before respiratory challenge with oxygen (1 dm$^3$/min) for a period of 255 s (images 6 to 56). Following a re-equilibration period of breathing air (15 minutes), a new baseline was measured for 25 s and then a bolus of Gd-DTPA (125 μl 0.1 mmol/kg, Magnevist™, Berlex) was injected manually via the tail vein catheter *in situ* over 1 s. A further series of echo planar images was acquired without changing animal position.
Relative signal intensity

Changes in signal intensity and model fitting were assessed on a voxel-by-voxel basis. Initial inspection showed occasional signal spikes, and thus, a pre filter was applied removing any data points, which deviated from the mean signal intensity by more than three standard deviations of the complete curve. The baseline signal intensity, $SI_b$, of each voxel was defined as the average of the five initial images under baseline conditions. The relative signal intensity changes of each tumor voxel with respect to each intervention (breathing oxygen or Gd-DTPA injection) were analyzed statistically using the equation:

$$\text{Relative Signal Intensity (ΔSI)} = \left( SI_E - SI_b \right) / SI_b \cdot 100\%,$$

where $SI_E$ refers to the enhanced signal intensity of the voxel. Image normalization yielded voxel-by-voxel signal intensity changes from baseline values expressed as a percentage change. Mean (ΔSI) is directly related to area under the curve (AUC). Each tumor was also divided into peripheral and central regions. The peripheral region occupied the two outermost voxels of the tumor. The boundary occupied a single voxel width and the remaining area was considered to be central.

Pharmacokinetic modeling

Contrast enhancement was quantified using the Brix two-compartment model (27) to assess the vascular permeability, $K_{ep}$. For a bolus injection:

$$\frac{SI_E}{SI_0} = 1 + A^H \cdot K_{ep} \left( \frac{e^{-K_{ep} \cdot t} - e^{-K_{ep} \cdot t}}{K_{el} - K_{ep}} \right)$$

where $A^H$ is a parameter that depends on properties of the tissue, the MR sequence, and the infusion rate; $SI_E$ is signal intensity after injection of contrast agent;
$S_i$ is the signal intensity before injection; $K_{ep}$ is the rate constant between extravascular extracellular space (EES) and plasma, which is effected by microvascular permeability; $K_{el}$ is the elimination rate of tracer from the central compartment. We have previously shown that $\Delta SI$ is proportional to [Gd-DTPA] using this pulse sequence in gel phantoms at 4.7 T (15).

**Histology**

Pimonidazole hydrochloride (Hypoxprobe-1; NPI, Belmont, MA) was injected into the tail vein at a dose of 60 mg/kg. Ninety minutes later the blue fluorescent dye Hoechst 33342 (Molecular Probes, Eugene, OR) was injected via the tail vein of anesthetized rats at a concentration of 10 mg/kg in 0.9% saline (0.1 ml), and the tumors were excised 1 min later. For immunohistochemistry, the tissues were immediately immersed in liquid nitrogen and stored at -80 °C. Tumor sections were double-stained for hypoxia (pimonidazole) and vasculature (CD31). Pimonidazole was detected with a polyclonal rabbit-anti-pimonidazole (gift J. A. Raleigh) and donkey-anti-rabbit F(ab')2 Alexa488 (Molecular Probes, Eugene, Oregon). For staining of the blood vessels, mouse anti rat CD31 monoclonal antibody (1:20; Serotec, Raleigh, NC) and HRP-conjugated goat anti mouse secondary antibody Cy3.

Grey-scale images were acquired with a high-resolution camera (12 bit, 1300x1300 pixels) on a fluorescence microscope (Axioskop, Zeiss, Weesp, The Netherlands) using a computer-controlled motorized stepping stage. The recorded fields were combined to a composite gray scale image. Using different filter sets, multiple scans yielded composite images. To capture hypoxia and vascular parameters, whole tumor sections were scanned sequentially three times at 100x magnification with a UV filter set for the Hoechst 33342 signal, as well as filter sets for the Alexa488 and Cy3.
signals. Each scan consisted of 144 (12X12) fields of 1.2 mm$^2$ (the maximum on this system), which comprised approximately 1/2-1/3 of the tumor sections evaluated in this study.

Statistics

Data processing used IDL software with programs written by us. Image display used a commercial graph display and analysis package (SIGMAPLOT 2000). All results are presented as mean ± s.e. Comparisons between the groups were performed using an Analysis of Variance (ANOVA) with significance set at p< 0.01 (Statview, SAS, Carey, NC). Data were assessed in terms of individual voxels, tumor regions, tumors, and the whole tumor group with respect to interventions based on numerical values.

Results

$^1$H MRI showed distinct heterogeneity in signal intensity across tumors of each type (Fig. 1) with mean signal stability during repeat measurements under baseline conditions (variation <2%, Fig. 2). Both tumor types showed significant regionally heterogeneous changes in the BOLD signal contrast with respect to oxygen inhalation (Fig. 1a) or Gd-DTPA infusion (Fig. 1b). In response to oxygen inhalation, mean signal intensity increased significantly, though there was a delay of about 40 s after switching gases. The mean signal intensity for the groups of tumors increased rapidly to a plateau of about 40% (AT1) (Fig 2a) and 30% (H) (Fig 2b) above baseline. Following Gd-DTPA infusion, signal intensity rapidly increased above baseline to a peak 50% for the AT1 tumors (Fig 2a) and 70% for the H tumors (Fig 2b) and then settled to equilibrium at values of 30% and 50% above baseline.
To further examine the spatial heterogeneity evident in Fig. 1, the regional response of each tumor was examined by dividing the tumors into central (mean area 18±1% for AT1 tumors, 24±2% for H tumors) and peripheral regions (60 ±2% for AT1 tumors, 55±3% for H tumors). As a group, the AT1 tumors showed a significantly higher response in the periphery compared to the center with both BOLD and DCE ((p<0.0001), Table 1, Fig. 3a and b). The group of H tumors showed the opposite effect for both interventions, but with a particularly large DCE in the tumor center (Table 1, Fig. 3c and d). Considering individuals, five of eight AT1 tumors showed significantly higher response to oxygen in the peripheral region compared to that in the central region (p<0.01). Of these, three tumors also showed significantly greater responses to Gd-DTPA in the peripheral region (p<0.01). Conversely, for the H tumors, four of eight showed a significantly higher BOLD response in the central region (p<0.01), but only one of eight showed a significantly higher response in the peripheral region (p<0.01). For DCE contrast, four H tumors showed significantly higher central response (p<0.01).

Tumors may also be considered in terms of the fate of individual voxels, i.e., spatial heterogeneity. For BOLD the response was delayed relative to DCE with minimal change after 20 s, but by 125 s after switching gas about 90% of the AT1 tumor regions had responded by > 20% (Fig. 4a). H tumors behaved similarly (Fig 4b). By comparison, for DCE the signal had changed by more than 20% in more than 70% of the tumor regions in the AT1 tumors within 20 s of administering Gd-DTPA (Fig. 4c). More than 30% of the voxels had changed more than 60% within 125 s, though intriguingly about one third showed a signal decline rather than increase. H tumors showed a rather similar time course, but the fraction of responding tumor was larger (~90% showed > 20% change after 20 s; Fig 4d). Intriguingly, about as many voxels showed a signal
decrease of >20%, as showed such an increase in response to either intervention in both tumor types. Signal loss was generally restricted to a 20 to 40% range, whereas 20% of voxels showed >80% signal gain in response to either intervention in both tumor types. The pharmacokinetic parameter mean $K_{ep}$ showed no consistent significant regional differences in either individual tumors or between tumor types. (Table 1, Fig. 5).

Immunohistochemistry showed that the undifferentiated AT1 tumors had lower vascular density, were more poorly perfused, and were substantially more hypoxic with more extensive micro-necroses in the center than in peripheral regions (Fig. 6a). H tumors showed more extensive well-perfused vasculature, overall greater homogeneity, and small regions of hypoxia towards the center of the tumor (Fig. 6b).

Following a single bolus of Gd-DTPA signal enhancement persisted in both tumor sublines for many minutes (Figs. 3 and 4c and d). The BOLD effect can also be made to persist by continuously breathing hyperoxic gas (Figs. 3 and 4a and b). However, if the inhaled gas was returned to air, the signal perturbation rapidly returned to baseline (data not shown). Within 1 min, the mean signal was no longer significantly different from baseline and over 75% of voxels returned to baseline within 95 s.

**Discussion**

Tumors of both sublines responded to respiratory challenge and Gd-DTPA infusion (Figs. 1 and 2). As expected, the oxygen response was relatively delayed due to transport of oxygen to the rat, then progressively into lungs, blood, and finally tumor. In most cases, the initial kinetic curves for BOLD were similar to DCE after the initial delay, suggesting that each intervention interrogates a similar flow pattern, presumably
first-pass through major vessels. After the initial delay, the BOLD response rises to a plateau, whereas DCE peaks and then settles to a lower value.

The peripheral regions of many of these AT1 tumors showed significantly greater and more rapid response to each intervention (Fig. 3). The marked heterogeneity between center and periphery in AT1 tumors observed here coincides with previous reports based on vascular and metabolic observations (15,28-32). Several H tumors showed the opposite behavior with substantially greater BOLD and DCE response in the center than the periphery, although in some cases there was no significant difference. The magnitude of response is expected to relate to vascular extent and indeed is corroborated by the histology (Fig. 6). We have previously found that AT1 tumors are significantly less well oxygenated than size matched H tumors and have significantly greater hypoxic fraction (23). Using the hot spot method, we also found that vascular density of AT1 tumors was significantly lower (23). Based on high-resolution gray-scale images of approximately half the surface of each section, we now find extensive hypoxia (pimonidazole binding) throughout the AT1 tumors. H tumors showed much less hypoxia, and mostly localized towards the center, with extensive perfusion (Hoechst) of blood vessels (CD31). Robinson et al. (12) previously showed that tumor MRI signal response to breathing carbogen or infusion of the blood pool agent NCI100150 was much greater in GH3 prolactinoma than RIF-1 tumors and this matched the extent of perfused vessels as judged by histology. However, they used separate cohorts of animals for each study. Here, we studied the same tumors for both BOLD and DCE sequentially in individual tumors for comparison.

Trying to differentiate tumor types by non-invasive imaging is a goal of many studies. The shape of DCE curves appears valuable in assessing breast cancer (27,33)
and response to therapy (34). There appears to be prognostic value for BOLD response to hyperoxic gas breathing in patients with locally advanced breast cancer undergoing preoperative chemotherapy (35). Others have shown the feasibility of using a BOLD response to identify chemically induced cholangioma from hepatocellular carcinoma in mice (36). Prostate cancer has often proved a greater challenge due to its multifocal nature. In the clinic Padhani et al. (37) found differences using DCE MRI of GD-DTPA between tumor and peripheral zone, but not central gland in patients. There was a weak correlation between tumor stage and vascular permeability assessed, but no significant correlation with Gleason score of PSA levels. Turnbull et al. (38) found significant kinetic contrast differences between tumor and fibromuscular benign prostatic hyperplasia.

BOLD MRI can be technically more challenging in the clinical setting, since patients wear a facemask and contrast changes may be much smaller. Nonetheless, we have successfully performed studies of the prostate in normal human volunteers (28). Taylor et al. (18) succeeded with four cancer patients and Diergarten et al. (39) examined a group of 32 patients finding significantly different signal enhancement between biopsy proven carcinoma of the prostate and the contra lateral normal side.

Meanwhile, several studies have shown differences between prostate tumor types based on dynamic MRI in animal models often noting that macromolecular contrast agents were more effective than small molecules such as Gd-DTPA. Based on the endothelial transfer constant ($K_{PS}^e$) Gossman et al. (40) could separate the more aggressive MAT-LyLu from PAP subline of the Dunning prostate R3327 syngeneic rat tumor systems at 1.5 T. Several investigators have worked with tumors in small animals at 4.7 T. Fan et al. (41) used spectroscopic imaging to differentiate benign Dunning prostate R3327-AT2.1 from metastatic AT3.1 based on image texture, tumor edge
morphology and change in $T_2^*$ following administration of the super paramagnetic particulate agent NC100150 (Clariscan). Bhujwalla et al. (42) found that metastatic prostate tumors formed vasculature with significantly higher permeability or vascular volume as assessed with albumin-GD-DTPA infusion. We have ourselves previously investigated the R3327-AT1 and H tumors using NMR oximetry and histology (23). While neither tumor is metastatic, they are characterized by substantially different growth rates (5 vs. 16 day volume doubling times) and levels of cellular differentiation. Both small and large H tumors had significantly higher mean and median $pO_2$, lower hypoxic fraction ($HF_5$ and $HF_{10}$), and better response to breathing hyperoxic gas, as judged by $^{19}$F NMR oximetry. Hot spot analysis showed significantly lower vascular density and greater overall pimonidazole uptake in AT1 tumors, as confirmed here. Here, we now report differences in magnitude of both DCE and BOLD responses, but not $K_{ep}$, provided that tumors were divided into central and peripheral regions (Table 1).

It is important to establish tumor characteristics, which can be used to monitor growth and response to therapy. While some authors favor more complex models with three or more compartments, we used a two-compartment model, which is mathematically stable during fitting and for which most clinical experience exists. The quality of the curve-fitting procedure is critical for model-based parametric methods that rely on fitting the data to a complex dynamic curve. For example, the $K_{ep}$ value is highly influenced by the accuracy of curve fitting algorithm, the blood flow, and the signal intensity curve. If the signal intensity curves of voxels are negative or unstable, the curve fitting fails or results in too high a $K_{ep}$ value. We found that some voxels did not show increased signal during DCE, but our fitting algorithm required that each voxel have a mean value (AUC) greater than zero with DCE contrast. Thus, it was necessary
to filter out negative data in calculating $K_{ep}$. For $K_{ep}$ regression analysis thresholding criteria were set such that $K_{ep} < 10 \text{ min}^{-1}$, $K_{ep}(\text{error}) < 5 \text{ min}^{-1}$, and ratio $K_{ep}(\text{error})/K_{ep} < 0.8 \text{ min}^{-1}$. Clearly, this issue needs to be further investigated and will markedly depend on the signal/noise ratio and the temporal resolution of the images and also on the model. Here, we found no significant differences between $K_{ep}$ in central and peripheral regions of either tumor type or between tumor types.

Loss of signal accompanying intervention may be rationalized on the basis of a “steal effect” for BOLD investigations, as reported by others (13,43). It is less clear why signal intensity should decrease for extended periods following gadolinium DTPA infusion, though this phenomenon has been reported by Peller et al. (13). Our MRI pulse sequence is sensitive to both $T_1$ and $T_2^*$ effects (15). While Gd-DTPA is expected to increase signal by shortening $T_1$, it can reduce the signal by shortening $T_2^*$, although we do not believe that local concentrations are sufficient to cause $T_2^*$ shortening in our investigations. A bolus of Gd-DTPA can cause $T_2^*$ signal loss, but this would most likely be a transient effect rather than long-term. Magnet or signal drift must be considered, but when a capillary phantom was included it showed central signal stability better than 5% during Gd-DTPA studies. We also tested infusion of saline and found minimal signal response.

Many investigators have used carbogen rather than oxygen to examine the effects of hyperoxic gas inhalation. Historically, carbogen has been favored in the clinic, since the CO$_2$ component is vasoactive, minimizing oxygen associated hypotension and potentially increasing blood flow to tumors. Indeed, carbogen is used in the highly successful ARCON clinical trial for head and neck cancer (44). Some investigators reported a differential response to oxygen or carbogen in rodent tumors, notably mouse
xenografts (16), but our studies, in general, have shown similar response to either gas on the basis of vascular oxygenation assessed by near infrared (NIR) of ΔHbO₂ (45-47) or FREDOM NMR oximetry of pO₂ (48-50). Rates of signal change with BOLD or DCE observed here closely match our previous observations using non-localized (global) interrogation of Dunning prostate R3327-AT1 rat tumors by near-infrared spectroscopy with respect to switching gas under similar conditions (51).

Conclusion

Overall, both techniques showed significant differences between the tumor types based on regional analysis and may be relevant to future clinical investigations. Macromolecular contrast agents might prove even more definitive, but they are not yet routinely used in the clinic. We previously found that the BOLD changes were rapidly reversible upon return to air breathing and this could allow rapid assessment of acute response during interventions.

Acknowledgements

We are grateful to Dr. Roddy McColl for valuable discussions and members of the MR Cancer Listserver (in particular, Dr. Yanping Lou, Abbott labs) for suggesting the IV infusion protocol. This work was supported in part by NIH R01 CA79515/EB002762 and DOD Prostate Initiative IDEA award PC050766 (W81XWH-06-1-0149). MR investigations were performed at the Mary Nell and Ralph B. Rogers Magnetic Resonance Center, an NIH BTRP Facility P41-RR02584, and in conjunction with the Cancer Imaging Program (Pre-ICMIC) P20 CA86354 and SAIRP U24 CA126608A.
References


6. Cao Y, Brown SL, Knight RA, Fenstermacher JD and Ewing JR. (2005) Effect of intravascular-to-extravascular water exchange on the determination of blood-to-
tissue transfer constant by magnetic resonance imaging. Magn Reson Med 53:282-293.


Table 1. The mean regional change in signal intensity ($\Delta SI$) of individual tumors after oxygen inhalation or injection of contrast agent and pharmacokinetic analysis

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>AT1#</th>
<th>H#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of tumors</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Volume (cm$^3$)</td>
<td>$3.3 \pm 1.6$</td>
<td>$2.4 \pm 0.5$</td>
</tr>
<tr>
<td>Region (%)@</td>
<td>Periphery</td>
<td>Center</td>
</tr>
<tr>
<td></td>
<td>60±2</td>
<td>18±1</td>
</tr>
<tr>
<td></td>
<td>55±2</td>
<td>24±2</td>
</tr>
<tr>
<td>$(\Delta SI)$ BOLD+</td>
<td>Mean</td>
<td>Periphery</td>
</tr>
<tr>
<td></td>
<td>33±2</td>
<td>42±3*‡</td>
</tr>
<tr>
<td>$(\Delta SI)$ DCE+</td>
<td>Mean</td>
<td>Periphery</td>
</tr>
<tr>
<td></td>
<td>36±1</td>
<td>43±1*‡</td>
</tr>
<tr>
<td>$K_{ep}$ (min$^{-1}$)</td>
<td>Mean</td>
<td>Periphery</td>
</tr>
<tr>
<td></td>
<td>3.05±0.37</td>
<td>3.11±0.44</td>
</tr>
</tbody>
</table>

@: Percentage of whole tumor slice
+: Relative % signal change from baseline mean ± s.e.
#

$$\sum_{T=1}^{n} \sum_{t=1}^{51} \frac{\Delta SI_{T,t}}{n \cdot 51},$$

where $\Delta SI$ is the mean for each tumor ($T$) at each time point post intervention ($t$), $n$ is the number of tumors in the group.

*: Mean value is significantly greater than that in other region of the same tumor subline, $p<0.0001$.
‡: Mean value is significantly greater than that in same region of other tumor subline, $p<0.0001$. 


Figure Legends

Figure 1  Proton MRI of tumor vascular dynamics

$^1$H MRI signal intensity response to respiratory challenge and Gd-DTPA injection in representative Dunning prostate tumors. AT1 is shown in upper panels and H tumors in lower panels. $^1$H MRI was obtained using a spin echo planar imaging sequence with T1-weighting providing sensitivity to changes in both T1 and T2* relaxation (TE= 33.5 ms, TR = 500 ms). Green line on center images indicates the boundary used to separate central and peripheral tumor regions.

a) BOLD with respect to hyperoxic gas challenge. Left: Control baseline images indicating considerable signal heterogeneity, while breathing air. Center: images acquired after 150 s breathing oxygen. Right: Contour maps showing changes in SI (150 s relative to baseline). The color scale indicates the magnitude of relative SI changes.

b) Dynamic contrast enhancement. Left: Control baseline images. Center: Images observed 70 s after Gd-DTPA infusion. Right: Contour maps showing changes in SI (70 s relative to baseline).

Figure 2  Comparison of vascular kinetics of two tumor types

Mean $^1$H MRI signal intensity in response to oxygen inhalation (BOLD) (♦) and Gd-DTPA infusion (□) for groups of (a) AT1 tumors (n=8) and (b) H tumors (n=8). Lines indicate mean±SE. Dotted vertical lines show start of intervention. An immediate signal response is seen for Gd-DTPA, whereas the BOLD response is somewhat delayed (~40 s).
**Figure 3**  **Comparison of regional vascular kinetics of AT1 and H tumors**

The mean $^1$H MR signal intensity in central region (C; filled symbols) and peripheral region (P, open symbols) in response to oxygen inhalation (BOLD) (upper) and Gd-DTPA infusion (DCE) (lower). The mean $\Delta$SI of AT1 tumors ($n=8$) in BOLD and DCE was significantly higher in the peripheral regions than that in the central regions ($p<0.0001$) (a and b). For H tumors ($n=8$) the mean response to BOLD and DCE in the peripheral regions was significant lower than that in the central regions ($p<0.0001$) (c and d). Lines indicate mean±SE.

**Figure 4**  **Magnitude of dynamic signal response to intervention**

Variations in distribution of relative signal intensity in response to intervention for the two tumor sublines. BOLD response to breathing oxygen is shown in a and b for groups of AT1 and H subline tumors, respectively. A more rapid response is observed following Gd-DTPA infusion (c and d). Hotter colors represent a larger fractional volume of tumor as shown by scale.

**Figure 5**  **Comparison of regional pharmacokinetic $K_{ep}$ of AT1 and H tumors**

While individual tumors showed differences in the mean value of $K_{ep}$ in peripheral and central regions, the differences were neither consistent nor significant. a) AT1 tumors; b) H tumors. Bars indicate mean±SE; open periphery; shaded, center.
Figure 6  Comparison of microvasculature and hypoxia in AT1 and H tumors.

Vascular endothelium marked by CD-31 (red), perfused vessels marked by Hoechst dye 33342 (blue) and hypoxia by pimonidazole hydrochloride (green).

a) The AT1 tumor shows extensive hypoxia and many vessels appeared to be non-perfused. Near the tumor periphery, perfusion is more effective as revealed by the purple appearance of vessels (red overlapping blue).

b) The H tumor shows more extensive vascular endothelium, which is well perfused throughout the tumor. Hypoxia occurs distant to perfused vessels and is less extensive.
Figure 1a

AT1

H

<table>
<thead>
<tr>
<th>AT1</th>
<th>H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>Control</td>
</tr>
<tr>
<td>BOLD (150s)</td>
<td>BOLD (150s)</td>
</tr>
<tr>
<td>Relative intensity map</td>
<td>Relative intensity map</td>
</tr>
</tbody>
</table>

ΔSI

<table>
<thead>
<tr>
<th>&gt; 60%</th>
<th>60% - 60%</th>
<th>40% - 60%</th>
<th>20% - 40%</th>
</tr>
</thead>
<tbody>
<tr>
<td>± 20%</td>
<td>-20% - 0%</td>
<td>-40% - -20%</td>
<td>-60% - -40%</td>
</tr>
<tr>
<td>&lt; -60%</td>
<td>&lt; -80%</td>
<td>&lt; -80%</td>
<td>&lt; -80%</td>
</tr>
</tbody>
</table>

<.00%
Figure 1b
Figure 2
Figure 3
Figure 4
Figure 5

AT1 tumor

- Kep periphery
- Kep center

H tumor

- Kep periphery
- Kep center
Figure 6b
Impact

Bavituximab: Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry

Ralph P. Mason\(^1\), Weina Cui\(^1\), Dawen Zhao\(^1\), Albert J. van der Kogel\(^1\) and Johan Businskij\(^2\) Jesús Pacheco Torres\(^3\), Jennifer McAnally\(^4\), Linda Watkins\(^5\), Peter Peschke\(^6\) and Philip Thorpe\(^2\)

\(^1\)Cancer Imaging Program, Department of Radiation Oncology, The University of Texas Southwest Medical Center, Dallas, TX
\(^2\)Department of Radiation Oncology, University Medical Center Nijmegen, Netherlands; Instituto de Investigaciones Biomédicas "Alberto Sols" CSIC/UAM, Madrid, Spain

**INTRODUCTION**

Imaging tumor microcirculation promises a new avenue for therapy. To provide tumor dose a blood supply is required for the delivery of chemotherapeutic drugs and for the proliferation of tumor cells. Dynamic contrast imaging (DCE-MRI) is a reliable technique to study the perfusion of tumors. Recently, it has been proposed that the dynamic effects of bavituximab (BM-31 uPA-R) on prostate tumor vasculature may result in increased vascular damage and tumor regression with minimal accompanying toxicity. It is hypothesized that this compound may target various tumors and induce vascular damage and tumor regression with minimal accompanying toxicity. The current study is aimed at evaluating the dynamic effects of bavituximab on prostate tumor vasculature, so as to optimize combination therapy in prostate cancer. A new effective therapy for prostate cancer, since a blood supply is required for the proliferation of tumor cells. Dynamic contrast imaging (DCE-MRI) is a reliable technique to study the perfusion of tumors. Recently, it has been proposed that the dynamic effects of bavituximab (BM-31 uPA-R) on prostate tumor vasculature may result in increased vascular damage and tumor regression with minimal accompanying toxicity. It is hypothesized that this compound may target various tumors and induce vascular damage and tumor regression with minimal accompanying toxicity. The current study is aimed at evaluating the dynamic effects of bavituximab on prostate tumor vasculature, so as to optimize combination therapy in prostate cancer.

**METHODS**

Recent studies have shown that dynamic contrast-enhanced imaging (DCE-MRI) can be used to evaluate the perfusion and development of tumor vasculature damage in vivo. In cancer, perfusion changes can be assessed with contrast-enhanced magnetic resonance imaging (CE-MRI). Dynamic contrast imaging (DCE-MRI) is a reliable technique to study the perfusion of tumors. Recently, it has been proposed that the dynamic effects of bavituximab (BM-31 uPA-R) on prostate tumor vasculature may result in increased vascular damage and tumor regression with minimal accompanying toxicity. It is hypothesized that this compound may target various tumors and induce vascular damage and tumor regression with minimal accompanying toxicity. The current study is aimed at evaluating the dynamic effects of bavituximab on prostate tumor vasculature, so as to optimize combination therapy in prostate cancer.

**RESULTS**

Bavituximab treated tumors received 2.5 mg/kg IP thrice weekly starting on day 1 and showed significant responses. Post-treatment tumor oxygenation was monitored by using a luciferase reporter. The results show that bavituximab-treated tumors have lower tumor oxygenation compared to control tumors. The findings suggest that bavituximab may be an effective treatment for prostate cancer.

**ACKNOWLEDGEMENTS**

This work was supported by DOD Prostate Initiative IDEA award PC050766 (W81XWH-06-1-0149). MR investigations were performed at the Mayo Clinic and Ralph P. Mason’s Research Center on an MR B.0195.00 GE 1.5T with the EPI Imaging Sequence for DCE-MRI.0666 1824.00.

**REFERENCES**

DOCENT-Dynamic Oxygen Challenge Evaluated by NMR T1 and T2* of Tumors

Dawen Zhao1, Jesús Pacheco Torres1,2, Peter Peschke3 and Ralph P. Mason1

Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX,
Instituto de Investigaciones Biomédicas “Alberto Sols” Madrid, Spain,
German Cancer Center, Heidelberg, Germany

Introduction

Hypoxia inhibits tumor response to radiation therapy. Thus, many techniques are being developed to assess hypoxia or quantitative pO2 (1). We have been developing NMR approaches to measuring oxygen tension dynamics (2) and have demonstrated differential size dependent hypoxia among diverse Dunning prostate tumor lines. Importantly, hypoxic tumors were found to respond less well to irradiation and, indeed, direct correlations were found between the volume doubling time following radiation and pO2 (3, 4). We are currently evaluating PESTEO (Proton Imaging of Tissue Oxygen Levels) as a potential T1 MRI alternative (5). However, such measurements require introduction of a reporter molecule. Prompted by the report of Marunuma et al. (6) we are exploring the ability to evaluate tumor hypoxia based on the response of tumor T1 and T2* weighted water signals to hypoxic gas breathing.

Methods

We examined Dunning prostate R3327-AT1 and HI tumors. When tumors reached ~1 cm diameter MR measurements were performed under general anesthesia at 4.7 T. We previously characterized these tumors using FREDOM in terms of response to hypoxic gas challenge (Figures 1-4).

Using quantitative “F” NMR oximetry we are able to categorize tumors according to baseline hypoxia and response to hypoxic gas breathing into three types: 1) well oxygenated and responsive; 2) hypoxic, but responsive to oxygen challenge; and 3) hypoxic and resistant to modulation (Figures 3 and 4).

Here, averages of interleaved T1- and T2*-weighted proton (water) imaging were acquired during transition from air to carbogen breathing to assess ability to detect tumor response. Measurements were repeated when tumors were ~2 cm diameter.

Results

• Tumors known from “F” MRI to be well oxygenated (small HI and AT1) showed a large response in both T1 and T2* signal with respect to breathing carbogen.

• Tumors known to be hypoxic, but responsive to hypoxic gas challenge (large HI) showed a large response in both T1 and T2* signal with respect to breathing carbogen.

• Tumors known to be hypoxic and not to respond to hypoxic gas breathing (large AT1) showed very small response in T1 or T2* weighted images in response to breathing carbogen.

For further information, you may contact Ralph.Mason@UTSouthwestern.edu

References